{"title": "vacunas anti-rotavirus al: Topics by WorldWideScience.org", "author": null, "url": null, "hostname": null, "description": null, "sitename": null, "date": "2013-04-11", "cleaned_text": "eficacia de una vacuna tetravalente obtenida por recombinaci\u00f3n gen\u00e9tica de rotavirus aislados de monos rhesus y seres humanos en Bel\u00e9m, Brasil Immunogenicity, safety and efficacy Full Text Available Se evalu\u00f3 la inocuidad, inmunogenicidad y eficacia de una vacuna tetravalente obtenida por recombinaci\u00f3n gen\u00e9tica de rotavirus aislados de monos rhesus y seres humanos (RRV-TV (4 x 10(4 unidades formadoras de placas por dosis en un ensayo prospectivo, aleatorio, a doble ciego y controlado con placebo que se efectu\u00f3 con 540 lactantes brasile\u00f1os. Se administraron dosis de vacuna o de placebo a la edad de 1, 3 y 5 meses. No se observaron diferencias significativas en la frecuencia de diarrea o v\u00f3mito en los beb\u00e9s de ninguno de los dos grupos despu\u00e9s de administrar la dosis correspondiente. De 2 a 3% de los vacunados tuvieron fiebre baja los d\u00edas tercero a quinto despu\u00e9s de recibir la primera dosis, pero no despu\u00e9s de las dosis segunda o tercera. Se observ\u00f3 una respuesta de anticuerpos del tipo IgA al rotavirus aislado de monos rhesus (RRV en 58% de los vacunados y en 33% de quienes recibieron placebo. La respuesta de anticuerpos neutralizantes a cada serotipo no pas\u00f3 de 20% cuando se determin\u00f3 con la prueba de reducci\u00f3n de focos de fluorescencia, pero fue superior a 40% al medirse con la prueba de neutralizaci\u00f3n a base de reducci\u00f3n de placas. Se presentaron 91 casos de diarrea causada por rotavirus entre los ni\u00f1os que recibieron las tres dosis (de vacuna o de placebo durante un seguimiento de 2 a\u00f1os, 36 de ellos en los ni\u00f1os vacunados. La eficacia general de la vacuna fue de 8% (P = 0,005 contra toda clase de diarrea y de 35% (P = 0,03 contra la diarrea causada por rotavirus. La protecci\u00f3n durante el primer a\u00f1o de seguimiento, cuando predomin\u00f3 el rotavirus G del serotipo 1, fue de 57% (P = 0,008, pero se redujo a 12% en el segundo a\u00f1o. Se obtuvieron resultados similares al restringir el an\u00e1lisis a episodios en que el rotavirus fue el \u00fanico agente pat\u00f3geno identificado. Se observ\u00f3 en la vacuna una mayor tendencia a proteger contra casos de enfermedad con un promedio de seis o m\u00e1s deposiciones diarias. Estos resultados [The Latina: perspectivas de vacunaci\u00f3n frente al rotavirus](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004001200002) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) M. in America. METHODS: We conducted a literature review of studies of children OBJETIVO: Valorar la carga de enfermedad e identificar las caracter\u00edsticas epidemiol\u00f3gicas de la diarrea causada por rotavirus en Am\u00e9rica Latina. M\u00c9TODOS: Realizamos una revisi\u00f3n de la literatura que abarcaba los estudios de ni\u00f1os menores de 5 a\u00f1os que fueron hospitalizados o atendidos como pacientes ambulatorios a causa de la diarrea, y en los cuales se busc\u00f3 al rotavirus como agente etiol\u00f3gico de la diarrea. Nuestro trabajo de revisi\u00f3n incluye los estudios publicados desde el a\u00f1o 1998 sobre pacientes ingresados y ambulatorios, que incluyeron a 100 ni\u00f1os o m\u00e1s, y que informaron sobre actividades de vigilancia que se prolongaron durante al menos 12 meses consecutivos. RESULTADOS: Un total de 18 estudios de pacientes ingresados y 10 estudios de pacientes ambulatorios satisficieron los criterios de inclusi\u00f3n de nuestro trabajo de revisi\u00f3n. Se detect\u00f3 el rotavirus en el 31% (mediano de los pacientes ingresados (intervalo del 16% al 52% y en el 30.5% de los pacientes ambulatorios (intervalo del 4% al 42%. La tasa mediana de detecci\u00f3n fue mayor en los estudios que emplearon un ensayo de encimoinmunoan\u00e1lisis (ELISA (pacientes ingresados: 38%, pacientes ambulatorios: 33% frente a otros m\u00e9todos de detecci\u00f3n menos sensibles. La distribuci\u00f3n de la enfermedad rotav\u00edrica seg\u00fan la edad difer\u00eda entre pa\u00edses, aunque la proporci\u00f3n de ni\u00f1os hospitalizados durante el primer a\u00f1o de vida fue del 65% al 85%. En la mayor\u00eda de los pa\u00edses se produjeron ingresos hospitalarios por rotavirus durante todo el a\u00f1o, y el rotavirus normalmente mostraba un m\u00e1ximo estacional en el invierno tanto en las zonas de clima tropical como en aquellas de clima templado. CONCLUSIONES: La importante carga de enfermedad que se atribuye al rotavirus en Am\u00e9rica Latina sugiere que las [Rotavirus diarrhea disease burden in Peru: the need for a vaccine and its potential cost savings Carga de morbilidad de la diarrea por rotavirus en Per\u00fa: la necesidad de una vacuna y su potencial de ahorro](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001001000004) [Directory of Open Access Journals rotavirus diarrhea Peru as well the need for and the potential cost savings with a rotavirus vaccine in that country. Methods. To assess the burden of rotavirus diarrhea was a number national to estimate both the burden of rotavirus diarrhea in the country and its associated medical costs. Results. Rotavirus is a significant cause of morbidity and mortality in Peruvian children. In their first 5 years of life, an estimated 1 in 1.6 children will experience an episode of rotavirus diarrhea, 1 in 9.4 will seek medical care, 1 in 19.7 will require hospitalization, and 1 in 375 will die of the disease. Per year, this represents approximately 384 000 cases, 64 000 clinic visits, 30 000 hospitalizations, and 1 600 deaths. The annual cost of medical care alone for these children is approximately US$ 2.6 million--and that does not take into account the indirect or costs and mortality from diarrhea in Peru, but a vaccine regimen would have to be relatively inexpensive, a few deaths and their efficacy with fewer than three doses. All three of these factors could increase the cost savings associated with a rotavirus vaccine.Objetivos. Evaluar la carga de morbilidad de la diarrea por rotavirus en Per\u00fa, la necesidad de una vacuna y el ahorro que esta podr\u00eda proporcionar en este pa\u00eds. M [Evaluaci\u00f3n del impacto de la vacuna contra rotavirus en Colombia usando m\u00e9todos r\u00e1pidos de evaluaci\u00f3n](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892013001000002&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Karol Cotes 2013-10-01 Full Text Available OBJETIVO: Estimar la efectividad de la vacuna monovalente antirrotav\u00edrica para prevenir la hospitalizaci\u00f3n por enfermedad diarreica aguda en ni\u00f1os menores de 2 a\u00f1os en cinco ciudades de Colombia. M\u00c9TODOS: Se realiz\u00f3 una encuesta poblacional sobre una muestra probabil\u00edstica de ni\u00f1os mayores de 2 meses y menores de 24 meses de edad en cinco ciudades de Colombia (Barranquilla, Bogot\u00e1, Cali, Cartagena y Riohacha en el per\u00edodo de agosto a octubre de 2010. La vacuna fue introducida en el Programa Ampliado de Inmunizaciones en enero de 2009. Se estimaron las coberturas de vacunaci\u00f3n contra rotavirus por grupos de edad y la incidencia acumulada de hospitalizaci\u00f3n por diarrea severa, y se evalu\u00f3 la magnitud de la asociaci\u00f3n entre la vacunaci\u00f3n con una o dos dosis de vacuna antirrotav\u00edrica y la hospitalizaci\u00f3n por diarrea, utilizando la raz\u00f3n de probabilidades (RP ajustada por edad y otros factores de importancia epidemiol\u00f3gica. La efectividad de la vacunaci\u00f3n se estim\u00f3 usando la expresi\u00f3n 1 - RP. RESULTADOS: La cobertura de vacunaci\u00f3n con una dosis de vacuna fue de 87,3%. En los 12 meses previos a la encuesta 43,2% (1 453 ni\u00f1os de menores de 24 meses presentaron diarrea, y de ellos, 5,2% (174 ni\u00f1os fueron hospitalizados por esta causa. La efectividad de dos dosis de vacuna antirrotav\u00edrica para prevenir la hospitalizaci\u00f3n por diarrea severa fue de 68% (intervalo de confianza de 95%: 55%-77%. CONCLUSIONES: La vacunaci\u00f3n contra rotavirus en Colombia protege contra la hospitalizaci\u00f3n por diarrea por cualquier causa. El uso de encuestas transversales se mostr\u00f3 adecuado para evaluar r\u00e1pidamente la efectividad de un programa de vacunaci\u00f3n con una nueva vacuna. [Anticipating rotavirus vaccines: review of epidemiologic studies of rotavirus diarrhea in Argentina En anticipaci\u00f3n de una vacuna antirrotavirus: revisi\u00f3n de estudios epidemiol\u00f3gicos sobre la diarrea por rotavirus en la Argentina](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998000200001) [Directory Open Access to more accurately assess the cost-effectiveness of vaccine program, and to indicate what methods might best be used to monitor such a program's impact.En todo el mundo, los rotavirus son la causa m\u00e1s com\u00fan de diarrea grave en los ni\u00f1os peque\u00f1os y actualmente se est\u00e1n ensayando sobre el terreno vacunas que posiblemente permitan inmunizar a la poblaci\u00f3n infantil dentro de varios a\u00f1os. Con el fin de estimar la carga de enfermedad por rotavirus en la Argentina y la utilidad de establecer en el pa\u00eds un sistema de vigilancia de la enfermedad, se revisaron datos sobre la detecci\u00f3n de estos virus, seg\u00fan estudios publicados y otros in\u00e9ditos de nueve ciudades argentinas y uno multic\u00e9ntrico. Los informes revisados indican que se detectaron rotavirus en 20% de 5 226 espec\u00edmenes (con un recorrido de 6 a 54% entre estudios tomados de ni\u00f1os hospitalizados por diarrea y en 9% de 6587 espec\u00edmenes (recorrido de 5 a 22% entre estudios tomados de pacientes ambulatorios, miembros de poblaciones mixtas (ni\u00f1os hospitalizados y ambulatorios y sujetos sometidos a encuestas comunitarias. Los datos correspondientes a hospitales muestran que, si bien los virus se detectaron durante todo el a\u00f1o, en los meses de invierno (mayo a julio hubo un pico de intensidad cuando hasta la mitad de los ni\u00f1os con diarrea tuvieron resultados positivos a los rotavirus. En tres laboratorios se logr\u00f3 serotipificar para la prote\u00edna G a 230 de 294 espec\u00edmenes positivos (78%; los resultados indican que el serotipo G1 fue el m\u00e1s com\u00fan (presente en 60% de los espec\u00edmenes serotipificados, seguido del G2 (en 20%, G4 (en 14% y G3 (en 5%. Sobre la base de los datos obtenidos en el pa\u00eds, se estim\u00f3 que en 1991 en la Argentina hubo aproximadamente 84 500 visitas de pacientes ambulatorios (uno de cada ocho nacimientos y 21 000 hospitalizaciones de 4 d\u00edas en promedio (uno de cada 31 nacimientos asociadas con rotavirus, que en conjunto costaron unos US$ 27,7 millones. Estos datos [Estudio de inmunogenicidad para dos vacunas recombinantes contra hepatitis of Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) O. Juliao la inmunogenicidad (seroconversi\u00f3n, seroprotecci\u00f3n e Hiperrespuesta, producida por dos vacunas recombinantes contra la hepatitis B (Engerix-B de B\u00e9lgica y Cubana, en dos esquemas (012 y 016 meses, empleando los m\u00e9todos de cuantificaci\u00f3n para Anti-HBsAg (Abbott y Organ\u00f3n, los cuales fueron tambi\u00e9n comparados. En el estudio participaron 257 voluntarios, divididos al azar en 4 grupos (dos vacunas, dos esquemas. Resultados: los dos m\u00e9todos de Abbon y Organon, no presentan diferencias estad\u00edsticas significativas. La vacuna cubana muestra una mayor respuesta inmunog\u00e9nica para dos dosis de vacuna y para el esquema 012. No hay diferencia entre los esquemas 012 y 016 y en el esquema 016 no se ven diferencias estad\u00edsticamente significativas con la vacuna Engerix-B. En esta \u00daltima el esquema 016 muestra mejores resultados que el 012. [En anticipaci\u00f3n de una vacuna antirrotavirus: revisi\u00f3n de estudios epidemiol\u00f3gicos sobre la diarrea por rotavirus en la Argentina](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998000600003&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Jorge A. G\u00f3mez 1998-06-01 Full Text Available En todo el mundo, los rotavirus son la causa m\u00e1s com\u00fan de diarrea grave en los ni\u00f1os peque\u00f1os y actualmente se est\u00e1n ensayando sobre el terreno vacunas que posiblemente permitan inmunizar a la poblaci\u00f3n infantil dentro de varios a\u00f1os. Con el fin de estimar la carga de enfermedad por rotavirus en la Argentina y la utilidad de establecer en el pa\u00eds un sistema de vigilancia de la enfermedad, se revisaron datos sobre la detecci\u00f3n de estos virus, seg\u00fan estudios publicados y otros in\u00e9ditos de nueve ciudades argentinas y uno multic\u00e9ntrico. Los informes revisados indican que se detectaron rotavirus en 20% de 5 226 espec\u00edmenes (con un recorrido de 6 a 54% entre estudios tomados de ni\u00f1os hospitalizados por diarrea y en 9% de 6 587 espec\u00edmenes (recorrido de 5 a 22% entre estudios tomados de pacientes ambulatorios, miembros de poblaciones mixtas (ni\u00f1os hospitalizados y ambulatorios y sujetos de encuestas comunitarias. Los datos hospitalarios muestran que, si bien los virus se detectaron durante todo el a\u00f1o, en los meses de invierno (mayo a julio hubo un pico de intensidad cuando hasta la mitad de los ni\u00f1os con diarrea dieron resultados positivos a los rotavirus. En tres laboratorios se logr\u00f3 serotipificar para la prote\u00edna G 230 de 294 espec\u00edmenes positivos (78%; los resultados indican que el serotipo G1 fue el m\u00e1s com\u00fan (presente en 60% de los espec\u00edmenes serotipificados seguido del G2 (en 20%, G4 (en 14% y G3 (en 5%. Sobre la base de los datos obtenidos en el pa\u00eds, se estim\u00f3 que en 1991 en la Argentina hubo aproximadamente 84 500 visitas de pacientes ambulatorios (1 de cada 8 nacimientos y 21 000 hospitalizaciones de 4 d\u00edas en promedio (1 de cada 31 nacimientos asociadas con rotavirus, que en conjunto costaron unos US$27,7 millones. Estos datos preliminares muestran que la carga de enfermedad por rotavirus en los ni\u00f1os argentinos es muy pesada y podr\u00eda disminuirse con una vacuna segura y efectiva. Adem\u00e1s se necesita ampliar la [En anticipaci\u00f3n de una vacuna antirrotavirus: revisi\u00f3n de estudios epidemiol\u00f3gicos sobre la diarrea por rotavirus en la Argentina](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998000600003) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) G\u00f3mez Jorge A. 1998-01-01 Full Text Available En todo el mundo, los rotavirus son la causa m\u00e1s com\u00fan de diarrea grave en los ni\u00f1os peque\u00f1os y actualmente se est\u00e1n ensayando sobre el terreno vacunas que posiblemente permitan inmunizar a la poblaci\u00f3n infantil dentro de varios a\u00f1os. Con el fin de estimar la carga de enfermedad por rotavirus en la Argentina y la utilidad de establecer en el pa\u00eds un sistema de vigilancia de la enfermedad, se revisaron datos sobre la detecci\u00f3n de estos virus, seg\u00fan estudios publicados y otros in\u00e9ditos de nueve ciudades argentinas y uno multic\u00e9ntrico. Los informes revisados indican que se detectaron rotavirus en 20% de 5 226 espec\u00edmenes (con un recorrido de 6 a 54% entre estudios tomados de ni\u00f1os hospitalizados por diarrea y en 9% de 6 587 espec\u00edmenes (recorrido de 5 a 22% entre estudios tomados de pacientes ambulatorios, miembros de poblaciones mixtas (ni\u00f1os hospitalizados y ambulatorios y sujetos de encuestas comunitarias. Los datos hospitalarios muestran que, si bien los virus se detectaron durante todo el a\u00f1o, en los meses de invierno (mayo a julio hubo un pico de intensidad cuando hasta la mitad de los ni\u00f1os con diarrea dieron resultados positivos a los rotavirus. En tres laboratorios se logr\u00f3 serotipificar para la prote\u00edna G 230 de 294 espec\u00edmenes positivos (78%; los resultados indican que el serotipo G1 fue el m\u00e1s com\u00fan (presente en 60% de los espec\u00edmenes serotipificados seguido del G2 (en 20%, G4 (en 14% y G3 (en 5%. Sobre la base de los datos obtenidos en el pa\u00eds, se estim\u00f3 que en 1991 en la Argentina hubo aproximadamente 84 500 visitas de pacientes ambulatorios (1 de cada 8 nacimientos y 21 000 hospitalizaciones de 4 d\u00edas en promedio (1 de cada 31 nacimientos asociadas con rotavirus, que en conjunto costaron unos US$27,7 millones. Estos datos preliminares muestran que la carga de enfermedad por rotavirus en los ni\u00f1os argentinos es muy pesada y podr\u00eda disminuirse con una vacuna segura y efectiva. Adem\u00e1s se necesita ampliar la [Outbreak of rotavirus gastroenteritis with high mortality, Nicaragua, 2005 Brote de gastroenteritis por rotavirus con alta mortalidad, Nicaragua, 2005](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000400008) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Juan Jos\u00e9 Amador 2008-04-01 \u00f1os de edad que provoc\u00f3 numerosas consultas, hospitalizaciones y muertes en Nicaragua. Se analiz\u00f3 si la vacunaci\u00f3n habr\u00eda evitado estos casos de enfermedad y fallecimiento, se buscaron factores de riesgo de muerte y se elabor\u00f3 un perfil cl\u00ednico de los ni\u00f1os hospitalizados con diarrea. M\u00c9TODOS: Se realiz\u00f3 un estudio de casos y controles para determinar si los ni\u00f1os que murieron tuvieron acceso a programas de vacunaci\u00f3n, como medida indirecta del acceso a la vacuna contra rotavirus. Se identificaron los factores de riesgo de muerte en los ni\u00f1os que fallecieron durante el brote en comparaci\u00f3n con los controles con diarrea sobrevivientes, emparejados seg\u00fan la edad. Se tomaron muestras de heces fecales, datos cl\u00ednicos y de vacunaci\u00f3n de los ni\u00f1os hospitalizados con diarrea para realizar el diagn\u00f3stico de rotavirus, elaborar el perfil cl\u00ednico y pronosticar el acceso futuro a una vacuna contra rotavirus. RESULTADOS: El brote ocurrido entre febrero y abril de 2005 ocasion\u00f3 47 470 consultas y 52 muertes. Aproximadamente 80% de los casos y controles y 60% de los ni\u00f1os hospitalizados con diarrea tuvieron acceso a la vacunaci\u00f3n programada y posiblemente tuvieron acceso a una vacuna contra rotavirus. Si en los programas de vacunaci\u00f3n se hubiera dispuesto de una vacuna de 85% de eficacia, se hubieran prevenido hasta 51% de los casos graves de rotavirus y hasta 68% de las muertes. El estudio de 35 pares de casos y controles demostr\u00f3 que la enfermedad grave, la desnutrici\u00f3n y la atenci\u00f3n por curanderos tradicionales fueron los factores de riesgo de muerte. Se encontr\u00f3 rotavirus en 42% de las muestras de ni\u00f1os hospitalizados, asociado con la enfermedad grave y la deshidrataci\u00f3n. CONCLUSIONES: El efecto de los brotes estacionales de la enfermedad por rotavirus podr\u00eda reducirse mediante la vacunaci\u00f3n contra rotavirus, el perfeccionamiento de los programas de rehidrataci\u00f3n oral y el entrenamiento de los curanderos tradicionales en el tratamiento correcto de [Regional meeting for the Americas assesses progress against rotavirus Reuni\u00f3n regional para las Am\u00e9ricas eval\u00faa el progreso contra los rotavirus](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004000100014) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) 2004-01-01 Full Text Available La diarrea provocada por la infecci\u00f3n por rotavirus es una de las principales causas de morbilidad y mortalidad en el mundo. Los rotavirus ocasionan un total de alrededor de 111 millones de casos de diarrea y 440 000 muertes, 82% de ellas en pa\u00edses en desarrollo. Solo en la Regi\u00f3n de las Am\u00e9ricas, los rotavirus causan aproximadamente 75 000 ingresos hospitalarios y 15 000 muertes cada a\u00f1o. Con el objetivo de evaluar la marcha de la lucha contra los rotavirus en la Regi\u00f3n, a principios de septiembre de 2003 se celebr\u00f3 en Lima, Per\u00fa, una reuni\u00f3n cuyos participantes examinaron la informaci\u00f3n epidemiol\u00f3gica, debatieron acerca de los adelantos alcanzados en el desarrollo de nuevas vacunas contra rotavirus y describieron sus experiencias con la vigilancia de la infecci\u00f3n rotav\u00edrica. En los pr\u00f3ximos a\u00f1os pueden aparecer en el mercado varias vacunas, entre ellas Rotarix (GlaxoSmithKline y RotaTeq (Merck. Ambas vacunas ya han pasado exitosamente por los estudios de fases I y II y en estos momentos se llevan a cabo extensos estudios de fase III. No obstante, a\u00fan no se conoce lo suficiente acerca del impacto econ\u00f3mico de la enfermedad, la efectividad en funci\u00f3n del costo que pueda llegar a alcanzar la vacunaci\u00f3n y la vigilancia de los rotavirus en el laboratorio. La reuni\u00f3n realizada en Lima gener\u00f3 varias recomendaciones, entre ellas algunas de car\u00e1cter general acerca de los estudios epidemiol\u00f3gicos sobre rotavirus, la metodolog\u00eda de los estudios de corte econ\u00f3mico y una base de datos para su vigilancia. En relaci\u00f3n con los laboratorios y las t\u00e9cnicas anal\u00edticas, las recomendaciones se centraron en las redes de laboratorios, el mejor momento para recolectar las muestras de heces y la manera de almacenar y procesar esas muestras. [A systematic review of anti-rotavirus pooled vaccine efficacy among countries with high vs titers. We observed correlation (r(2) P and IgA titers for vaccines (r(2) = 0.56; P = .005). Postimmunization anti-rotavirus IgA GMC vaccine efficacy. Efficacy during first 2 years of life was significantly lower among countries with IgA GMC a significant between IgA titers and rotavirus vaccine efficacy and hypothesize that a critical level of IgA antibody titer is associated with a sufficient level Brazil An\u00e1lisis de la relaci\u00f3n costo-efectividad de la vacunaci\u00f3n programada contra rotavirus en Brasil](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000400001) Full Text objective of this study was to conduct a cost-effectiveness analysis of a universal rotavirus vaccination program among children OBJETIVO: Analizar la relaci\u00f3n costo-efectividad de un programa universal de vacunaci\u00f3n contra rotavirus en ni\u00f1os de hasta 5 a\u00f1os en Brasil. M\u00c9TODOS: Se consider\u00f3 una cohorte hipot\u00e9tica anual de aproximadamente 3 300 000 reci\u00e9n nacidos con un seguimiento de 5 a\u00f1os. Mediante un modelo de \u00e1rbol de decisi\u00f3n se analizaron los posibles efectos cl\u00ednicos y econ\u00f3micos de la infecci\u00f3n por rotavirus con la vacunaci\u00f3n programada de ni\u00f1os y sin ella. Las probabilidades y los costos unitarios se tomaron de investigaciones publicadas y de los datos oficiales nacionales. Para evaluar el impacto de diferentes estimados de los par\u00e1metros clave se realiz\u00f3 un an\u00e1lisis de sensibilidad. El an\u00e1lisis se efectu\u00f3 tanto desde la perspectiva del sistema sanitario como de la sociedad. RESULTADOS: Se estim\u00f3 que el programa de vacunaci\u00f3n evitar\u00eda aproximadamente 1 735 351 (54% de los 3 210 361 casos de gastroenteritis por rotavirus y 703 (75% de las 933 muertes asociadas con la infecci\u00f3n por rotavirus en un per\u00edodo de 5 a\u00f1os. A un precio de la vacuna de 18,6 reales brasile\u00f1os (R$ por dosis, este programa costar\u00eda R$ 121 673 966 y ahorrar\u00eda R$ 38 536 514 en costos directos al sistema de salud p\u00fablica y R$ 71 778 377 en costos directos e indirectos a la sociedad. El costo estimado del programa por a\u00f1o de vida salvado ser\u00eda de R$ 1 028 y R$ 1 713, desde el punto de vista de la sociedad y del sistema de salud, respectivamente. CONCLUSIONES: La estrategia de vacunaci\u00f3n universal contra rotavirus present\u00f3 una buena relaci\u00f3n costo-efectividad seg\u00fan ambas perspectivas. Sin embargo, estos resultados son muy sensibles a cambios en la incidencia de diarreas, la proporci\u00f3n de casos graves, la cobertura de vacunaci\u00f3n y el precio de la vacuna. Crawford, Sue E.; are leading cause of severe, dehydrating gastroenteritis in children rotavirus over a addition, rotavirus infections can lead to (which is severe manifestations of acute A management of rotavirus infection focuses on the prevention and treatment of dehydration, although the use of antiviral and anti-emetic drugs can be indicated in some cases. PMID:29119972 [Evaluaci\u00f3n del impacto econ\u00f3mico de la vacuna antirrotav\u00edrica en Venezuela Assessment of the economic impact of the antiretroviral vaccine Text Available OBJETIVO: El objetivo de este estudio fue evaluar el costo de la atenci\u00f3n m\u00e9dica de la gastroenteritis por rotavirus y la relaci\u00f3n costo-efectividad de la vacuna antirrotav\u00edrica en la poblaci\u00f3n venezolana menor de 5 a\u00f1os de edad. M\u00c9TODOS: Se utiliz\u00f3 un modelo econ\u00f3mico que integra la informaci\u00f3n epidemiol\u00f3gica, la eficacia de la vacuna y los costos de atenci\u00f3n m\u00e9dica de la gastroenteritis por rotavirus, desde la perspectiva de la sociedad. Para determinar la efectividad de la vacuna, se estim\u00f3 el n\u00famero de casos de hospitalizaci\u00f3n, de consultas m\u00e9dicas y de muertes evitados despu\u00e9s de su administraci\u00f3n. La relaci\u00f3n costo-efectividad de la vacuna se evalu\u00f3 partiendo del n\u00famero de a\u00f1os de vida ajustados por discapacidad (AVAD y de casos evitados. RESULTADOS: En Venezuela, los servicios de salud invierten, aproximadamente, 4,2 millones de d\u00f3lares estadounidenses (US$ por a\u00f1o para cubrir los costos de atenci\u00f3n m\u00e9dica causados por el rotavirus. Un programa de vacunaci\u00f3n antirrotav\u00edrica evitar\u00eda aproximadamente el 52% (186 de las muertes, el 54% (7 232 de las hospitalizaciones y el 50% (55 168 de las consultas ambulatorias durante los primeros cinco a\u00f1os de vida, en una cohorte vacunada. Para un precio estimado de US$ 24 por r\u00e9gimen de vacuna, se genera una relaci\u00f3n costo-efectividad de US$ 1 352 por AVAD. CONCLUSIONES: Los resultados de este estudio apuntan a que la vacunaci\u00f3n antirrotav\u00edrica es una estrategia costoefectiva en la prevenci\u00f3n de la gastroenteritis por rotavirus en Venezuela, ya que puede evitar muertes y a\u00f1os de vida ajustados por discapacidad en la poblaci\u00f3n menor de cinco a\u00f1os de edad.OBJECTIVE: To assess the cost of medical care for rotavirus gastroenteritis and the cost-effectiveness of the antiretroviral vaccine in Venezuelan children under five. METHODS: We used an economic model that comprises epidemiologic information, vaccine efficacy, and the cost of medical care in connection with [Rotavirus morbidity and mortality in children in Brazil Morbilidad y mortalidad por rotavirus en ni\u00f1os en Brasil](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000200004) la epidemiolog\u00eda del rotavirus y estimar la morbilidad y la mortalidad asociadas con las infecciones por rotavirus en ni\u00f1os < 5 a\u00f1os de edad en Brasil en 2004, antes de incluir la vacuna contra el rotavirus en el Programa Nacional de Inmunizaciones (PNI. M\u00c9TODOS: Para estimar la morbilidad por rotavirus se revisaron los estudios publicados (1999-2006 que abordaban la incidencia de diarrea aguda en ni\u00f1os < 5 a\u00f1os de edad y la frecuencia de las infecciones por rotavirus en ni\u00f1os con diarrea en Brasil. Los casos de diarrea se dividieron en tres categor\u00edas de gravedad seg\u00fan el nivel de atenci\u00f3n que requirieron: casos leves que solo requirieron atenci\u00f3n domiciliaria, casos moderados que requirieron la visita a un servicio ambulatorio de salud y casos graves que requirieron hospitalizaci\u00f3n. Para estimar la mortalidad por rotavirus se utiliz\u00f3 el n\u00famero de muertes registradas por diarrea en ni\u00f1os de < 5 a\u00f1os, seg\u00fan el Sistema de Informaci\u00f3n sobre Mortalidad (SIM del Sistema \u00danico de Salud (SUS de Brasil, y se calcul\u00f3 la proporci\u00f3n de muertes causadas por este virus. RESULTADOS: Se estim\u00f3 que las infecciones por rotavirus causan anualmente 3 525 053 casos de diarrea, 655 853 visitas a servicios ambulatorios de salud, 92 453 hospitalizaciones y 850 muertes en ni\u00f1os < 5 a\u00f1os de edad en Brasil. CONCLUSIONES: Las infecciones por rotavirus constituyen una importante causa de morbilidad y mortalidad en Brasil. [Realidad y nuevos horizontes de la vacuna del virus del papiloma humano](https://www.openaire.eu/search/publication?articleId=od______1472::a09ac4cf255ae73a6b4363b1bbc0a6ad) Garc\u00eda G\u00f3mez, Nuria 2014-01-01 La vacuna frente al VPH es la primera vacuna destinada a la prevenci\u00f3n del c\u00e1ncer inducido por un virus, el CCU (problema de salud p\u00fablica mundial), y de lesiones precursoras. Disponemos de 2 vacunas profil\u00e1cticas: Gardasil\u00ae (frente a VPH 6, 11, 16 y 18) y Cervarix\u00ae (frente a VPH 16 y 18). El trabajo consiste en una revisi\u00f3n bibliogr\u00e1fica que tiene como objetivo conocer la situaci\u00f3n que vive actualmente la vacuna del VPH en Espa\u00f1a, utilizando como palabras clave virus, vacun... children worldwide. However, no correlate of vaccine efficacy (VE) has yet been established. This paper presents 2 analyses which aimed to investigate whether serum anti-RV IgA ELISA or 2 mo post-vaccination can serve as a correlate of efficacy against RVGE: (1) In a large Phase III efficacy trial (Rota-037), Prentice criteria whether a significant assessed immunogenicity at 1 or 2 mo post-vaccination in all or a sub-cohort of enrolled subjects and had at least 10 RVGE were in a meta-analysis to measure the between clinical Rota-037, IgA seropositivity post-vaccination of any or severe RVGE, however, the proportion only 43.6% and 32.7% respectively. This low proportion was due to the vaccine group effect observed in seronegative subjects. In the meta-analysis, clinical VE and VE1 was statistically significant. RV1 p\u00fablicos productores [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Akira Homma Full Text Available Los laboratorios p\u00fablicos productores de vacunas de Am\u00e9rica Latina y el Caribe han contribuido en diferente grado al control y a la erradicaci\u00f3n de las enfermedades prevenibles por vacunaci\u00f3n y varios est\u00e1n produciendo las vacunas que se aplican rutinariamente en los programas nacionales de inmunizaci\u00f3n, como la vacuna antituberculosa (a base del bacilo de Calmette-Gu\u00e9rin, BCG, la vacuna difteria-t\u00e9tanos-pertussis (DTP, el la vacuna antisarampionosa y la vacuna antipoliomiel\u00edtica oral. Gracias a los adelantos cient\u00edficos recientes, se prev\u00e9 un aumento importante del n\u00famero de vacunas seguras y eficaces que estar\u00e1n disponibles en un futuro cercano para uso en los programas normales de vacunaci\u00f3n. Sin embargo, los gastos asociados con el desarrollo de estas vacunas y con los derechos de propiedad intelectual que las protegen son cuantiosos. Adem\u00e1s, pocos laboratorios en Am\u00e9rica Latina poseen la capacidad t\u00e9cnica para investigar y elaborar estas vacunas. Tales factores tendr\u00e1n un impacto en la celeridad con que se incorporar\u00e1n en los esquemas de vacunaci\u00f3n de los pa\u00edses de la Regi\u00f3n. En la actualidad, los laboratorios p\u00fablicos productores de vacunas de la Regi\u00f3n no est\u00e1n capacitados para competir en este nuevo contexto y corren el riesgo de ser desplazados del mercado por completo. De ah\u00ed la necesidad de que cambien radicalmente su manejo gerencial y su capacidad cientificot\u00e9cnica, lo cual exige que los gobiernos se comprometan a mejorar y fortalecer aquellos aspectos pol\u00edticos y financieros que garanticen la participaci\u00f3n de los laboratorios nacionales en el suministro sostenible de vacunas a los programas de vacunaci\u00f3n, as\u00ed como en la investigaci\u00f3n, desarrollo y producci\u00f3n de vacunas nuevas [Vacuna Sint\u00e9tica contra la Malaria](http://revistamedicina.net/ojsanm/index.php/Revistamedicina/article/view/903) Text Available El doctor Manuel Elkin Patarroyo hace un recuento de lo que fueron sus primeros a\u00f1os de estudio y los primeros pasos que se dieron para fundar el Instituto de Inmunolog\u00eda, ayudado por muchos de los Acad\u00e9micos. Siempre ha querido representar al pueblo colombiano en sus valores de trabajo, disciplina, estudio, pensamiento y generosidad, en aras de un pueblo que sufre, que en definitiva es el objetivo del M\u00e9dico, el paciente. Posteriormente comenta qu\u00e9 es lo que se ha hecho con toda la profundidad que se merece pero con simpleza de palabras y en t\u00e9rminos sencillos, c\u00f3mo se desarroll\u00f3 la Vacuna Sint\u00e9tica contra la malaria: \u00bfPor qu\u00e9 malaria?, porque esta es una enfermedad de gran trascendencia; aclara que \u00e9l no le teme ni le molesta el cuestionamiento cient\u00edfico sobre el desarrollo de esta investigaci\u00f3n, por el contrario lo acepta y lo goza porque es el ejercicio intelectual; lo que s\u00ed le molesta es el morbo alrededor de ello, por esto pidi\u00f3 al doctor Mu\u00f1oz que al final se adelante un debate al respecto. Dice a continuaci\u00f3n que las vacunas tradicionales son biol\u00f3gicas como todo el mundo lo sabe, es el microorganismo causal mismo que se muta ose mata, pero que descomponiendo la estructura qu\u00edmica de sus mol\u00e9culas, con el concepto de la s\u00edntesis qu\u00edmica se podr\u00edan rehacer qu\u00edmicamente y ser utilizadas como vacuna. Decidieron entonces atacar el problema de la vacuna a trav\u00e9s de esta metodolog\u00eda creando la vacuna contra la malaria de la cual se conoce su estructura qu\u00edmica, y aclara que las vacunas qu\u00edmicas tienen otra ventaja, que son puras, con menos reacciones adversas que las tradicionales. Dice el doctor Patarroyo que decidieron aislar, e identificar m\u00e1s de la mitad de las prote\u00ednas del par\u00e1sito y dividiendo la muestra en dos fracciones, una de ellas se seleccion\u00f3 para averiguar su composici\u00f3n qu\u00edmica y la otra para saber cu\u00e1l podr\u00eda ser \u00fatil como vacuna. As\u00ed, fueron al Amazonas y all [Aproximaci\u00f3n al uso de hongos entomopat\u00f3genos y vacunas para el control sostenible de garrapatas en sistemas ganaderos: revisi\u00f3n](http://www.redalyc.org/articulo.oa?id=83743886006) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Ana Carolina Moncada Gonz\u00e1lez 2015-01-01 Full Text Available La resistencia desarrollada por las garrapatas frente a los acaricidas de s\u00edntesis, hace necesario replantear las estrategias utilizadas actualmen - te para su control. Los programas de manejo integrado de par\u00e1sitos se presentan como una alternativa que, al promover estrategias de con - trol basadas en la ecolog\u00eda y la epidemiolog\u00eda de cada especie de par\u00e1sito, reducen el riesgo de desarrollo de resistencia. Dichas estrategias incluyen la aplicaci\u00f3n de vacunas antigarrapata y hongos entomopat\u00f3genos que afectan la viabi - lidad y la reproducci\u00f3n en las garrapatas. Sin embargo, la informaci\u00f3n obtenida entre estudios sobre hongos y vacunas ha sido inconsistente, por lo que hoy en d\u00eda ambas representan \u00e1reas de investigaci\u00f3n bastante activas. El prop\u00f3sito de este trabajo consisti\u00f3 en realizar una revisi\u00f3n descriptiva sobre los mecanismos de acci\u00f3n de la vacuna antigarrapata y los hongos entomopat\u00f3genos, en la b\u00fasqueda de una po - sible complementariedad que permita el dise\u00f1o de planes de aplicaci\u00f3n conjunta, con miras a mejorar los resultados de control en sistemas ganaderos. En la primera parte del documento se revisa la actual problem\u00e1tica asociada al uso y abuso de los acaricidas de s\u00edntesis, haciendo un \u00e9nfasis particular en el tema de resistencia; posteriormente, se describen los mecanismos de acci\u00f3n de hongos y vacunas que afectan la re - producci\u00f3n y supervivencia en garrapatas, y se incluye informaci\u00f3n relevante sobre su eficacia. Se espera que la informaci\u00f3n aqu\u00ed recolectada, sirva como base para elaborar estudios que permitan identificar la utilidad de los hongos entomopat\u00f3genos y las vacunas antigarrapata al interior de los programas de manejo integrado de par\u00e1sitos en ganader\u00eda. [Vaccines against dengue: a review of current candidate vaccines at advanced development stages Vacunas contra el dengue: una revisi\u00f3n de las vacunas candidatas en etapas avanzadas de desarrollo](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007000300011) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Joachim Hombach 2007-04-01 Full Text Available Los esfuerzos sistem\u00e1ticos para desarrollar una vacuna contra el dengue comenzaron durante la Segunda Guerra Mundial, inspirados en el desarrollo exitoso de una vacuna contra la fiebre amarilla. Sin embargo, la falta de modelos adecuados de la enfermedad, la informaci\u00f3n incompleta acerca de los mecanismos patog\u00e9nicos y los insuficientes incentivos econ\u00f3micos han dificultado los avances. Debido al impacto actual del dengue en todo el mundo y su explosiva diseminaci\u00f3n, ha aumentado el inter\u00e9s en el desarrollo de vacunas contra el dengue y se ha avanzado considerablemente en el camino hacia la evaluaci\u00f3n cl\u00ednica de vacunas candidatas. La Iniciativa para la Investigaci\u00f3n en Vacunas, de la Organizaci\u00f3n Mundial de la Salud, est\u00e1 facilitando el desarrollo de y los ensayos con las vacunas candidatas. Las vacunas contra el dengue que se encuentran actualmente en etapas avanzadas de desarrollo son de tres tipos fundamentales: 1 vivas atenuadas; 2 vivas recombinantes; y 3 de subunidades e inactivadas. La mayor\u00eda de las vacunas en cartera son vivas atenuadas, siguiendo el camino exitoso de otras vacunas vivas contra flavivirus, especialmente de la desarrollada contra la fiebre amarilla. En general, las vacunas contra el dengue que se encuentran actualmente en desarrollo est\u00e1n bastante avanzadas y son muy diversas. Muy pronto comenzar\u00e1 la evaluaci\u00f3n de estas vacuna candidatas en ensayos de eficacia basados en poblaciones expuestas, lo que requerir\u00e1 resolver varios problemas t\u00e9cnicos, operacionales y regulatorios. [La vacuna en Cuba durante el gobierno de Someruelos](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::9c7220297c636745e06628ec37f2b47e) V\u00e1zquez Cienfuegos, Sigfrido 2004-01-01 La Real Expedici\u00f3n Filantr\u00f3pica de la Vacuna (1803-1806), dirigida por Francisco Javier de Balmis, se dirigi\u00f3 al Nuevo Mundo para paliar las epidemias de viruelas que hab\u00edan venido asolando Am\u00e9rica desde casi el mismo momento del Descubrimiento. Para entonces en la isla de Cuba ya se hab\u00eda iniciado una labor con el mismo objetivo por el m\u00e9dico cubano Tom\u00e1s Romay, apoyado en el fomento de la introducci\u00f3n y aplicaci\u00f3n de la vacuna por el marqu\u00e9s de Someruelos gobernador y capit\u00e1n general de la ... [PRACTICAS MEDICAS, PRACTICAS POLITICAS. ROSAS Y LA \u00abVACUNA INDIGENA\u00bb](http://www.revistas.usach.cl/ojs/index.php/historiasocial/article/view/319) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) MAR\u00cdA SILVIA DI LISCIA 2011-10-01 Full Text Available BUENOS AIRES, 1830. Se declara una epidemia de viruela entre los indios \u00abpampas\u00bb que est\u00e1n en la ciudad para honrar al Restaurador de las Leyes. Los caciques no disimulan su admiraci\u00f3n ante la valent\u00eda de Rosas, quien los visita sin alarma ante el contagio y los estimula a vacunarse para eliminar el temible mal. Un n\u00famero estimado en m\u00e1s de cien indios acepta, entonces, inmunizarse, coloc\u00e1ndose, seg\u00fan el testimonio de Parish, la \u00abvacuna a ind\u00edgenas \u00bb. Buenos Aires, 1833. Francisco X. Mu\u00f1iz, m\u00e9dico de la campa\u00f1a bonaerense, inicia las investigaciones con las que diez a\u00f1os despu\u00e9s se logra el redescubrimiento del cow pox, es decir, la viruela vacuna, llamada por Sarmiento \u00abla vacuna ind\u00edgena\u00bb. [Estudio de inmunogenicidad de la de vax-TyVi\u00ae en ratones](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200001&lng=es&nrm=iso&tlng=es) [Directory of Open Access Text Available Salmonella enterica serovar Typhi es un microorganismo que provoca m\u00e1s de 16 millones de casos de fiebre tifoidea con aproximadamente 600 000 muertes al a\u00f1o en todo el mundo. Dentro de las vacunas antitifo\u00eddicas la de polisac\u00e1rido capsular Vi ha encontrado, gracias a sus incuestionables ventajas, una gran aceptaci\u00f3n entre productores y consumidores. El presente trabajo aborda el estudio de inmunogenicidad de la vacuna antitifo\u00eddica cubana de polisac\u00e1rido Vi vax-TyVi\u00e2 en ratones. El estudio estuvo conformado por un grupo control no inoculado y un segundo grupo que recibi\u00f3 0,05 mL de la vacuna por v\u00eda intramuscular. Se tomaron muestras de sangre a los -3, 7, 14, 21, 28, 42, 56 y 84 d\u00edas. La actividad de anticuerpos IgG antipolisac\u00e1rido Vi de los sueros individuales fue determinada por ELISA. Los datos fueron analizados por grupo y por sexo y se calcul\u00f3 el porcentaje de seroconversi\u00f3n, consider\u00e1ndose respondedor aquel animal que al menos aumentara en cuatro veces su t\u00edtulo inicial. La respuesta de anticuerpos inducida por la vacuna mostr\u00f3 un aumento notable de los t\u00edtulos de IgG antipolisac\u00e1rido Vi en el grupo vacunado (100% de seroconversi\u00f3n, mientras que el grupo control no increment\u00f3 sus niveles m\u00ednimos iniciales (0% de respondedores. Aunque m\u00e1s dispersa, la respuesta de anticuerpos antiVi fue significativamente mayor en las hembras que en los machos. [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Alejandro Roque Vald\u00e9s 2004-04-01 Full Text Available El presente trabajo es un art\u00edculo de revisi\u00f3n que pretende abordar un tema tan controvertido como actual: la posible asociaci\u00f3n causal que se ha querido establecer entre el autismo y las vacunas infantiles. A partir de la \u00faltima d\u00e9cada del siglo XX se producen una serie de cambios en la clasificaci\u00f3n, nomenclatura y criterios diagn\u00f3sticos del autismo. Los hallazgos de estudios epidemiol\u00f3gicos llevados a cabo bajo estos nuevos ponderados han revelado que las tasas de prevalencia del autismo son en la actualidad muy superiores a las de hace 15 a\u00f1os. Entre los factores que se esgrimen para explicar este fen\u00f3meno est\u00e1n las vacunas, y entre los mecanismos que se invocan para tratar de inculpar a las vacunas en la etiolog\u00eda del autismo est\u00e1n el exceso de mercurio derivado del tiomersal que se emplea como conservante de las mismas y procesos autoinmunes que de forma directa o indirectamente act\u00faan sobre el SNC, induciendo lesiones a nivel de la mucosa intestinal, lo cual favorecer\u00e1 la absorci\u00f3n de macromol\u00e9culas, ant\u00edgenos y toxinas que una vez en el torrente sangu\u00edneo llegar\u00edan al SNC produciendo all\u00ed las lesiones responsables de la g\u00e9nesis del autismo. [Inhibition of rotavirus the leading cause of severe diarrheal disease in young children. Intestinal mucosal IgA layer proteins, VP4 and VP7, which are responsible do the complex. The attachment of 7D9 IgA to VP6 introduces a conformational change in protection in vivo by viral transcription at the start of the a rotavirus vaccination program in Mexico Impacto econ\u00f3mico de un programa de vacunaci\u00f3n contra rotavirus en Dagna Constenla 2009-06-01 vacunar. A partir de datos nacionales publicados se estim\u00f3 el n\u00famero de casos y muertes por rotavirus, los a\u00f1os de vida ajustados por la discapacidad (AVAD que se evitar\u00edan y la relaci\u00f3n costo-efectividad incremental (US$/AVAD de una cohorte anual hipot\u00e9tica de 2 285 000 ni\u00f1os; se parti\u00f3 de algunos supuestos sobre el costo, la cobertura y las tasas de eficacia. RESULTADOS: Con una cobertura de 93% y un precio de la vacuna de US$ 16,00 por esquema (dos dosis, se estima que un programa de vacunaci\u00f3n contra rotavirus en M\u00e9xico evitar\u00eda 651 muertes (0,28 muertes por 1 000 ni\u00f1os, 13 833 hospitalizaciones (6,05 hospitalizaciones por 1 000 ni\u00f1os y 414 927 visitas de consulta externa (182 consultas por 1 000 ni\u00f1os por gastroenteritis aguda asociada a rotavirus (GAR. La vacunaci\u00f3n podr\u00eda reducir la carga econ\u00f3mica por GAR en M\u00e9xico al evitar gastos por US$ 14 millones (71% de la carga total por atenci\u00f3n sanitaria. A un precio de US$ 16,00 por esquema, la relaci\u00f3n costo-efectividad ser\u00eda de US$ 1 139,00 por AVAD evitado. Una reducci\u00f3n en el precio del programa de vacunaci\u00f3n contra rotavirus (US $8,00 por esquema generar\u00eda una menor costo-efectividad incremental de US$ 303,00 por AVAD evitado. CONCLUSIONES: Un programa nacional de vacunaci\u00f3n contra rotavirus en M\u00e9xico reducir\u00eda la incidencia y la mortalidad infantiles y ser\u00eda altamente efectivo en funci\u00f3n del costo, seg\u00fan los umbrales de las intervenciones de costo-efectividad de la Organizaci\u00f3n Mundial de la Salud. [Vaccines against dengue: a review of current candidate vaccines at advanced development stages Vacunas contra el dengue: una revisi\u00f3n de las vacunas candidatas en etapas avanzadas de desarrollo](https://www.openaire.eu/search/publication?articleId=doajarticles::d1c5d56abb3c55f6f0d140a1ec694442) Joachim Hombach 2007-01-01 Los esfuerzos sistem\u00e1ticos para desarrollar una vacuna contra el dengue comenzaron durante la Segunda Guerra Mundial, inspirados en el desarrollo exitoso de una vacuna contra la fiebre amarilla. Sin embargo, la falta de modelos adecuados de la enfermedad, la informaci\u00f3n incompleta acerca de los mecanismos patog\u00e9nicos y los insuficientes incentivos econ\u00f3micos han dificultado los avances. Debido al impacto actual del dengue en todo el mundo y su explosiva diseminaci\u00f3n, ha aumentado el inter\u00e9s e... [Prescripci\u00f3n de vacunas no incluidas en el calendario vacunal en la Comunitat Valenciana durante el per\u00edodo 2004-2009](http://www.redalyc.org/articulo.oa?id=17020115007) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Ana Ruiz Palacio 2011-01-01 Full Text Available Fundamentos, En el marco de las pol\u00edticas de uso racional del medicamento, y al objeto de conseguir una gesti\u00f3n eficiente de los programas de vacunaciones, el objetivo de este trabajo es conocer el n\u00famero de envases de las vacunas prescritas no incluidas en los programas de vacunaci\u00f3n en la Comunitat Valenciana y en sus departamentos de salud, as\u00ed como el gasto que produjeron en 2009, y analizar la evoluci\u00f3n desde 2004, centrando el an\u00e1lisis en la vacuna heptavalente conjugada frente al Streptococcus pneumoniae en menores de dos a\u00f1os. M\u00e9todo, Estudio descriptivo retrospectivo de las vacunas prescritas mediante receta en la Comunitat Valenciana durante el a\u00f1o 2009 y su evoluci\u00f3n desde 2004. Variables, n\u00famero de envases, tipo de beneficiario (activo/pensionista, departamento y gasto generado. Fuentes, Gestor de Prestaci\u00f3n Farmac\u00e9utica (GAIA y Sistema Informaci\u00f3n Poblacional (SIP. Resultados: En 2009 la prescripci\u00f3n mediante receta de vacunas no incluidas en los programas de vacunaci\u00f3n gener\u00f3 un gasto de 683.445,71 ] correspondiente a 17.353 envases, lo que supuso el 87! del total del gasto en vacunas recetadas. La vacuna frente al S. pneumoniae gener\u00f3 el 72! del gasto total de las vacunas no incluidas en el calendario. La evoluci\u00f3n 2004-2009 muestra un aumento del gasto de 735.334 ] (24,66! en 2005 a partir del cual se produjo un descenso acusado y paulatino que alcanz\u00f3 los 1.562.650,67 ] (-228.64!. El gasto por departamentos para la vacuna del neumococo conjugada heptavalente por mil ni\u00f1os/as menores de dos a\u00f1os oscil\u00f3 entre 17.377 y 324 ]. Conclusiones: La tendencia descendente del gasto en recetas prescritas se mantuvo durante 2009, fundamentalmente de vacunas conjugadas frente a neumococo. No obstante, se observ\u00f3 gran variabilidad interdepartamental en las tasas de prescripci\u00f3n que debe ser corregida. [Los laboratorios p\u00fablicos productores de vacunas: el nuevo paradigma](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998001000001) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Akira Homma 1998-10-01 Full Text Available Los laboratorios p\u00fablicos productores de vacunas de Am\u00e9rica Latina y el Caribe han contribuido en diferente grado al control y a la erradicaci\u00f3n de las enfermedades prevenibles por vacunaci\u00f3n y varios est\u00e1n produciendo las vacunas que se aplican rutinariamente en los programas nacionales de inmunizaci\u00f3n, como la vacuna antituberculosa (a base del bacilo de Calmette-Gu\u00e9rin, BCG, la vacuna difteria-t\u00e9tanos-pertussis (DTP, el la vacuna antisarampionosa y la vacuna antipoliomiel\u00edtica oral. Gracias a los adelantos cient\u00edficos recientes, se prev\u00e9 un aumento importante del n\u00famero de vacunas seguras y eficaces que estar\u00e1n disponibles en un futuro cercano para uso en los programas normales de vacunaci\u00f3n. Sin embargo, los gastos asociados con el desarrollo de estas vacunas y con los derechos de propiedad intelectual que las protegen son cuantiosos. Adem\u00e1s, pocos laboratorios en Am\u00e9rica Latina poseen la capacidad t\u00e9cnica para investigar y elaborar estas vacunas. Tales factores tendr\u00e1n un impacto en la celeridad con que se incorporar\u00e1n en los esquemas de vacunaci\u00f3n de los pa\u00edses de la Regi\u00f3n. En la actualidad, los laboratorios p\u00fablicos productores de vacunas de la Regi\u00f3n no est\u00e1n capacitados para competir en este nuevo contexto y corren el riesgo de ser desplazados del mercado por completo. De ah\u00ed la necesidad de que cambien radicalmente su manejo gerencial y su capacidad cientificot\u00e9cnica, lo cual exige que los gobiernos se comprometan a mejorar y fortalecer aquellos aspectos pol\u00edticos y financieros que garanticen la participaci\u00f3n de los laboratorios nacionales en el suministro sostenible de vacunas a los programas de vacunaci\u00f3n, as\u00ed como en la investigaci\u00f3n, desarrollo y producci\u00f3n de vacunas nuevasIn Latin America and the Caribbean, public laboratories that produce vaccines have contributed in varying degrees to the control of vaccine-preventable diseases, and several of them [El estado actual de las vacunas contra las drogas](http://riiad.org/index.php/riiad/article/view/riiad.2017.2.05) [Directory of Open Access Journals Full Text Available Introducci\u00f3n: por lo com\u00fan, la adicci\u00f3n a las drogas se trata con psicoterapia y farmacolog\u00eda que evita la uni\u00f3n de las sustancias psicoactivas a receptores espec\u00edficos en el cerebro. El resultado de estos tratamientos no ha sido del todo satisfactorio, por lo que el desarrollo de terapias m\u00e1s eficaces representa un reto constante para tratar las adicciones. Una alternativa a la farmacolog\u00eda antiadictiva es la vacunaci\u00f3n activa dirigida contra las sustancias de abuso. Objetivo: esta revisi\u00f3n re\u00fane la informaci\u00f3n disponible sobre los fundamentos y avances cient\u00edficos en la generaci\u00f3n de una terapia inmunol\u00f3gica, que coadyuve al tratamiento de la adicci\u00f3n a sustancias como la hero\u00edna-morfina, la coca\u00edna, la nicotina y la anfetamina. M\u00e9todo: se consideraron los reportes cient\u00edficos disponibles en PubMed -de 2005 a abril de 2017-, sobre los fundamentos, la metodolog\u00eda empleada, los estudios precl\u00ednicos y cl\u00ednicos, y los resultados obtenidos en dichas investigaciones para generar vacunas contra las drogas. Resultados: las vacunas lograron mitigar los efectos producidos por las sustancias en los estudios precl\u00ednicos en modelos de estudio en animales; sin embargo, con pacientes humanos los resultados no han sido del todo satisfactorios. Discusi\u00f3n y conclusiones: a pesar de los esfuerzos realizados por diferentes grupos de investigaci\u00f3n y compa\u00f1\u00edas farmac\u00e9uticas para generar vacunas terap\u00e9uticas contra el uso de diferentes drogas, ninguna ha alcanzado la fase III de estudios cl\u00ednicos. En la actualidad, se contin\u00faa con los esfuerzos para lograr que las vacunas contra las adicciones alcancen su m\u00e1xima eficiencia y eficacia, y contribuyan al tratamiento de la adicci\u00f3n a las drogas. Llor Vila, Carles 2005-01-01 La vacunaci\u00f3n antigripal, con m\u00e1s de 50 a\u00f1os de existencia, tiene una eficacia, una efectividad y una seguridad contrastadas, pero la respuesta inmunitaria oscila entre el 60 y el 90%, siendo algo menor en la poblaci\u00f3n anciana. Cl\u00e1sicamente se han utilizado las vacunas inactivadas trivalentes en las campa\u00f1as de vacunaci\u00f3n antigripal pero se considera que su aceptabilidad no es \u00f3ptima. Desde hace unos a\u00f1os se est\u00e1n investigando otros tipos de vacunas antigripales con el objetivo de mejorar su ... [Evaluaci\u00f3n de la informaci\u00f3n sanitaria disponible en internet sobre la vacuna antigripal](https://www.openaire.eu/search/publication?articleId=doajarticles::10bf287ae0007ca1c04dfbe102687a3b) I. Hern\u00e1ndez-Garc\u00eda; R. Gonz\u00e1lez Celador 2014-01-01 Fundamento: La calidad de la informaci\u00f3n sanitaria en internet preocupa a gobiernos y usuarios. Nuestro objetivo fue determinar en qu\u00e9 medida la informaci\u00f3n sobre la vacuna antigripal se adhiere al gold est\u00e1ndar representado por lo establecido por el Ministerio de Sanidad espa\u00f1ol. Material y m\u00e9todos: Entre junio-julio 2014 se evalu\u00f3 la adhesi\u00f3n al gold est\u00e1ndar de la informaci\u00f3n sobre indicaciones, efectos adversos y contraindicaciones de la vacuna. Dicha informaci\u00f3n se obtuvo a trav\u00e9s de Goo... [Identidad de la vacuna contra Streptococcus pneumoniae \"Quimi-Vio\" mediante la t\u00e9cnica Dot Blot empleando los anticuerpos monoclonales contra los polisac\u00e1ridos capsulares 1,5, 6B, 14 y 19F de la bacteria](http://revistabionatura.com/2017.02.01.7.html) of Open Access Journals Full Text Available Streptococcus pneumoniae (neumococo constituye una de las principales causas de enfermedades infecciosas bacterianas, particularmente en ni\u00f1os menores de 2 a\u00f1os de edad. Basadas en el polisac\u00e1rido capsular (PsC, su principal factor de virulencia, existen dos tipos de vacunas aprobadas para uso en humanos: las vacunas polisacar\u00eddicas planas y las vacunas polisacar\u00eddicas conjugadas. Quimi-Vio, la vacuna antineumoc\u00f3cica cubana, pertenece al segundo grupo y est\u00e1 compuesta por los PsC de los siete serotipos de mayor incidencia y circulaci\u00f3n en Cuba (1, 5, 6B, 14, 18C, 19F y 23F. El objetivo de este trabajo fue realizar el ensayo de identidad de la vacuna cubana Quimi-Vio empleando los AcM contra los PsC 1, 5, 6B, 14, y 19F de Sp obtenidos recientemente en el Instituto Finlay de Vacunas, teniendo en cuenta que los Ensayos de identidad de las vacunas son requisito indispensable para la liberaci\u00f3n final de los lotes. La t\u00e9cnica empleada para la realizaci\u00f3n del ensayo de identidad de Quimi-Vio fue el Dot Blot, donde empleando membrana de Nitrocelulosa se realiz\u00f3 la captura de tres lotes de vacuna Quimi-Vio y como control positivo de la t\u00e9cnica los respectivos PsC de los serotipos 1, 5, 6B, 14, y 19F sin conjugar y una vacuna comercial Prevenar-13. Para la identidad de los PsC de neumococo se emplearon los respectivos AcM a una concentraci\u00f3n de 10\u00b5g/mL y como segundo anticuerpo anti IgG de rat\u00f3n conjugado a peroxidasa teniendo en cuenta que los AcMs empleados son murinos. Cada AcM fue capaz de identificar de forma altamente especifica al PsC homologo (mismo serotipo, tanto en su forma no conjugada y monovalente como en el contexto de las vacunas Quimi-Vio y Prevenar 13V, donde adem\u00e1s de estar conjugado al TT se encuentra mezclado con otros PsC de forma multivalente. La t\u00e9cnica Dot Blot empleando los AcMs contra los PsC serotipos 1, 5,6B, 14 y 19F permite identificar de forma espec\u00edfica cada PsC en la formulaci\u00f3n multivalente, por lo [Eficacia de la vacuna meningoc\u00f3cica de polisac\u00e1rido del grupo C](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1135-57271997000200003) [Directory of Open Gonz\u00e1lez Enr\u00edquez Jes\u00fas 1997-01-01 Full Text Available FUNDAMENTO: Este trabajo consiste esencialmente en una revisi\u00f3n sistem\u00e1tica de la literatura cient\u00edfica sobre los efectos, intensidad y duraci\u00f3n de la respuesta serol\u00f3gica, as\u00ed como sobre la eficacia, efectividad y seguridad de la vacuna meningoc\u00f3cica de polisac\u00e1rido capsular del grupo C. M\u00c9TODOS: B\u00fasqueda en repertorio MEDLINE en el periodo 1970-1996. B\u00fasqueda espec\u00edfica de ensayos cl\u00ednicos aleatorizados y estudios de intervenci\u00f3n prospectivos en humanos con vacunas de polisac\u00e1ridos capsulares de meningococo en el mismo repertorio y periodo. An\u00e1lisis cr\u00edtico de literatura cient\u00edfica y s\u00edntesis de evidencia. RESULTADOS: La vacuna de polisac\u00e1rido capsular del serogrupo C es considerada segura y ha mostrado una eficacia superior al 85% en adultos y ni\u00f1os mayores, 70% (IC95%: 5-91% en ni\u00f1os menores de 5 a\u00f1os y 55% (IC90%: 14-76% en ni\u00f1os de 2-3 a\u00f1os. La vacuna no se ha mostrado eficaz en ni\u00f1os menores de 2 a\u00f1os. La duraci\u00f3n de niveles de anticuerpos protectores disminuye con la edad. La proporci\u00f3n de ni\u00f1os menores de 6 a\u00f1os efectivamente protegidos al a\u00f1o de la vacunaci\u00f3n es baja. La vacunaci\u00f3n no limita la respuesta serol\u00f3gica de vacunaciones ulteriores. CONCLUSIONES: La vacuna meningoc\u00f3cica de polisac\u00e1rido capsular del serogrupo C est\u00e1 indicada en adultos y ni\u00f1os mayores de 2 a\u00f1os como protecci\u00f3n contra la enfermedad meningoc\u00f3cica causada por este serogrupo en situaciones de alto riesgo de enfermedad. La escasa protecci\u00f3n que ofrece la vacuna en los menores de 2 a\u00f1os, la limitada eficacia en menores de 5 a\u00f1os y la corta duraci\u00f3n de la inmunidad que confiere a estas edades, hace que la vacunaci\u00f3n rutinaria no est\u00e9 recomendada y que la vacuna se use fundamentalmente en el control de brotes epid\u00e9micos causados por serogrupo C. [Modulation of rotavirus diarrhea are about 2.2 million; children are the most vulnerable age group to severe gastroenteritis, representing group A rotaviruses as the main cause of disease. One of the main factors of rotavirus pathogenesis is the NSP4 protein, which has viral and incidence reinfections. In this we discuss in detail about the rotavirus pathogenesis species combination prevention or modulation of rotavirus severe gastroenteritis. [VARIABILIDAD EN LA NOTIFICACI\u00d3N DE REACCIONES ADVERSAS A LAS VACUNAS DE LA GRIPE PAND\u00c9MICA Y ESTACIONAL. TEMPORADAS 2009-2010 Y 2010-2011, COMUNITAT VALENCIANA](http://www.redalyc.org/articulo.oa?id=17023106004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Ana Mar\u00eda Alguacil Ramos 2012-01-01 Full Text Available Fundamentos: La p\u00e9rdida de confianza en la seguridad de las vacunas derivada de situaciones de alarma, como en el caso de la gripe pand\u00e9mica, puede afectar tanto a las coberturas vacunales como a la sensibilidad frente a la notificaci\u00f3n de las sospechas de reacciones adversas asociadas a vacunas (SRAAV. El objetivo del trabajo es describir los efectos adversos a la vacuna frente a la gripe pand\u00e9mica notificados en la temporada 2009-2010 y comparar si existen diferencias con los descritos con la vacuna de la gripe estacional en las temporadas 2009-2010 y 2010-2011 en la Comunitat Valenciana (CV. M\u00e9todos: Se realiz\u00f3 un estudio descriptivo de los individuos vacunados frente a la gripe que presentaron alguna SRAAV a la vacuna antigripal y que fue notificada a trav\u00e9s del Sistema de Informaci\u00f3n Vacunal, durante las temporadas 2009-2010 (incluyendo la vacunaci\u00f3n pand\u00e9mica y 2010-2011 en CV. se calcularon las tasas de notificaci\u00f3n de sospechas de reacciones adversas asociadas a vacunas por cada mil dosis de vacunas administradas y sus intervalos de confianza al 95%. Resultados: Durante el periodo 2009-2010 la tasa de notificaci\u00f3n de SRAAV para la vacuna de la gripe estacional fue de 0,02 por mil dosis administradas, para la vacuna pand\u00e9mica de 0,95. En el periodo 2010-2011 la tasa para la vacuna de la gripe estacional fue de 0,04 por mil. Conclusiones: Durante las temporadas analizadas se increment\u00f3 el n\u00famero de notificaciones de SRAAV para las vacunas pand\u00e9micas en comparaci\u00f3n con el resto de vacunas antigripales. La mayor tasa de notificaci\u00f3n de SRAAV correspondi\u00f3 al grupo de profesionales sociosanitarios, tanto para las vacunas frente a la gripe estacional como pand\u00e9- mica. [Registro de ensayos con vacunas del Programa Mundial de Vacunas e Inmunizaci\u00f3n de la OMS](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891998001000006) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Robertson S. E. 1998-01-01 Full Text Available En 1995, el Programa Mundial de Vacunas e Inmunizaci\u00f3n de la OMS estableci\u00f3 un registro para ensayos con vacunas. En septiembre de 1996, este registro conten\u00eda 50 ensayos de vacunaci\u00f3n patrocinados por la OMS, de los cuales 25 (50% eran estudios ya terminados. Las vacunas que se hab\u00edan estudiado con mayor frecuencia fueron las de sarampi\u00f3n (9 ensayos, poliovirus (8 ensayos, c\u00f3lera (8 ensayos, Escherichia coli enterotox\u00edgena (4 ensayos y neumococo (4 ensayos. Casi 80% de estos ensayos se llevaron a cabo en pa\u00edses en desarrollo, principalmente en el \u00c1frica. En los 25 ensayos ya terminados, los resultados investigados fueron la respuesta inmunitaria (24 ensayos, las reacciones adversas (13 ensayos, la morbilidad (4 ensayos y la mortalidad (1 ensayo. La OMS contribuy\u00f3 a estos ensayos con el aporte indirecto de fondos, ayuda con el dise\u00f1o metodol\u00f3gico, visitas a las localidades, el an\u00e1lisis de los datos, la adquisici\u00f3n de vacunas y la investigaci\u00f3n de su potencia. [Vacuna contra el VPH (HPV Vaccine)](https://www2c.cdc.gov/podcasts/player.asp?f=8630175) [Centers for Disease Control (CDC) Podcasts](http://www2c.cdc.gov/podcasts/search.asp) 2013-07-25 Desde el 2006, hay una vacuna que protege contra los tipos de VPH que causan c\u00c3\u00a1ncer con mayor frecuencia. Este podcast habla sobre la importancia de que los padres hablen con los proveedores de atenci\u00c3\u00b3n m\u00c3\u00a9dica de sus hijos sobre ponerles la vacuna Created: 7/25/2013 by MMWR. Date Released: 11/4/2013. [Evaluaci\u00f3n de la toxicidad por dosis \u00fanica y tolerancia local de la vacuna vax-SPIRAL\u00ae en ratas Sprague Dawley](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2004000200002&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Juan F. Infante 2004-04-01 Full Text Available Las pruebas precl\u00ednicas de toxicidad en dosis \u00fanica y en dosis repetidas brindan una valiosa informaci\u00f3n sobre la seguridad del producto, al incluir el estudio macrosc\u00f3pico e histopatol\u00f3gico de \u00f3rganos importantes, as\u00ed como evaluaciones de las v\u00edas de administraci\u00f3n y el r\u00e9gimen de dosificaci\u00f3n. Cuba desarroll\u00f3 una vacuna polivalente de c\u00e9lulas inactivadas qu\u00edmicamente adyuvadas con hidr\u00f3xido de aluminio, vax-SPIRAL\u00ae. Esta vacuna presenta ventajas en relaci\u00f3n con otras vacunas como la procedente de la antigua URSS. El esquema de vacunaci\u00f3n para humanos consiste en dos dosis de 0,5 mL, separadas por un intervalo \u00f3ptimo de seis semanas. El objetivo de este estudio de toxicidad en ratas Sprague Dawley fue determinar la toxicidad potencial, letalidad, \u00f3rganos y sistemas susceptibles y otros eventos adversos, as\u00ed como la toxicidad en el sitio de inoculaci\u00f3n despu\u00e9s de la administraci\u00f3n de una dosis de la vacuna en estudio. Los resultados indicaron que, bajo las condiciones en estudio y seg\u00fan los criterios establecidos para evaluar los datos obtenidos, la vacuna antileptospir\u00f3sica trivalente no produce efectos t\u00f3xicos en el modelo animal usado. Las \u00fanicas alteraciones encontradas fueron formaciones granulomatosas a nivel del sitio de inoculaci\u00f3n. Estas formaciones han sido reportadas como pertenecientes al adyuvante de dep\u00f3sito (hidr\u00f3xido de aluminio, tambi\u00e9n usado en otras vacunas de aplicaci\u00f3n parenteral. [La vacuna contra el virus del papiloma humano](https://www.openaire.eu/search/publication?articleId=od______3040::cc271e44d67bb301b8673ae704eb1321) Tobar Ruiz, Mar\u00eda 2015-01-01 La carciog\u00e9nesis est\u00e1 condicionada por factores dependientes del virus como de los h\u00e1bitos del hu\u00e9sped. En cuanto a la vacunaci\u00f3n se han descubierto vacunas seguras y eficaces, siendo las dos vacunas destacadas la tetravalente o Gardasil y la bivalente o Cervarix. E nfermer\u00eda es la profesional que administra la vacuna y conoce los efectos adversos posibl es a causa de su administraci\u00f3n, y es por esa raz\u00f3n por la que mi inter\u00e9s se centr\u00f3 en la vacunaci\u00f3n. [Vacuna contra la fiebre hemorr\u00e1gica argentina Candid#1 producida en Inmunogenicidad y A. Enria 2010-06-01 Full Text Available Se realiz\u00f3 un estudio cl\u00ednico en 946 voluntarios humanos sanos, donde se compar\u00f3 la vacuna Candid#1 producida en Argentina con la elaborada en EE.UU., que hab\u00eda sido utilizada en estudios previos. Como objetivo primario se evalu\u00f3 la equivalencia en la eficacia utilizando como marcador subrogante a la inmunogenicidad medida por detecci\u00f3n de anticuerpos neutralizantes. Como objetivo secundario se evalu\u00f3 la equivalencia en inocuidad comparando las tasas de reacciones adversas. Ambas vacunas mostraron una tasa equivalente de inmunogenicidad ligeramente superior al 95.5%, que es la eficacia estimada para Candid #1 en estudios previos. No se observaron eventos adversos graves relacionados con la vacuna. Los eventos adversos generales considerados relacionados fueron de escasa significaci\u00f3n cl\u00ednica y de resoluci\u00f3n espont\u00e1nea o con tratamiento sintom\u00e1tico; se presentaron en los receptores de ambas vacunas en tasas equivalentes (29.9% para la vacuna fabricada en la Argentina y 35.0% para la fabricada en EE.UU., e incluyeron: cefalea, decaimiento, mialgias, plaquetopenia leve (< 150 000 plaquetas/mm\u00b3, n\u00e1useas y/o v\u00f3mitos, leucopenia leve (< 4 000 blancos/mm\u00b3, fiebre, dolor retroocular, mareos, microhematuria, lumbalgia y exantema. Estos resultados indican que la vacuna Candid #1 elaborada en la Argentina es equivalente a la elaborada en los EE.UU. Este estudio permiti\u00f3 el registro del biol\u00f3gico producido en la Argentina ante la autoridad regulatoria del pa\u00eds (ANMAT. [Vacunas de bacterias recombinantes vivas](https://www.openaire.eu/search/publication?articleId=od______3272::e04c2a8ca070b76a97f8c299cefc6434) Blanco Le\u00f3n, Marina 2016-01-01 La vacunaci\u00f3n es uno de los logros m\u00e1s importantes en la historia de la medicina, que ha ido evolucionando a lo largo de los a\u00f1os permitiendo una reducci\u00f3n significativa de la mortalidad infantil, una disminuci\u00f3n de la incidencia de enfermedades e incluso la erradicaci\u00f3n de algunas de ellas en pa\u00edses enteros. Las vacunas de nueva generaci\u00f3n surgen para reducir o eliminar las carencias de las vacunas \"tradicionales\". T\u00e9cnicas biotecnol\u00f3gicas basadas en el ADN recombinante han dado lugar, entre... [Un caso de osteocondritis costal t\u00edfica tratado con vacunas y antivirus](https://www.openaire.eu/search/publication?articleId=od______1326::8fd162326a4cf806bef07884700a3945) Lleras Acosta, F.; Rueda H., Alfonso 2011-01-01 Por considerala de importancia pr\u00e1ctica, presentamos la historiacl\u00ednica de una enferma afectada de osteocondritis costal de origen Eberthiano, tratada con \u00e9xito completo por las autovacunas y antivirus, Debemos esta interesante observaci\u00f3n al Dr. Juan N. Carpas y al interno de su servicio de mujeres, Sr. Azuero, quienes galantemente nos suministraron los datos cl\u00ednicos y las observaciones relativas a los efectos producidos por las vacunas. [Potential cost-effectiveness of vaccination for rotavirus gastroenteritis in eight Latin American and Caribbean countries Efectividad potencial en funci\u00f3n del costo de la vacunaci\u00f3n contra la gastroenteritis por rotavirus en ocho pa\u00edses de Am\u00e9rica Latina y el Caribe](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892007000300003) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Richard D. Rheingans 2007-04-01 , Chile, Honduras, M\u00e9xico, Panam\u00e1, Rep\u00fablica Dominicana y Venezuela. M\u00c9TODOS: Se elabor\u00f3 un modelo econ\u00f3mico para estimar la efectividad en funci\u00f3n del costo de la vacunaci\u00f3n, desde la perspectiva del sistema de salud, a partir de las constancias epidemiol\u00f3gicas nacionales oficiales y publicadas, los estimados de costos espec\u00edficos de cada pa\u00eds y los datos de eficacia de la vacuna. El modelo se aplic\u00f3 a los primeros cinco a\u00f1os de vida de la cohorte de nacidos en 2003 en cada uno de esos pa\u00edses. La principal medida de salud fueron los a\u00f1os de vida ajustados por discapacidad (AVAD y la principal medida sint\u00e9tica fue el costo incremental por AVAD evitado. Se emple\u00f3 una tasa de descuento de 3% para el pron\u00f3stico de los costos y beneficios. El impacto de la incertidumbre relacionada con las variables clave sobre la efectividad en funci\u00f3n del costo se realiz\u00f3 mediante el an\u00e1lisis de sensibilidad. RESULTADOS: Seg\u00fan los estimados obtenidos mediante el modelo econ\u00f3mico, la vacunaci\u00f3n podr\u00eda evitar m\u00e1s de 65% de las consultas m\u00e9dicas, de las muertes y del costo de tratamiento asociados con la gastroenteritis por rotavirus en los ocho pa\u00edses analizados. Con un costo total de US$ 24,00 (por las dos dosis de la vacuna, la raz\u00f3n incremental de la efectividad en funci\u00f3n del costo vari\u00f3 entre US$ 269/AVAD en Honduras y US$ 10 656/AVAD en Chile. Las razones de la efectividad en funci\u00f3n del costo fueron sensibles a las diversas hip\u00f3tesis sobre el precio de la vacuna, la mortalidad y la eficacia de la vacuna. CONCLUSIONES: La vacunaci\u00f3n permitir\u00eda reducir eficazmente la carga de morbilidad y los costos de la atenci\u00f3n sanitaria de la gastroenteritis por rotavirus en los pa\u00edses analizados de Am\u00e9rica Latina y el Caribe. Desde la perspectiva de los sistemas de salud, se prev\u00e9 que la vacunaci\u00f3n universal de todos los ni\u00f1os ser\u00e1 efectiva en funci\u00f3n del costo, seg\u00fan los est\u00e1ndares vigentes en la actualidad. Why get vaccinated?Rotavirus is a virus that causes diarrhea, mostly in babies and young children. The diarrhea be severe, and lead ... and fever vaccine, [Un Osteocondritis costal t\u00edfica tratado con vacunas y antivirus](https://revistas.unal.edu.co/index.php/revfacmed/article/view/22140) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) F. Lleras Acosta 1932-05-01 Full Text Available Por considerala de importancia pr\u00e1ctica, presentamos la historia cl\u00ednica de una enferma afectada de osteocondritis costal de origen Eberthiano, tratada con \u00e9xito completo por las autovacunas y antivirus, Debemos esta interesante observaci\u00f3n al Dr. Juan N. Carpas y al interno de su servicio de mujeres, Sr. Azuero, quienes galantemente nos suministraron los datos cl\u00ednicos y las observaciones relativas a los efectos producidos por las vacunas. [Inmunoterapia en melanoma: vacunas de c\u00e9lulas dendr\u00edticas](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342015000300021&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Ivan Lozada-Requena Full Text Available La presente es una revisi\u00f3n narrativa que muestra la informaci\u00f3n accesible a la comunidad cient\u00edfica sobre melanoma e inmunoterapia. Las c\u00e9lulas dendr\u00edticas tienen la capacidad de participar en la inmunidad innata y adaptativa, pero no son ajenas a la evasi\u00f3n inmune de los tumores. Conocer su biolog\u00eda y rol ha llevado a generar in vitro varios prospectos de vacunas celulares aut\u00f3logas contra diversos tipos de c\u00e1ncer en humanos y modelos animales; sin embargo, en vista de la poca eficiencia que han mostrado, se deben implementar estrategias para potenciar su capacidad natural ya sea a trav\u00e9s de la coexpresi\u00f3n de mol\u00e9culas clave para activar o reactivar al sistema inmune, en combinaci\u00f3n con biosimilares o drogas quimioterape\u00faticas y no se debe descartar la acci\u00f3n de productos naturales como alternativa inmunoestimulante o adyuvante. Todos los tipos de inmunoterap\u00eda deber\u00edan medir el impacto de las c\u00e9lulas supresoras de origen mieloide, las que pueden atacar al sistema inmune y ayudar a la progresi\u00f3n tumoral, respectivamente. Esto puede reducir la actividad de las vacunas celulares y/o sus combinaciones pudiendo ser la diferencia entre el \u00e9xito o no de la inmunoterapia. Aunque en melanoma existen biosimilares aprobados por la Food and Drug Administration (FDA no todos tienen el \u00e9xito esperado por lo que es necesario evaluar otras estrategias que incluyan vacunas celulares cargadas con p\u00e9ptidos antig\u00e9nicos tumorales expresados exclusivamente o ant\u00edgenos provenientes de extractos tumorales y sus respectivos adyuvantes. [Perspectivas para nuevas vacunas antituberculosas en la era posgen\u00f3mica.](http://www.revistabiomedica.org/index.php/biomedica/article/view/1320) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Luis F. Garc\u00eda 2004-06-01 Full Text Available A pesar de que la vacunaci\u00f3n con Mycobacterium bovis BCG es el procedimiento m\u00e1s utilizado a nivel mundial para prevenir la tuberculosis, su eficicacia es muy cuestionable, lo cual ha motivado la b\u00fasqueda de nuevas opciones inmunoprofil\u00e1cticas. El conocimiento generado con el secuenciamiento completo de una cepa de Mycobacterium tuberculosis H37Rv y la aplicaci\u00f3n de nuevas tecnolog\u00edas inmunol\u00f3gicas, bioqu\u00edmicas y gen\u00e9ticas han permitido realizar una disecci\u00f3n fina del transcriptoma y el proteoma de M. tuberculosis, lo cual ha generado una gran cantidad de conocimiento sobre la biolog\u00eda de este microorganismo. Dado que alrededor de una tercera parte de la poblaci\u00f3n mundial puede estar infectada con M. tuberculosis y que \u00e9ste s\u00f3lo se detecta cuando se inicia la enfermedad, la mayor parte de los esfuerzos se han dedicado al dise\u00f1o de vacunas posinfecci\u00f3n que induzcan un aumento selectivo de la inmunidad celular espec\u00edfica del hospedero a largo plazo, no generen reacciones adversas y sean de bajo costo. Dentro de las nuevas estrategias que est\u00e1n siendo utilizadas para el desarrollo de vacunas, se destaca la utilizaci\u00f3n de mezclas de prote\u00ednas con una alta inmunogenicidad, cepas de M. bovis BCG recombinantes y de M. tuberculosis gen\u00e9ticamente atenuadas o modificadas para inducir una mayor respuesta inmune, y las vacunas de ADN desnudo. Los candidatos con m\u00e1s potencial incluyen las vacunas de subunidades micobacterianas, las cuales expresan mol\u00e9culas ampliamente reconocidas por el sistema inmune y cuyo reconocimiento resulta en el incremento de la respuesta Th1 y aqu\u00e9llas que utilizan vectores virales dise\u00f1ados para expresar mol\u00e9culas micobacterianas antig\u00e9nicas. Aunque los modelos animales son de valor limitado, puesto que la patolog\u00eda observada en ellos s\u00f3lo reproduce parcialmente la observada en humanos, los resultados obtenidos con estas vacunas son muy prometedores y algunas est\u00e1n siendo actualmente evaluadas en ... Staying Safe Videos for Educators Search Parents / Rotavirus What's in this article? ... the Doctor Print en espa\u00f1ol El rotavirus About Rotavirus Almost all kids have 9557 stool samples 5 and with acute gastroenteritis were screened for rotavirus A. Rotavirus G and P genotypes were after The direct, indirect, total and vaccine effectiveness was 86% (95% confidence interval (CI) 83.2-89.1%), 48% (95% CI 42.8-52.6%), 91.3-94.3%) and (95% was in past decade. The vaccines analysed in this article provide lead a continued upward trend in the overall vaccine efficiency. Copyright European Society of Clinical Microbiology by Ltd. Yen, Jacqueline full public health impact these vaccines has not been realized. Most countries, including those rotavirus vaccines into national immunization programs. and program-level vaccine introduction. PMID:24755452 [Desarrollo de vacunas contra el virus de la inmunodeficiencia humana tipo 1: Relevancia de la inmunidad celular contra subtipos](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802010000600014&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Ana Mar\u00eda Rodr\u00edguez 2010-12-01 Full Text Available Han pasado casi 30 a\u00f1os de la detecci\u00f3n de los primeros casos de infecci\u00f3n con HIV-1 y a\u00fan no se ha conseguido desarrollar una vacuna efectiva y segura. A pesar del impacto positivo sobre la pandemia que se ha conseguido gracias a los avances en la terapia antirretroviral (TARV, el HIV/sida sigue constituyendo un grave problema para la salud p\u00fablica, especialmente en los pa\u00edses en desarrollo, donde es dif\u00edcil el acceso al tratamiento. En el mundo, 33 millones de personas viven con el virus del sida, mientras que en la Argentina se calcula que habr\u00eda unos 120 000 infectados. Uno de los desaf\u00edos para lograr una vacuna contra el HIV es la variabilidad viral. El grupo M, responsable de la pandemia, se encuentra dividido en 10 subtipos y varios sub-subtipos, adem\u00e1s de las 48 formas recombinantes circulantes y m\u00e1s de cien formas recombinantes \u00fanicas. La epidemia de HIV en nuestro pa\u00eds es tan compleja como en el resto del mundo, con la co-circulaci\u00f3n principalmente de virus pertenecientes al subtipo B y recombinantes BF (CRF12_BF y derivadas. A pesar de la cantidad de trabajos dedicados a la caracterizaci\u00f3n de la respuesta inmune y al desarrollo de vacunas, no queda claro cu\u00e1l es el impacto de la variabilidad en la elecci\u00f3n del ant\u00edgeno. Trabajos realizados en nuestro laboratorio demuestran el papel que juega la inmunidad celular con respecto a las variantes recombinantes BF, tanto en humanos como en modelos animales. Estos resultados son de importancia en el desarrollo de futuras vacunas para nuestra regi\u00f3n. [Vacunas, biotecnolog\u00eda y su relaci\u00f3n con el aborto provocado](https://www.openaire.eu/search/publication?articleId=doajarticles::4639710bd8874709386dd27339826e1d) Jos\u00e9 Luis Redondo Calder\u00f3n 2008-01-01 Las vacunas de c\u00e9lulas diploides humanas (WI-38, MRC-5) tienen un origen \u00e9ticamente objetable, dado que dichas c\u00e9lulas proceden de abortos provocados. Entre ellas destacan vacunas empleadas contra rub\u00e9ola, sarampi\u00f3n, parotiditis, rabia, poliomielitis, viruela, hepatitis A, varicela y herpes z\u00f3ster. Actualmente se encuentran en desarrollo otras vacunas cultivadas en c\u00e9lulas (293, PER.C6) transformadas mediante virus, procedentes de abortos. Entre ellas hay vacunas contra la gripe, virus respi... ... Search Form Controls Cancel Submit Search The CDC Note: Javascript is disabled or is not Note: Javascript is disabled or is not Lee, E; human neonatal rotavirus strain (G3P[6]) that been associated with asymptomatic neonatal and replicates well in the infant gut. RV3-BB rotavirus vaccine has been developed as a safety and tolerability of a single oral dose of the second generation RV3-BB rotavirus vaccine (8.3\u00d710(6)FFU/mL) in 20 adults, 20 children and 20 infants (10 vaccine and 10 placebo per age cohort). Vaccine take was defined as seroconversion (a baseline day 28 post-dose) or evidence of RV3-BB viral replication in the faeces RT-PCR analysis 3-6 days post-vaccination. RV3-BB presence was by sequence analysis. The RV3-BB vaccine was well tolerated in all participants, with no pattern of adverse events shown to be associated with the study vaccine. In the infant cohort, vaccine take was demonstrated in 8/9 infants following dose of vaccine compared with In the infant vaccine group, either IgA or 0/10 infants evidence of replication in the placebo group. Two infants in the placebo group had serological evidence of a rotavirus infection within the 28-day study period: one demonstrated an IgA and the other an SNA response, with wild-type virus replication detected in another infant. RV3-BB vaccine was support progression of RV3-BB to Phase II immunogenicity and efficacy \u00a9 reserved. through multiple levels of [Desarrollo de una profil\u00e1ctica de segunda generaci\u00f3n contra el papilomavirus humano](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802011000500015&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Full Text Available Los papilomavirus humanos (HPV son el agente etiol\u00f3gico del c\u00e1ncer cervical (CC, la segunda causa de muerte por c\u00e1ncer en mujeres. Se estima que medio mill\u00f3n de nuevos c\u00e1nceres se diagnostica cada a\u00f1o, ocurriendo la mayor\u00eda de ellos en pa\u00edses en v\u00edas de desarrollo debido a la ausencia o ineficiencia de los programas masivos de detecci\u00f3n temprana. Recientemente se han introducido en el mercado dos vacunas profil\u00e1cticas contra las principales cepas oncog\u00e9nicas de HPV, la cepa 16 y 18, responsables por el 80% de todos los CC. Estas vacunas se obtienen en forma recombinante y han demostrado ser extremadamente seguras y eficaces. Sin embargo, su impacto inmediato en la incidencia de la infecci\u00f3n por HPV en pa\u00edses en v\u00edas de desarrollo ser\u00e1 m\u00ednimo, debido principalmente al alto costo de las mismas. Existe la necesidad de contar con vacunas de segunda generaci\u00f3n, de bajo costo y de aplicaci\u00f3n masiva que permitan disminuir sensiblemente el n\u00famero de CC en la poblaci\u00f3n. Con este objetivo hemos desarrollado una plataforma de expresi\u00f3n recombinante que permite obtener part\u00edculas tipo virus (VLPs con las cuales es posible formular vacunas efectivas y accesibles contra la infecci\u00f3n por HPV. [Chicken Egg Yolk Antibodies (IgY) for Prophylaxis diarrhea of human and animal neonates is a major public health concern worldwide. egg yolk antibody has emerged of as a fresh alternative strategy to control infectious diseases of the alimentary tract and has been applied in the treatment of diarrhea due to rotavirus infection. The purpose of this concise review is to evaluate evidence on the properties and performance of anti-rotavirus immunoglobulin Y (IgY) for prevention and treatment of rotavirus diarrhea in human and animal neonates. A IgY have been reviewed and of control or placebo group. The accumulated information as a whole depicts oral IgY to be a safe and efficacious option treatment rotavirus diarrhea in There however a human rotavirus Nicotiana benthamiana.](https://www.ncbi.nlm.nih.gov/pubmed/26626122) P\u00eara, Francisco Human rotaviruses are the main cause of severe gastroenteritis in children and are responsible for over 500 000 deaths annually. There are two and other novel rotavirus serotypes in Africa and Asia has prompted fears that current vaccines might not be fully effective against these new varieties. report an effort to develop an affordable vaccine against The vaccine is based highly immunogenic expression, allow rapid production of antigens at lower costs, without the risk of contamination by animal pathogens. Western blot analysis of plant and expression never be detected for either protein. We therefore the part of VP4 (VP8*) to VP6 in an but regular TEM, even when co-expressed specifically for the Available evaluate its for macaques that had no rotavirus immunoglobulin A (IgA in plasma. To measure the interferon (IFN- and CD4+ cells cells from one infected macaque of CD4+ T cells with the VP6 281-331 domain. A VP6 301-315 region was identified as the epitope responsible for IFN- production while a broader VP6 was linked TNF production. human the management of rotavirus infection: review of in Santana; de Quintans, Jullyana; de Oliveira Mara; are effective against severe lower efficacy in low income countries in Africa. Anti-rotavirus treatment is not available. This systematic review of articles in English published from 2010 to 2016 reporting agents with in vivo antirotavirus activity for the management of rotavirus infection. The search was carried in PubMed, EMBASE, Scopus and Web of Science. Animal experiments where cytokines were investigated to assess the outcome of rotavirus therapy were included. A total of 869 publications were identified. Of these, 19 pertained the objectives of the review, and 11 articles probiotics/commensals primary and booster of infants in Latin America Nueva vacuna combinada DTPw-HB/Hib para la vacunaci\u00f3n primaria y de refuerzo de menores de un a\u00f1o en Am\u00e9rica Latina](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892006000300006) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Miguel Tregnaghi 2006-03-01 , la Organizaci\u00f3n Mundial de la Salud (OMS recomend\u00f3 que se incluyeran vacunas conjugadas contra Haemophilus influenzae tipo B (Hib en los programas de vacunaci\u00f3n de ni\u00f1os menores de un a\u00f1o, siempre que ello estuviera en consonancia con las prioridades nacionales. La compa\u00f1\u00eda GlaxoSmithKline Biologicals ha creado una nueva vacuna pentavalente que es una combinaci\u00f3n de la vacuna contra la difteria (D, el t\u00e9tanos (T y la tos ferina (P (con ant\u00edgeno tosfer\u00ednico a base de c\u00e9lulas completas y las vacunas contra la hepatitis B (HB y contra Haemophilus influenzae tipo B (Hib (DTPw-HB/Hib, con un total de 5 \u00b5g de fosfato de polirribosilrribitol (FPR. Hemos evaluado la inmunogenia y reactogenia observadas al aplicarse las dosis primaria y de refuerzo de esta nueva vacuna a ni\u00f1os sanos y las hemos comparado con las observadas al aplicar un r\u00e9gimen de referencia a base de las vacunas autorizadas DTPw-HB (Tritanrix y antiHib (Hiberix en forma de inyecciones simult\u00e1neas. M\u00c9TODOS: Llevamos a cabo un estudio aleatorizado y con doble enmascaramiento de septiembre de 1998 a agosto de 1999 para establecer la inmunogenia y reactogenia observadas al administrarles a ni\u00f1os sanos la nueva vacuna combinada pentavalente (DTPw-HB/Hib en una sola inyecci\u00f3n, y compararlas con las observadas con el r\u00e9gimen de referencia. RESULTADOS: Se obtuvieron excelentes respuestas inmunitarias con ambos reg\u00edmenes. Todos los ni\u00f1os vacunados en ambos grupos alcanzaron concentraciones s\u00e9ricas protectoras de anticuerpos antiFPR > 0,15 \u00b5g un mes despu\u00e9s de recibir la dosis primaria. La vacuna combinada DTPw-HB/Hib no dio resultados inferiores a los obtenidos con las vacunas autorizadas en t\u00e9rminos de los porcentajes de seroprotecci\u00f3n, seropositividad y respuesta frente a todos los componentes antig\u00e9nicos de la vacuna. La persistencia de anticuerpos contra todos los ant\u00edgenos contenidos en ella hasta el momento en que se administr\u00f3 la dosis de refuerzo fue parecida en ambos grupos, y [Una vacuna contra la tuberculosi, provada en cabres](https://www.openaire.eu/search/publication?articleId=od______1404::6574285bd1662fef225103ab5f2fa6f1) P\u00e9rez del Val, Bernat 2012-01-01 Investigadors del CReSA han dut a terme el primer estudi de vacunaci\u00f3 contra la tuberculosi utilitzant com a model experimental la cabra dom\u00e8stica, que reprodueix amb molta similitud la resposta a la en La anomenada estat dissenyada investigadors McMaster prevenir la tuberculosi en i es estudi vacuna, com a refor... [INTRODUCCI\u00d3N DE NUEVAS VACUNAS: PROCESOS POL\u00cdTICOS, ADMINISTRATIVOS Y FINANCIEROS EN LA TOMA DE DECISIONES DEL PAI-BRASIL](http://revistamedicina.net/ojsanm/index.php/Revistamedicina/article/view/92) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Carla Magda A.S. Domingues 2012-07-01 Full Text Available Se presentan los antecedentes del PAI en el Brasil remont\u00e1ndose al a\u00f1o de 1804 en que se inicia el programa de vacunaci\u00f3n en Brasil aplicando la vacuna contra la viruela hasta llegar a 1973 cuando se crea el Programa Nacional de Inmunizaciones en Brasil, y a partir de ah\u00ed se mantiene un esquema b\u00e1sico de vacunaci\u00f3n hasta llegar al 2012 cuando se introducen las vacunas VIP y pentavalentes. Muestra las alteraciones sufridas en el Calendario de Vacunaci\u00f3n del 2012, para llegar a la reformulaci\u00f3n de un Nuevo Calendario de Vacunaci\u00f3n a partir del 2012. Se\u00f1ala las estrategias nacionales de vacunaci\u00f3n enmarcadas en acciones de rutina, campa\u00f1as y control de brotes. Hace referencia a los criterios de inclusi\u00f3n de nuevas vacunas referidos a aspectos: epidemiol\u00f3gicos, inmunol\u00f3gicos, tecnol\u00f3gicos, log\u00edstica, socio-econ\u00f3micos, aprobaci\u00f3n por los Comit\u00e9s y presupuesto. Registra las novedades ocurridas en el Sistema de Informaciones del Programa Nacional de Inmunizaciones, relacionadas con la situaci\u00f3n actual, propuesta y Resoluci\u00f3n Ministerial. Por \u00faltimo se\u00f1ala los desaf\u00edos que debe enfrentar el Sistema enmarcados principalmente en la capacidad para mantener altas coberturas de vacunaci\u00f3n. [Rotavirus infection and the current Text Available Among children, rotaviruses are the most common cause of severe gastroenteritis worldwide and of diarrheal deaths across the world continues to drive the remarkable pace of vaccine development. This review assesses the global epidemiological and economic burden of rotavirus of the development of rotavirus vaccines, and presents data on the efficacy and effectiveness licensed vaccines (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Dr. Rodolfo Villena 2017-01-01 Full Text Available Las vacunas han demostrado ser una excelente estrategia para reducir la morbimortalidad en infecciones respiratorias, con un perfil de seguridad adecuado. Nuestro PNI incorpora varias de ellas con este objetivo, logrando resultados de alto impacto a nivel de salud p\u00fablica. Para que esto prosiga se requiere de nuestro compromiso y conocimiento para estimular, difundir y obtener altas tasas de cobertura, de manera de lograr efectos de protecci\u00f3n indirecta, conocidos como inmunidad comunitaria. Por otro lado, se debe mantener la vigilancia epidemiol\u00f3gica de los agentes inmunoprevenibles para conocer su oscilaci\u00f3n temporal, serogrupos, sero y/o genotipos, de manera de establecer directrices adecuadas de edad y esquemas de vacunaci\u00f3n para la poblaci\u00f3n. Debemos avanzar en estos temas y realizar estudios de efectividad de las vacunas que hemos introducido, para conocer su aporte en la prevenci\u00f3n de infecciones respiratorias, de manera de objetivar sus beneficios, conocer el impacto en poblaciones de riesgo y avanzar en la vacunaci\u00f3n de embarazadas, para otorgar mejores estrategias de prevenci\u00f3n a nuestra poblaci\u00f3n. [Impact of rotavirus vaccination in countries with high be established. The RV1 rotavirus vaccine was introduced in Bolivia in August 2008. This study describes the trends in deaths, hospitalizations, and healthcare among children rotavirus-related manifested by in seasonality and by a shift in the mean age of those with rotavirus infection. The significant decrease main AGE-related health children rotavirus vaccine provides evidence of a substantial public health impact of rotavirus vaccination in Bolivia, as a measure for protecting children against AGE. Copyright \u00a9 2017 The Published Rotavirus vaccine development focused on the delivery of live attenuated rotavirus strains rotavirus a vaccine to severe illness that can lead to dehydration in infants and young children in both... [La evidencia acerca de la controversia de las vacunas que contienen timerosal y su asociaci\u00f3n con el autismo](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342013000200018&lng=en&tlng=en) [Directory of Text Available La vacunaci\u00f3n es una de las medidas de mayor impacto en la salud p\u00fablica para la reducci\u00f3n de la morbimortalidad infantil. El timerosal es un compuesto org\u00e1nico del mercurio utilizado como preservante de los frascos multidosis. Eventualmente, en el Per\u00fa, surgen olas de controversia acerca de la seguridad de estas vacunas, asoci\u00e1ndolas especialmente con el autismo. Como resultado de estas controversias, se han propuesto, incluso, leyes que proh\u00edben este tipo de vacunas, lo que tendr\u00eda un importante impacto en los costos y en los aspectos log\u00edsticos de la estrategia nacional de vacunaci\u00f3n. En este art\u00edculo se revisa la literatura sobre las principales controversias acerca de las vacunas que contienen timerosal y su supuesta asociaci\u00f3n con el autismo. Se realiza una aproximaci\u00f3n hist\u00f3rica sobre estas controversias, se hace una actualizaci\u00f3n de la evidencia cient\u00edfica disponible al momento, y se revisa la posici\u00f3n de los organismos internacionales m\u00e1s importantes con respecto a este tema. Se concluye que la evidencia cient\u00edfica no apoya la noci\u00f3n que exista una asociaci\u00f3n entre el uso del timerosal en las vacunas con los trastornos del espectro autista en ni\u00f1os. [Burden of Norovirus and Rotavirus in 2016-01-01 The effectiveness of rotavirus vaccine in the field may set the stage for a changing landscape of diarrheal illness affecting children Norovirus are the two major viral enteropathogens of childhood. This study describes the prevalence rotavirus Bolivia. Stool samples gastroenteritis aged 5-24 months without AGE recruited from serving Bolivia's third largest in AGE 13/71 those of typed specimens). This is a trend norovirus predominance 2016-01-01 The effectiveness of rotavirus vaccine in the field may set the stage for a changing landscape of diarrheal illness affecting children Norovirus are the two major viral enteropathogens of childhood. This study describes the prevalence rotavirus Bolivia. Stool samples gastroenteritis aged 5-24 months without AGE recruited from serving Bolivia's third largest in AGE 13/71 those of typed specimens). This is a trend norovirus predominance rotavirus in children after widespread vaccination against rotavirus. \u00a9 The American Society of Tropical Medicine and Hygiene. [Efectividad comunitaria de las vacunas frente a la Parotiditis Infecciosa. Estudio de casos](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1135-57271999000400003) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Lim\u00f3n Mora Juan 1999-01-01 Full Text Available FUNDAMENTO: En nuestro pa\u00eds existen dos tipos de vacunas disponibles frente a la parotiditis infecciosa. En los \u00faltimos tiempos se han planteado dudas sobre la eficacia global de estas vacunas y de la eficacia comparada entre ambas (cepa Rubini y cepa Jeryl Lynn. En el distrito sanitario de A.P. \"Sevilla Este\" se registraron 256 casos durante 1997 (90,1 casos por 100.000 habitantes. Con este estudio se pretende aprovechar la aparici\u00f3n de casos de parotiditis para evaluar poblaciones afectadas e incidencia comparada seg\u00fan tipo de vacuna recibida durante la infancia. M\u00c9TODOS: An\u00e1lisis descriptivo de los casos (edad, distribuci\u00f3n territorial, antecedentes vacunales,... y an\u00e1lisis evolutivo (tasas de incidencia anuales en el distrito sanitario y su entorno. Se eval\u00faa la efectividad global de las vacunas frente a la parotiditis. Igualmente se estiman las tasas de incidencia de casos entre los vacunados con cepa Rubini y Jeryl Lynn. RESULTADOS: Se observan las tasas de incidencias m\u00e1s elevadas en ni\u00f1os entre 1 y 4 a\u00f1os. Se han estimado niveles de efectividad global para estas vacunas. Adem\u00e1s se observa una incidencia de casos significativamente m\u00e1s elevada entre los ni\u00f1os vacunados con cepa Rubini que en los que lo hicieron con Jeryl Lynn (riesgo relativo de 6,5 con Intervalo de confianza 95% 3,6-11,8. CONCLUSIONES: La efectividad que se desprende de este estudio no parece ser tan buena como la eficacia te\u00f3rica preconizada para las vacunas frente a la parotiditis. Se plantea la conveniencia de realizar otros estudios de casos seg\u00fan tipos de vacunas utilizadas. Igualmente son de gran inter\u00e9s los datos a suministrar por estudios seroepidemiol\u00f3gicos. [Vacunas en situaciones especiales. Embarazo, inmunodepresi\u00f3n, transplante](https://www.openaire.eu/search/publication?articleId=od______1404::05502ca26081377cb9ac9b967d7e66d8) Farjas Abad\u00eda, M\u00aa Pilar 2005-01-01 En las recomendaciones de vacunaci\u00f3n de grupos de poblaci\u00f3n que por su situaci\u00f3n de salud requieren medidas espec\u00edficas deben conjugarse: Las limitaciones en la aplicaci\u00f3n de determinadas vacunas por la mayor probabilidad de efectos secundarios en estos pacientes (por ejemplo la aplicaci\u00f3n de vacunas de virus vivos en pacientes inmunodeprimidos). El mayor riesgo de infecci\u00f3n frente a determinados agentes que genera la patolog\u00eda o situaci\u00f3n inmunitaria del paciente, y que determina un mayor in... [Current status of rotavirus diarrheal world continues to drive the remarkable pace of vaccine development. were searched using \"rotavirus\" and \"rotavirus vaccine\" in MEDLINE and PubMed. Articles not published in the English language, articles without abstracts, and opinion articles were excluded from the After screening, articles were reviewed and synthesized overview of current vaccines and vaccination programs. In review the vaccines and vaccination programs, the principles of rotavirus and the efficacy of the currently licensed from both developed and developing Rotavirus is a common cause of children in both developed and active surveillance for rotavirus gastroenteritis among children under 5 years old before and after the vaccine introduction. We surveyed hospitalization rates for rotavirus gastroenteritis in children in Tsu City, Mie Prefecture, Japan, from 2007 to 2015 and surveyed the number of outpatient visits at a Tsu City clinic from 2010 to 2015. Stool samples were obtained for coverage infants the pre-vaccine years (2007-2011), hospitalization rates for rotavirus gastroenteritis in children under 5 years old were 5.5, 4.3, 3.1 and 3.9 cases per 1000 person-years, respectively. In the post-vaccine years (2011-2015), the rates were 3.0, 3.5, 0.8 and 0.6 cases per 1000 person-years, respectively. The hospitalization 2014-2015 seasons compared to the average of the seasons before vaccine introduction (P rotavirus infection was 66. In the post-vaccine years (2011-2015), the numbers for each season was 23, 23, 7 and 5, respectively. dominant rotavirus genotype coverage of one dose of rotavirus vaccine in Tsu City was 56.5% in 2014. Conclusion After the vaccine introduction, U.S. are likely to be infected with rotavirus before their INMUNOCOMPETENTE DE 65 A\u00d1OS: ANALISIS DEL IMPACTO PRESUPUESTARIO EN ESPA\u00d1A APLICANDO UN MODELO DE TRANSMISI\u00d3N DIN\u00c1MICA](http://www.redalyc.org/articulo.oa?id=17043728001) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Reyes Lorente Anto\u00f1anzas 2016-01-01 Full Text Available Fundamentos: Las infecciones causadas por el Streptococcus pneumoniae en el adulto tienen repercusiones importantes en la salud. El objetivo fue analizar el impacto econ\u00f3mico y sanitario en 5 a\u00f1os de la vacunaci\u00f3n de la cohorte espa\u00f1ola de 65 a\u00f1os inmunocompetente con la vacuna antineumoc\u00f3cica conjugada 13-valente.M\u00e9todos: Mediante un modelo de transmisi\u00f3n din\u00e1mica basado en ecuaciones diferenciales se analiz\u00f3 la carga de la enfermedad neumoc\u00f3cica (EN en sujetos de 65 a\u00f1os en 5 a\u00f1os, siendo vacunada anualmente el 36,5% de la cohorte. Se aplic\u00f3 la eficacia de la vacuna del 52,5% observada en el estudio CAPITA en pacientes de 65 a\u00f1os inmunocompetentes, cobertura de serotipos vacunales del 63,4% (estudio CAPA, incidencia de infecci\u00f3n neumoc\u00f3cica de 162,2/100.000 casos a\u00f1o (CMBD 2010-2013 y proporci\u00f3n de vacunados previamente al arranque del modelo del 0,99%. La perspectiva fue la del Sistema Nacional de Salud (SNS. Costes de casos de EN seg\u00fan CMBD y precio de venta de laboratorio de la vacuna conjugada.Resultados: En 5 a\u00f1os la vacunaci\u00f3n con vacuna conjugada 13-valente espera evitar 10.360 casos de EN (7.411 hospitalizaciones por neumon\u00edas y 699 muertes (14.736 a\u00f1os de vida ganados -AVG-, en una cohorte de 65 a 69 a\u00f1os de edad. El coste de vacunaci\u00f3n esperado de 36,5 millones de euros se compensar\u00eda completamente por la reducci\u00f3n de 41,5 millones de costes m\u00e9dicos evitados, con un ahorro neto acumulado de 3,8 millones de euros a precios constantes (4,9 a precios corrientes.Conclusi\u00f3n: La vacunaci\u00f3n con vacuna conjugada 13-valente en adultos de 65 a\u00f1os inmunocompetentes resulta eficiente para el Sistema Nacional de Salud, reduciendo la carga de enfermedad y evitando un n\u00famero importante de muertes. [VACUNAS E INFECCIONES RESPIRATORIAS](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::61ee14b25b56c72855596bb426219d56) Dr. Rodolfo Villena 2017-01-01 Las vacunas han demostrado ser una excelente estrategia para reducir la morbimortalidad en infecciones respiratorias, con un perfil de seguridad adecuado. Nuestro PNI incorpora varias de ellas con este objetivo, logrando resultados de alto impacto a nivel de salud p\u00fablica. Para que esto prosiga se requiere de nuestro compromiso y conocimiento para estimular, difundir y obtener altas tasas de cobertura, de manera de lograr efectos de protecci\u00f3n indirecta, conocidos como inmunidad comunitaria. ... [VIGILANCIA DE LA GRIPE PAND\u00c9MICA EN LA COMUNIDAD VALENCIANA Y VACUNA ANTIGRIPAL ESTACIONAL](http://www.redalyc.org/articulo.oa?id=17015304012) [Directory Open Access 2010-01-01 Full Text Available Fundamento: En la Comunidad Valenciana se ha llevado a cabo la vigilancia de la Gripe pand\u00e9mica. Algunos estudios sobre efectividad de la vacuna estacional para Gripe AnH1N1 han presentado resultados no consistentes. El objetivo del trabajo es describir los resultados de la vigilancia epidemiol\u00f3gica y la efectividad de la vacuna estacional para Gripe pand\u00e9mica en las semanas 28 a 51 de 2009. M\u00e9todos: Se estudiaron los casos en atenci\u00f3n primaria, hospitalizados confirmados, aislamientos virales y prote\u00edna C reactiva (PCR y coberturas vacunales. Se calcul\u00f3 la efectividad vacunal por el m\u00e9todo de screening de Farrington, en tres grupos de edad y dos periodos: vacunados de las temporadas 2008-9 y 2009-10. Resultados: En el primer periodo (semanas 28 a 40 los casos se concentraron en el grupo de 15 a 64 a\u00f1os (7.207 casos, seguido de los menores de 15 a\u00f1os (1.596 casos. En el segundo periodo (semanas 45 a 47 afect\u00f3 m\u00e1s a menores de 15 a\u00f1os (28.218 casos. En ambos periodos las tasas de incidencia en mayores de 65 a\u00f1os fue de 56,3 y 125,1 respectivamente. En el periodo estudiado (semanas 28 a 51 se confirmaron 5.481 casos de los que 1.746 (31,8% fueron hospitalizados. La curva de personas hospitalizadas presentaba un perfil similar al de atenci\u00f3n primaria, y tambi\u00e9n el seguimiento microbiol\u00f3gico del virus. La efectividad vacunal en el segundo periodo fue del 25% en adultos entre 15 y 64 a\u00f1os y del 51% en mayores de 64 a\u00f1os. Conclusiones: Se observ\u00f3 una protecci\u00f3n edad dependiente con efectividad vacunal positiva en los mayores de 64 a\u00f1os, aunque puede estar confundida por exposici\u00f3n natural al virus, vacunas previas y o respuesta inmunitaria. [Characterization of in leading cause of severe diarrhea disease tree. The extract is approved for use in humans by the FDA for use in beverages as a food addictive. We have demonstrated that Quillaja extracts have strong antiviral activities in vitro against six different viruses. In this study, we evaluated the in vivo antiviral activity of these extracts against rhesus rotavirus (RRV) using a mouse model. We mice are exposed to 500 plaque-forming-units (PFU) for each of both the the amount of mouse, the diarrhea under a variety of the treated mice were greatly reduced receive the Quillaja extracts. Mechanistically, there is antivirals reduce the disease in humans. PMID:21549151 [Impacto de la introducci\u00f3n de la vacuna contra el rotavirus en la hospitalizaci\u00f3n por gastroenteritis aguda grave en el Hospital del Ni\u00f1o de la Ciudad de Panam\u00e1 Impact of rotavirus vaccine introduction on hospital admissions for the City](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000900005) of Open Access Javier Nieto Guevara 2008-09-01 Full Text Available OBJETIVOS: Determinar si la introducci\u00f3n de la vacunaci\u00f3n infantil contra el rotavirus en Panam\u00e1 permiti\u00f3 reducir la tasa de hospitalizaci\u00f3n por gastroenteritis en ni\u00f1os menores de 5 a\u00f1os. M\u00c9TODOS: Estudio observacional de corte transversal en dos per\u00edodos: del 1 de enero al 31 de agosto de 2005 (antes de la introducci\u00f3n de la vacunaci\u00f3n contra el rotavirus y del 1 de enero al 31 de agosto de 2007 (un a\u00f1o despu\u00e9s de la introducci\u00f3n. Se estudiaron todos los ni\u00f1os y ni\u00f1as entre 2 meses y 5 a\u00f1os de edad hospitalizados con diagn\u00f3stico de gastroenteritis aguda grave en la sala de corta estancia de gastroenteritis del Hospital del Ni\u00f1o, en Ciudad de Panam\u00e1, Panam\u00e1. Las variables fueron: n\u00famero de episodios de gastroenteritis, n\u00famero de casos hospitalizados por gastroenteritis aguda grave, d\u00edas de hospitalizaci\u00f3n y uso de antibi\u00f3ticos, seg\u00fan dos grupos de edad (de 2 meses a 1 a\u00f1o y de m\u00e1s de 1 a\u00f1o a 5 a\u00f1os. Se calcul\u00f3 el riesgo relativo (RR con intervalos de confianza de 95% (IC95% y un nivel de significaci\u00f3n P OBJECTIVES: To determine if infant rotavirus vaccination in Panama has reduced the rate of hospital admission for gastroenteritis among children under 5 years of age. METHODS: An observational, cross-sectional study of two time periods: 1 January-31 August 2005 (prior to initiating rotavirus vaccination and 1 January-31 August 2007 (one year after introducing rotavirus vaccination. All the children from 2 months-5 years of age admitted with a diagnosis of acute gastroenteritis to the short-stay gastroenteritis area of the Children's Hospital in Panama City, Panama, were studied. The hospitalized; and antibiotics treatment for each of the two age groups (2 months-1 year and >1-5 years. The relative risk (RR was calculated with a 95% confidence interval (95%CI and a significance level of P [El legado de la Real Expedici\u00f3n Filantr\u00f3pica de la Vacuna (1803-1810: las juntas de vacuna](http://asclepio.revistas.csic.es/index.php/asclepio/article/view/71/74) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Ram\u00edrez Mart\u00edn, Susana 2004-06-01 Full Text Available The Royal Vaccination Expedition, directed by the physicians Francisco Xavier Balmis and Jos\u00e9 Salvany, was the most important scientific and medical achievement of the Spanish colonial era. It took place at a time of political restlessness, and its achievements were thus conditioned by each of the cultures into which the was introduced. As its legacy, the philantropic expedition left the Vaccination established of medical expertise to sustain the expedition\u00b4s principal objetive: the battle against the smallpox epidemics in pursuit of public health. La Expedici\u00f3n de la Vacuna, dirigida por los m\u00e9dicos Francisco Xavier Balmis y Jos\u00e9 Salvany, es la gesta cient\u00edfica y sanitaria m\u00e1s importante de \u00e9poca colonial. Su desarrollo tuvo lugar en un momento pol\u00edtico convulso y los resultados estuvieron condicionados por las sociedades donde la vacuna se estableci\u00f3. El legado de esta expedici\u00f3n filantr\u00f3pica fue la creaci\u00f3n de las Juntas de Vacuna. Estas instituciones se erigieron como centros creadores de saber m\u00e9dico en Am\u00e9rica y consolidaron el objetivo primario de la expedici\u00f3n: la b\u00fasqueda de la salud p\u00fablica luchando contra las epidemias de viruela. [Primary and booster vaccination with DTPw-HB/Hib pentavalent vaccine children who had received a birth dose of hepatitis B vaccine Vacunaci\u00f3n primaria y de refuerzo con la vacuna pentavalente DTPw-HB/Hib en ni\u00f1os costarricenses vacunados al nacer contra la hepatitis B](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892002001000005) [Directory for diphtheria and Bordetella pertussis. At 15 months of responded with the DTPw-HB/Hib pentavalent vaccine regimens were equally well tolerated, indicating that up to five doses of the HB vaccine can be given without impact on safety. Conclusions. Our study confirms that vaccine is immunogenic as a primary vaccination in children who received HB vaccine the pentavalent both for primary routine use of as part of childhood vaccination programs in Latin America and the Caribbean.Objetivos. La vacuna combinada pentavalente DTPw-HB/Hib ha sido creada siguiendo la recomendaci\u00f3n de la Organizaci\u00f3n Mundial de la Salud de a\u00f1adir las vacunas contra la hepatitis b (HB y el Haemophilus influenzae tipo b (Hib a los programas de vacunaci\u00f3n infantil. Los objetivos del presente estudio consistieron en: 1 analizar la inmunogenicidad y reactogenicidad de la vacuna combinada pentavalente DTPw-HB/Hib en comparaci\u00f3n con las inyecciones separadas de las vacunas DTPw-HB e Hib como vacunaci\u00f3n primaria en un grupo de ni\u00f1os que hab\u00edan recibido al nacer una dosis de vacuna contra la HB, y 2 evaluar la persistencia de anticuerpos en el segundo a\u00f1o de vida, as\u00ed como la respuesta a las dosis de recuerdo de DTPw-HB/Hib o DTPw/Hib. M\u00e9todos. En la primera parte del estudio (fase de vacunaci\u00f3n primaria, realizada en 1998-1999, se analiz\u00f3 la inmunogenicidad y reactogenicidad de la vacuna combinada DTPw-HB/Hib en comparaci\u00f3n con inyecciones separadas de las vacunas DTPw-HB e Hib como vacunaci\u00f3n primaria a [Perfil de seguridad de la 2010-12-01 Full Text Available Con el objetivo de mostrar el perfil de seguridad de la vacuna antileptospir\u00f3sica cubana, vax-SPIRAL\u00ae, se realiz\u00f3 un estudio observacional descriptivo y transversal, a partir de la base de datos de la red nacional de farmacovigilancia a medicamentos. Se estim\u00f3 la frecuencia de reportes por dosis de vacunas administradas, la valoraci\u00f3n de causalidad, severidad, localizaci\u00f3n y los eventos adversos con mayor asociaci\u00f3n estad\u00edstica, a partir del c\u00e1lculo de disproporcionalidad de las combinaciones de eventos adversos a vacunas de todos los diagn\u00f3sticos en los reportes de eventos del grupo farmacol\u00f3gico de vacunas y el c\u00e1lculo de la Raz\u00f3n de Riesgo Proporcional (PRR y la Raz\u00f3n Diferencial de Riesgo (ROR. Hubo 1,62 reportes por 100 000 dosis administradas y 1,9 diagn\u00f3sticos por reporte en personas entre 18 y 77 a\u00f1os de edad y una media \u00b1DE de 40 \u00b1 13 a\u00f1os, con predominio del sexo femenino (65,54%. No se reportaron casos graves; el 74,17% fueron con severidad leve y el 66,96% fueron manifestaciones adversas sist\u00e9micas. El 94,17% de los reportes estuvieron relacionados con la vacuna. Los eventos adversos m\u00e1s frecuentes fueron: fiebre/hipertermia (18,75%, cefalea (14,73%, dolor local (13,84%, sitio de inyecci\u00f3n (12,05%, malestar general (8,48% y manifestaciones de hipersensibilidad m\u00ednimas, s\u00f3lo a nivel cut\u00e1neo. Entre los que mostraron mayor asociaci\u00f3n: cefalea, malestar general y rubor. Los resultados obtenidos son similares y con mejor perfil de seguridad que los de la vacuna francesa SPIROLEPT, por lo cual se recomienda para la protecci\u00f3n en grupos de riesgo de leptospirosis. [IMPLICACIONES \u00c9TICAS Y SOCIALES DE LA INTRODUCCI\u00d3N DE LA VACUNA CONTRA EL VIRUS DEL PAPILOMA HUMANO EN M\u00c9XICO: REFLEXIONES SOBRE UNA PROPUESTA DE INTERVENCI\u00d3N](https://www.openaire.eu/search/publication?articleId=od______3056::d4191acb1173d7dbea934cb8c961809f) Prieto de Guti\u00e9rrez Delgado,Cristina; Feinholz Klip,Dafna; Morales Gonz\u00e1lez,Gisela; Witlen,Renee 2008-01-01 El objetivo de este trabajo es identificar aspectos \u00e9ticos y sociales relacionados con la introducci\u00f3n de la vacuna contra el virus del papiloma humano (VPH) en M\u00e9xico para una decisi\u00f3n informada y justa que considere no s\u00f3lo los aspectos financieros. De acuerdo con la informaci\u00f3n sobre eficiencia y costo de la vacuna, su introducci\u00f3n al sistema p\u00fablico mexicano puede acarrear consecuencias no previstas para las participantes y para toda la sociedad, por lo que debe examinarse en el contexto relationships for latitude. used linear regression to identify variables that seasonal intensity rotavirus. Results regions of the disease was more likely to be seasonal. The level of country development was a stronger predictor of strength of countries similar geographical location, climate and level of development indicate that a unifying explanation global seasonality of rotavirus disease. PMID:23190782 [Aceptabilidad de la vacuna contra el virus papiloma humano en padres de adolescentes, en colombia](https://www.openaire.eu/search/publication?articleId=od______1326::8ba7ba7cedd44552d4d60ca52f50c9aa) Wiesner, Carolina; Pi\u00f1eros, Marion; Cort\u00e9s, Claudia; Jaime Ardila, Jaime Ardila 2012-01-01 Objetivo La vacuna contra el VPH es una nueva tecnolog\u00eda disponible para el control del c\u00e1ncer de cuello uterino. Se espera, que en el menor tiempo posible esta vacuna pueda tener cobertura universal. Este art\u00edculo presenta la aceptabilidad que tiene los padres de adolescentes en Colombia hacia la vacuna contra el VPH y hace una aproximaci\u00f3n a sus determinantes. M\u00e9todos Estudio cualitativo en cuatro regiones en Colombia. Se realizaron 17 grupos focales con padres de ni\u00f1as y ni\u00f1os entre 11 a 1... [Human neonatal randomized, placebo-controlled trial in Indonesia to evaluate the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) to prevent RV3-BB administered in a neonatal schedule at 0-5 days, 8 and 14 weeks or infant schedule at 8, 14 and 18 weeks, or placebo. Laboratory-confirmed rotavirus gastroenteritis was graded using a analysis was efficacy against severe rotavirus gastroenteritis from two weeks after all doses to 18 months in the combined vaccine group (neonatal and infant schedule) compared with placebo. Results Vaccine efficacy against severe rotavirus gastroenteritis to 18 months was 63% in the combined vaccine group (95% CI 34, 80; p<0.001), 75% in the neonatal vaccine group (95% confidence interval [CI] 44, 91; p<0.001) and 51% in the infant vaccine group (95% CI 7, 76; p=0.03) in the per protocol analysis, with similar results in the intention-to-treat analysis. Vaccine efficacy to 12 months was 94% in the neonatal vaccine group (95%CI 56, 99; p=0.006). Vaccine take occurred in 78/83 (94%) in the neonatal vaccine group and 83/84 (99%) in the infant vaccine group. The vaccine was well tolerated, with similar incidence of adverse events was efficacious, immunogenic and well-tolerated when in PMID:29466164 [Impact of into the National Immunization Program in Kenya in July 2014. We examined the impact of the vaccine on hospitalization for all-cause acute gastroenteritis (AGE) and rotavirus-specific AGE and strain distribution at a large referral hospital which serves a predominantly peri-urban population in Central Kenya. Data on AGE strain distribution were derived from ongoing AGE rotavirus and strain distribution. introduction, the rotavirus declined by 30% (95% CI: 19-45%) in the first year and 64% (95% CI: 49-77%) in the second year. Reductions in pronounced the vaccine introduction. Thus, introducing the rotavirus vaccine into the routine immunization program in Kenya has resulted in a notable decline in rotavirus and all-cause AGE hospitalizations in Central Kenya. This provides early evidence for public health policy makers in Kenya to support the sustained use of rotavirus vaccine in routine Lennart 2007-09-01 Full Text Available Abstract a worldwide cause of infectious infantile diarrhea that claims over 600,000 lives annually. Recently, two new vaccine candidates have been developed but their efficacy in developing countries, still remains to proven. Oral delivery of immunoglobulins provides passive bacteria for rotavirus we report an evaluation of the therapeutic potential of different probiotics and their combination with anti - rotavirus antibodies in a mouse model of rotavirus six probiotic advantages associated with immunoglobulins and probiotics that the treatment provides rapid therapeutic effect and is cost efficient. These components do not storage conditions that is currently used. [Manejo m\u00e9dico de la exposici\u00f3n al virus de la hepatitis B](https://www.openaire.eu/search/publication?articleId=doajarticles::e763456eb267d72953262b77223c70f4) Mancel Mart\u00ednez; Craig Shapiro; Ana Bracho; Fernando De La Hoz 1991-01-01 Se hace una revisi\u00f3n de los conocimientos actuales sobre el tratamiento en el caso de una probable exposici\u00f3n al virus de la hepatitis B. Se presenta la pormenorizaci\u00f3n de las diferentes clases de exposici\u00f3n as\u00ed como la indicaci\u00f3n y dosificaci\u00f3n de la inmunoglobulina espec\u00edfica y de la vacuna anti-hepatitis B. Esta revisi\u00f3n tiene como fundamento las recomendaciones del CDC de Atlanta y de la Organizaci\u00f3n Mundial de la Salud. [Manejo m\u00e9dico de la exposici\u00f3n al virus de la hepatitis B](http://www.revistabiomedica.org/index.php/biomedica/article/view/2007) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Mancel Mart\u00ednez 1991-12-01 Full Text Available Se hace una revisi\u00f3n de los conocimientos actuales sobre el tratamiento en el caso de una probable exposici\u00f3n al virus de la hepatitis B. Se presenta la pormenorizaci\u00f3n de las diferentes clases de exposici\u00f3n as\u00ed como la indicaci\u00f3n y dosificaci\u00f3n de la inmunoglobulina espec\u00edfica y de la vacuna anti-hepatitis B. Esta revisi\u00f3n tiene como fundamento las recomendaciones del CDC de Atlanta y de la Organizaci\u00f3n Mundial de la Salud. [Development of a rotavirus vaccine: clinical safety, not cause illness in infants and young children because of their species-specific tropism. The common G (G1, G2, G3, G4) or P (P1A[8]) types worldwide. The present review focuses on the development of the pentavalent rotavirus vaccine of a large-scale (ED) visits, for up to 2 years post-vaccination, were 95% in Europe, 97% in the United States, and 90% in the Latin American/Caribbean regions. RotaTeq was recently shown to be up to 100% effective in routine use in the US in reducing Additional reduction and Asian countries than in middle or high-income countries. Additionally, these two vaccines have recently been associated rare case of intussusception in vaccinated infants. We developed a novel recombinant subunit high VP8* proteins may be a plausible additional candidate as new parenteral rotavirus vaccines. Published by Elsevier Ltd. Patarroyo, Manuel Elkin 2017-01-01 La malaria es una enfermedad parasitaria producida por la picadura de un mosquito; una afecci\u00f3n que en el a\u00f1o 2015 registr\u00f3 212 millones de casos y 429.000 muertes. Cada dos minutos, la malaria provoc\u00f3 la muerte de un ni\u00f1o menor de cinco a\u00f1os en todo el mundo. Diferentes cient\u00edficos a lo largo de todo el mundo han hecho m\u00faltiples intentos para combatir esta enfermedad con una vacuna efectiva que pueda erradicarla de ra\u00edz. [ESTRUCTURA MOLECULAR Y ANTIG\u00c9NICA DE LA VACUNA](https://revistas.unal.edu.co/index.php/actabiol/article/view/11338) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) V\u00cdCTOR ANDR\u00c9S VANEGAS 2008-09-01 Full Text Available La prote\u00edna L1 del Virus del Papiloma Humano (VPH constituye el 80% de la c\u00e1pside viral. Las vacunas profil\u00e1cticas contra el VPH son sintetizadas a partir de la prote\u00edna L1 ensamblada en Part\u00edculas similares al Virus (del ingl\u00e9s VLP, las cuales son altamente inmunog\u00e9nicas generando anticuerpos espec\u00edficos de tipo y en algunos casos pueden presentar reacci\u00f3n cruzada entre tipos de VPH filogen\u00e9ticamente pr\u00f3ximos. La estructura de la prote\u00edna L1 del VPH es importante porque confiere estabilidad a la c\u00e1pside mediante el establecimiento de interacciones intra e intercapsom\u00e9ricas lo que asegura la integridad viral y antig\u00e9nicamente porque contiene los ep\u00edtopes que inducen la respuesta inmune protectora. En estudios en los que se evalu\u00f3 la antigenicidad de la prote\u00edna L1 se determin\u00f3 que los ep\u00edtopes inmunodominantes de la c\u00e1pside viral se encuentran en los bucles B-C, D-E, F-G, H-I y en el extremo C-terminal. Estos bucles son poco conservados entre los diferentes genotipos y se encuentran en segmentos de la prote\u00edna expuestos en la superficie de la c\u00e1pside. Los amino\u00e1cidos situados en los bucles B-C, F-G y H-I son primordiales para el reconocimiento por los anticuerpos neutralizantes. Los diferentes subtipos y variantes presentan cambios en estos amino\u00e1cidos o en residuos que conforman otros ep\u00edtopes. En esta revisi\u00f3n se presentar\u00e1 un estado del arte de la prote\u00edna L1 del VPH genotipo 16, la estructura y su importancia en el desarrollo de vacunas contra la infecci\u00f3n producida por este virus. [Efectividad de la vacuna VA-MENGOC-BC\u00ae contra cepas heter\u00f3logas de Ochoa-Azze 2016-08-01 Full Text Available La efectividad de las vacunas de ves\u00edculas de membrana externa de Neisseria meningitidis serogrupo B ha sido cuestionada por algunos investigadores, limit\u00e1ndola a la cepa vacunal. VA-MENGOC-BC\u00ae es una vacuna antimeningoc\u00f3cica basada en dicha tecnolog\u00eda. Presentamos un metaan\u00e1lisis de estudios realizados en diferentes contextos epidemiol\u00f3gicos, evaluando su efectividad contra cepas heter\u00f3logas de meningococo B en varios grupos de edades. Se demuestra que la vacuna es efectiva contra cepas hom\u00f3logas, heter\u00f3logas y de diferentes complejos clonales. [Evaluaci\u00f3n de la toxicidad por dosis \u00fanica de la vacuna antitet\u00e1nica vax-TET en ratas Sprague Dawley](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2007000300004&lng=es&nrm=iso&tlng=es) [Directory of Yulie\u00e9 L\u00f3pez. 2007-12-01 Full Text Available La vacuna vax-TET\u00ae est\u00e1 indicada en la prevenci\u00f3n del t\u00e9tanos y es efectiva si se logra un completo y apropiado esquema de inmunizaci\u00f3n. Para investigar el potencial t\u00f3xico de este producto se realiz\u00f3 una prueba toxicol\u00f3gica con una dosis \u00fanica, por v\u00eda intramuscular, en un volumen de 0,2 mL en ratas Sprague Dawley. La composici\u00f3n de la vacuna de ensayo probada fue la misma de la vacuna comercial. Los animales fueron observados diariamente en busca de s\u00edntomas locales y sist\u00e9micos de toxicidad. Se realizaron mediciones del consumo de agua y alimento, as\u00ed como del peso corporal. Dos semanas despu\u00e9s de la inoculaci\u00f3n las ratas fueron sacrificadas por m\u00e9todos de eutanasia sin dolor y sometidas a necropsia. No se observaron muertes ni s\u00edntomas de toxicidad en los animales estudiados. Tampoco se encontraron diferencias de inter\u00e9s toxicol\u00f3gico entre los grupos experimentales en cuanto a las variables medidas. El estudio anatomopatol\u00f3gico revel\u00f3 la presencia de formaciones granulomatosas de tipo macrof\u00e1gico asociadas, fundamentalmente, al hidr\u00f3xido de aluminio. Estos resultados permitieron concluir que, bajo las condiciones del estudio y seg\u00fan los criterios establecidos, esta vacuna no produce efectos adversos en el modelo animal usado, por lo que se considera potencialmente no t\u00f3xica para humanos. [Influenza. Vacunas cl\u00e1sicas y novedosas a las puertas de otra pandemia](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200005&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Raiza Mart\u00ednez 2006-08-01 Full Text Available Los virus de la influenza A, adem\u00e1s del hombre, infectan otros mam\u00edferos y una gran variedad de especies de aves. Desde 1997 se sabe que cepas aviares son capaces de infectar al hombre provocando una enfermedad generalmente leve. El brote actual de gripe aviar H5N1 en humanos ha puesto en alerta a la comunidad cient\u00edfica internacional, no solo por su elevada mortalidad sino por su potencialidad en la generaci\u00f3n de una nueva pandemia. Las autoridades sanitarias han puesto en marcha un amplio programa para la preparaci\u00f3n ante esta contingencia, que abarca diferentes campos, desde el diagn\u00f3stico y la detecci\u00f3n precoz de los brotes tanto en animales como en humanos, la caracterizaci\u00f3n sistem\u00e1tica de las cepas circulantes, el sacrificio de aves infectadas, la producci\u00f3n masiva de antivirales y por supuesto el desarrollo y producci\u00f3n a gran escala de vacunas eficaces. En este \u00faltimo tema se trabaja intensamente tanto en el mejoramiento de las vacunas ya existentes como en la b\u00fasqueda de alternativas basadas en tecnolog\u00edas de nueva generaci\u00f3n. [Enfermedad meningoc\u00f3cica: epidemiolog\u00eda y vacunas, un enfoque pr\u00e1ctico](http://www.sciencedirect.com/science/article/pii/S0716864014700689) [Directory Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) C. Giannina Izquierdo, Dra. 2014-05-01 Las principales estrategias para la prevenci\u00f3n de la enfermedad son el uso de vacunas (prevenci\u00f3n primaria y el uso de quimioprofilaxis a los contactos de un caso \u00edndice (prevenci\u00f3n secundaria. A la fecha existen numerosas vacunas contra Nmen, todas ellas con adecuados perfiles de seguridad e inmunogenicidad, por lo que la elecci\u00f3n de la vacuna a utilizar depender\u00e1 del serogrupo prevalente en cada pa\u00eds; de las caracter\u00edsticas de la poblaci\u00f3n m\u00e1s afectada y de la factibilidad de disponer de ella e insertarla dentro de los programas nacionales o campa\u00f1as respectivas de vacunaci\u00f3n. [Annual changes in rotavirus hospitalization rates US with rotavirus by lower rotavirus vaccination in children (59% to 73% from 2010-2015), resulting in accumulation aged rotavirus and AGE from years. The clearest biennial pattern in early with higher rates in 2009 and 2011 than in 2008 and 2010. The pattern diminishes in the late post-vaccine period. For rotavirus hospitalizations, the median age and the difference in age biennial seasons was highest during the early post-vaccine period; these differences were no has with the As this pattern higher vaccine coverage widespread use of rotavirus vaccines, rotavirus was a leading cause of gastroenteritis among children. Navajo and White Mountain Apache children suffer a disproportionate burden of severe rotavirus disease compared with the general population. We enrolled Navajo and White Mountain Apache infants received 3 doses of vaccine or placebo at 4 to 10 week intervals, with the first dose given between 6 and 12 weeks of age. Gastroenteritis episodes were identified by active surveillance. Disease severity was determined by a standardized scoring system. There were 509 and 494 randomized children who received vaccine and placebo, respectively. Among risk of adverse events was similar for the vaccine and placebo groups. PRV was highly effective in preventing rotavirus disease care in these American Indian infants. Vaccine efficacy and immunogenicity were similar to the overall study population enrolled in the multicenter trial. African nations to introduce monovalent rotavirus vaccine (RV1) into its childhood immunization We to impact vaccine introduction on rotavirus acute (AGE) hospitalizations and to (VE). teaching rotavirus admissions by age 95% to 100% for dose 1 and 93% to 100% for dose 2. In the first 3 years after vaccine introduction, the percentage of hospital admissions positive for rotavirus fell any-dose VE 60% (95% CI, -2% to 84%;P= .056). Results with and with efficacy estimates from elsewhere in sub-Saharan Africa. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US. [Prevention of rotavirus gastroenteritis in infants and children: efficacy, of Health Systems, 2Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USAAbstract: Rotavirus infection is the most common cause of severe gastroenteritis globally, with greater than 86% of deaths currently licensed in the United States and prequalified by the World Health Organization. RV1 is a monovalent human rotavirus vaccine, three LLV, is a lamb rotavirus strain a dose, only in China. RV1 and and and are promising as well. At least three other vaccines are in development, which being by and coverage gastroenteritis is an important public health problem all over the world, causing a notable economic burden in both developing and developed rotavirus gastroenteritis, and its severity in Egyptian children. Material and methods: A cross sectional case control study was conducted on 231 cases of acute gastroenteritis attending the outpatient clinic of Al-Zahraa University Hospital. Full history taking, clinical examination, and clinical data collection were done. collected for an ABO grouping. Stool samples for viral gastroenteritis agents. Results positive cases of GE were significantly more prevalent among cases with blood group A (p < 0.05 and significantly less among cases with blood group B (p < 0.05. The rate of hospitalisation was highly significantly greater among cases with group A (p < 0.005, and significantly lower among cases with group AB and O (p < 0.05. As regards the degree of dehydration, moderate and severe cases were highly significant in groups and duration of fever (p < 0.005. Conclusions : Blood group A is highly associated with paediatric rotavirus gastroenteritis. This could highlight an important risk factor, which could play a significant role for the pathogenesis of rotavirus gastroenteritis and well. Furthermore, more intervention care could be needed A paediatric patients, if at birth to target early prevention of rotavirus gastroenteritis may address some of the barriers to global implementation of a rotavirus vaccine. We conducted a randomized, double-blind, placebo-controlled trial in Indonesia to evaluate the efficacy of an oral human neonatal rotavirus vaccine (RV3-BB) in preventing according to a neonatal schedule (0 to 5 days, 8 weeks, and 14 weeks of age) or an infant schedule (8 weeks, 14 weeks, and 18 weeks of age), or placebo. The primary analysis was conducted in the per-protocol population, which included only participants who received all four doses of vaccine or placebo within the visit windows, with secondary analyses performed in gastroenteritis occurred up to the age of 18 months in 5.6% of the participants in the placebo group (28 of 504 babies), in 1.4% in the neonatal-schedule vaccine group (7 of 498), and in 2.7% in the infant-schedule vaccine group (14 of 511). This resulted in a vaccine efficacy of 75% (95% confidence interval [CI], 44 to 91) in the neonatal-schedule group (PBill and Melinda Gates Foundation and others; potential of rotavirus diarrhea in Peru as well the need for and the potential cost savings with a rotavirus vaccine in that country. To assess the burden of rotavirus diarrhea in Peru, was a number national to estimate both the burden of rotavirus diarrhea in the country and its associated medical costs. Rotavirus is a significant cause of morbidity and mortality in Peruvian children. In their first 5 years of life, an estimated 1 in 1.6 children will experience an episode of rotavirus diarrhea, 1 in 9.4 will seek medical care, 1 in 19.7 will require hospitalization, and 1 in 375 will die of the disease. Per year, this represents approximately 384,000 cases, 64,000 clinic visits, 30,000 hospitalizations, and 1,600 deaths. The annual cost of medical care alone for these children is approximately US$ 2.6 million--and that does not take into account the indirect or societal costs of the morbidity and mortality from diarrhea in Peru, but a vaccine regimen would have to be relatively inexpensive, a few deaths and their efficacy with fewer than three doses. All three of these factors could increase the cost savings associated [Rotavirus disease burden in Peru: the vaccine and its potential cost savings](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001001000004&lng=en&tlng=en) [Directory of rotavirus diarrhea Peru as well the need for and the potential cost savings with a rotavirus vaccine in that country. Methods. To assess the burden of rotavirus diarrhea was a number national to estimate both the burden of rotavirus diarrhea in the country and its associated medical costs. Results. Rotavirus is a significant cause of morbidity and mortality in Peruvian children. In their first 5 years of life, an estimated 1 in 1.6 children will experience an episode of rotavirus diarrhea, 1 in 9.4 will seek medical care, 1 in 19.7 will require hospitalization, and 1 in 375 will die of the disease. Per year, this represents approximately 384 000 cases, 64 000 clinic visits, 30 000 hospitalizations, and 1 600 deaths. The annual cost of medical care alone for these children is approximately US$ 2.6 million--and that does not take into account the indirect or costs and mortality from diarrhea in Peru, but a vaccine regimen would have to be relatively inexpensive, a few deaths and their efficacy with fewer than three doses. All three of these factors could increase the cost savings associated with a (Spanish) Recommend on Facebook ... likely to get rotavirus from December June. podcast, los ni\u00c3\u00b1os de Kidtastics hablan sobre la importancia de las vacunas y c\u00c3\u00b3mo funcionan. Created: 4/23/2013 by Centers 12/11/2013. every E; Neuzil, Kathleen M 2017-10-09 The Center for Vaccine Development - Mali (CVD - Mali), the World Health Organization's regional office in Africa (WHO/AFRO), and the CVD at the University of Maryland School of Medicine hosted the 10th African Rotavirus Symposium in Bamako, Mali on 1-2 June 2016. The symposium is coordinated by WHO/AFRO, the Regional Rotavirus Reference Laboratories, and the African Rotavirus Network (ARN), with support from the Bill & Melinda Gates Foundation. The event brings together leading rotavirus researchers, scientists, and policy-makers from across Africa and the world. Over 150 participants, from 31 countries, including 27 in Africa, joined forces to address the theme \"Reaching Every Child in Africa with Rotavirus Vaccines.\" This symposium, the first in francophone Africa, occurred at an unprecedented time when 33 African countries had introduced rotavirus vaccines into their national immunization programs. The symposium concluded with a Call to Action to introduce rotavirus vaccines in the 21 remaining African the Rotavirus Efficacy and Safety Trial (REST), the period between the administration of dose 1 through 13 days after the administration of dose 3, there were more wild-type rotavirus vaccine efficacy against RVGE of any severity was the accuracy of type categorization of all these RVGE cases in vaccine recipients during the vaccination phase of The assay (90%) of 163 re-assayed RVGE cases (69.3%) In the large-scale cohort (N = 68,038), 33 samples from RVGE cases care contacts that occurred during the vaccination phase of the Rotavirus Efficacy and Safety Trial (REST), the period between the administration of dose 1 through 13 days after the administration of dose 3, there were more wild-type rotavirus vaccine efficacy against RVGE of any severity was the accuracy of type categorization of all these RVGE cases in vaccine recipients during the vaccination phase of The assay (90%) of 163 re-assayed RVGE cases (69.3%) In the large-scale cohort (N = 68,038), 33 samples from RVGE cases care contacts that occurred during the vaccination phase of most common cause of gastroenteritis in children requiring hospitalization. It is a very resistant and contagious virus causing nosocomial gastroenteritis. In France, the vaccine against rotavirus has been available since 2006, but the vaccine is not recommended for infant vaccination. The aim of this retrospective study was to describe nosocomial rotavirus gastroenteritis (NRGE) and to assess its impact on children hospitalized in the General Pediatrics Department of Robert-Debr\u00e9 Hospital (Paris) between 1 January 2009 and 31 December 2013. We analyzed intravenous hydration), and assessed whether these 1000 days of hospitalization. The incidence of NRGE was stable between 2009 and 2013 despite the introduction of specific hygiene measures. The average age of the months (range: 0.5-111 requiring prolonged (median: days). One-third of children were born premature (25%). Hydration was oral in 80 patients (59%), by intravenous infusion in 18 patients (13%), and intraosseous in of the patients were aged less than 5 vaccination. the number of hospital cross-infections of hospitalized children who are too young to be vaccinated. Copyright \u00a9 2016 Elsevier Masson a clinical trial in South Africa and Malawi, but vaccine efficacy was lower in Malawi (49.5%) than reported in South Africa (76.9%) and elsewhere. The aim of this study was to the relationships of circulating wild-type contained in Rotarix) and VP4 (P) genotype designations were confirmed, were either I1E1 or I2E2, to either the Wa-like or DS-1 like human rotaviruses. Overall, the their genetic make-up to rotaviruses described in countries where vaccine efficacy is greater, suggesting that the lower efficacy in Malawi is unlikely to be explained by the this of All Topics To use the sharing features ... [Estrategia y resultados de la farmacovigilancia de vacunas desde el Instituto Finlay, 2009](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2010000200006&lng=es&nrm=iso) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Iv\u00e1n E. Cuevas-Valdespino 2010-08-01 Full Text Available El objetivo de este trabajo fue mostrar la estrategia y los resultados de la farmacovigilancia desde el Instituto Finlay, como titular de registros sanitarios. Se concret\u00f3 la biograf\u00eda de los productos en la etapa de poscomercializaci\u00f3n y se examin\u00f3 el balance riesgo/beneficio. Esto fue posible gracias a convenios con instituciones que permitieron el acceso a bases de datos digitales y auditables, donde se encontr\u00f3 la notificaci\u00f3n espont\u00e1nea de eventos adversos y el cumplimiento de las buenas pr\u00e1cticas, reglamentos y regulaciones de la autoridad reguladora. La miner\u00eda de datos para la b\u00fasqueda de la agrupaci\u00f3n de eventos raros e inesperados para un mismo lote o de accidentes, la confecci\u00f3n de los informes peri\u00f3dicos de seguridad y la pr\u00e1ctica sistem\u00e1tica para completar la informaci\u00f3n de seguridad solicitada en subpoblaciones y grupos especiales permiti\u00f3 actualizar el perfil de seguridad de las vacunas. Se confirm\u00f3 que la vacuna antileptospir\u00f3sica trivalente, la antitifo\u00eddica Vi y el toxoide tet\u00e1nico, presentaron una frecuencia de eventos adversos menor de 0,1 reporte por cada 100.000 dosis administradas, mientras las dem\u00e1s vacunas tuvieron valores entre 1 y 10 por cada 10.000 vacunados. Entre el 80% y 95% de las notificaciones fueron relacionadas causalmente con la vacuna, y solo el 0,89% fueron de severidad grave, casi todas en ni\u00f1os menores de un a\u00f1o. Las manifestaciones generales fueron las que predominaron. Los resultados presentados muestran la importancia que tiene la farmacovigilancia desde la industria para obtener una valiosa informaci\u00f3n de la seguridad en la aplicaci\u00f3n de las vacunas. [Efectividad y duraci\u00f3n de la inmunidad de la vacuna frente al meningococo serogrupo A y C](http://www.redalyc.org/articulo.oa?id=17074415) [Directory of Open Access Luis Garc\u00eda Comas 2000-01-01 Full Text Available FUNDAMENTO: La Comunidad de Madrid detect\u00f3 a partir de 1995 un incremento del n\u00famero de casos de enfermedad meningoc\u00f3cica por serogrupo C. En 1997 se realiz\u00f3 una campa\u00f1a de inmunizaci\u00f3n masiva sobre la poblaci\u00f3n de 18 meses a 19 a\u00f1os. El objetivo de este estudio es conocer la respuesta inmunitaria producida por la vacuna y su relaci\u00f3n con la edad. M\u00c9TODOS: Se seleccion\u00f3 una muestra de 1.003 ni\u00f1os vacunados durante la campa\u00f1a. Se extrajo una muestra de sangre antes de la vacunaci\u00f3n y tras uno, seis (solo <5a y doce meses. Para valorar la respuesta inmune se midieron niveles de anticuerpos bactericidas y totales. RESULTADOS: La prevalencia de seroconversi\u00f3n medida por anticuerpos bactericidas es 89,6%. La respuesta es baja en menores de 3 a\u00f1os (34,8%, aumenta con la edad y a partir de los 7 a\u00f1os supera el 90%. A los 6 meses, la prevalencia de niveles protectores en menores de 5 a\u00f1os desciende notablemente (31,3%. Al a\u00f1o, la prevalencia desciende notablemente, especialmente en menores de 7 a\u00f1os. La proporci\u00f3n de individuos con respuesta de anticuerpos totales al mes supera el 90% y se mantiene elevada al a\u00f1o en todos los grupos edad (97,5%. CONCLUSIONES: La respuesta medida mediante anticuerpos totales entra en contradicci\u00f3n con la respuesta cl\u00ednica a la vacunaci\u00f3n y la medida mediante anticuerpos bactericidas infraestima la protecci\u00f3n si se compara con los resultados de efectividad vacunal, por lo que es necesario buscar indicadores biol\u00f3gicos que se correlacionen de manera adecuada con la respuesta cl\u00ednica tras la vacunaci\u00f3n. [Cost-effectiveness of Rotavirus vaccination in Vietnam](http://www.biomedcentral.com/1471-2458/9/29) (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Sue J 2009-01-01 Full Text Available Abstract Background Rotavirus is the most common cause of severe diarrhea leading to hospitalization or disease-specific death qualitative insights into the health additional of vaccination. We using the most recent the 2004 birth and re-evaluated the cost-effectiveness to vaccination, the nature of vaccine immunity, visits, hospitalizations, or deaths by about 67% over the first 5 years of life. Under base-case assumptions (94% coverage and $5 per from vaccination compared no the a clinical trial in South Africa and Malawi, but vaccine efficacy was lower in Malawi (49.5%) than reported in South Africa (76.9%) and elsewhere. The aim of this study was to the relationships of circulating wild-type contained in Rotarix) and VP4 (P) genotype designations were confirmed, were either I1E1 or I2E2, common to either the Wa-like or the DS-1 like human rotaviruses. Overall, the Malawi appear their genetic make-up to rotaviruses described in countries where vaccine efficacy is greater, suggesting that the lower efficacy in Malawi is unlikely to be explained by the diversity of circulating causative agent of severe gastroenteritis infants and young children worldwide, leads to high morbidity in both developing of rotavirus in Saudi Arabia through a review of 22 published studies of rotavirus and the antilogy diarrhea carried out from 1982 to 2003. The prevalence of rotavirus ranged between 10% to 46% with a median of 30%. Most cases were among children less than 2 years of age, and particularly in first year of life. There were significant differences in the seasonability within Saudi Arabia with increased infection during winter in some cities and during summer in others. G1 was the predominant serotype followed by G4, G3 and G2, in 4 have 11.0% were P types... Results of electropherotyping in 4 studies revealed that the long data on rotavirus strains in circulation are limited. And there is an urgent need for up-to-date and comprehensive in circulation and identify be incorporated into future vaccines. (author) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Kang G 2006-01-01 Full Text Available Rotavirus, the most common cause of severe diarrhea and a leading cause of mortality in children, has been a priority target for vaccine development for the past several years. The first rotavirus vaccine licensed in the United States was withdrawn because of an association of the vaccine with intussusception. However, the need for a vaccine is greatest in the developing world, because the benefits of of strains. In India, two candidate vaccines are in the development process, but have not yet reached efficacy trials. Many challenges regarding vaccine efficacy and In addition to completing clinical evaluations disease burden and virus diversity, there is also theory about corruption; causes, effects and type (tilawah. Second, keep yourself in order not to fall in corruption (tazkiyah, third, establish and foster self-confidence in dealing with the problem (takwiniyah not to fear in the truth, learning manners and wise (hikmah. Fourth, Growing power of faith and self-confidence (quwwatul Imaniyah, and the fifth, and action (mutabaah. [Rotavirus antigenemia in children is associated with viremia.](http://europepmc.org/articles/PMC1852122?pdf=render) Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) analyze a defined patient population to determine if infectious virus could be detected in sera from children with rotavirus antigenemia.Serum samples obtained upon hospitalization from children with and 41 rotavirus-negative, children with diagnosed bronchiolitis of known (n = 58 or unknown (n = 17 viral etiology, children with noninfectious, nonchronic conditions (n = 17, and adults tested attributes of the children. Rotavirus antigenemia in (51/57 of children with rotavirus-positive stools, in 89% (8/9 of children without diarrhea but with rotavirus-positive stools, in 12% (2/17 of children with bronchiolitis of unknown etiology without gastroenteritis, and in 12% (5/41 of children with gastroenteritis but with rotavirus-negative stools. Antigenemia was not detected in sera from nonchronic conditions, children with bronchiolitis healthy adults. Neither age nor timing of serum collection after onset of gastroenteritis significantly affected levels of antigenemia, and no correlation between antigenemia and viral genotype. However, there p = 0.025 and IgG (r = -0.40, p = 0.01 titers. We examined 11 antigen-positive and nine antigen-negative sera for infectious virus after three blind serial with analyze a defined patient population to determine if infectious virus could be detected in sera from Serum and 41 rotavirus-negative), children with diagnosed bronchiolitis of known (n = 58) or unknown (n = 17) viral etiology, children with noninfectious, nonchronic conditions (n = 17), and adults tested attributes of the children. Rotavirus antigenemia in (51/57) of children with rotavirus-positive stools, in 89% (8/9) of children without diarrhea but with rotavirus-positive stools, in 12% (2/17) of children with bronchiolitis of unknown etiology without gastroenteritis, and in 12% (5/41) of children with gastroenteritis but with rotavirus-negative stools. Antigenemia was not detected in sera from nonchronic conditions, children with bronchiolitis healthy adults. Neither age nor timing of serum collection after onset of gastroenteritis significantly affected levels of antigenemia, and no correlation between antigenemia and viral genotype. However, there and acute rotavirus-specific serum IgA (r = 0.44, p = 0.025) and IgG (r = 0.40, p = 0.01) titers. We examined 11 antigen-positive and nine antigen-negative sera for infectious virus after three blind serial Knipping Karen 2012-07-01 Full Text Available Abstract Background are the single most important cause of severe diarrhea in young children worldwide. The applications were in vitro on MA-104 cells for leaves were found to have strong significant with a 50% inhibitory concentration (IC50 was found to have activity (IC50 46 M, (IC50 respectively 129 M and apigenin-7-O-glucoside from Melissa officinalis (IC50 150 M. lower than in developed countries. The cause for this has been associated with several host and maternal factors including poor water sanitation and to poor vaccine uptake and response. The aim of this study was to examine the association between serological biomarkers of EED and seroconversion to rotavirus vaccine in Zambian infants. This was a retrospective cohort study of 142 infants who had been fully immunized with Rotarix, and had known seroconversion status. Seroconversion was as or more rotavirus-specific titres 395.1), 21.5 (IQR = 21.5, 21.5), 0.3 (IQR = 0.3, 0.3), and (IQR = 6.4, In independent effect of other biomarkers confounders (i.e. age of child at vaccination, breast-milk anti-rotavirus IgA, infant serum anti-rotavirus IgG, and IgA seropositivity at baseline), there was strong evidence of about in seroconversion due to doubling Zonulin concentration (Adjusted risk (aRR) = 1.12 to1.37; pzonulin and IFABP [No se ha demostrado asociaci\u00f3n entre la presencia del timerosal en las vacunas y el autismo](https://www.openaire.eu/search/publication?articleId=od______3056::5d7a8a9d35638166a4e7ccabd8678667) Cabezas S\u00e1nchez, C\u00e9sar 2007-01-01 El timerosal es un compuesto org\u00e1nico que contiene etilmercurio, el cual ha sido usado como preservante de algunas vacunas, sobre todo en la presentaci\u00f3n de multidosis desde los a\u00f1os 30. El etilmercurio es diferente del metilmercurio, este \u00faltimo s\u00ed se conoce que es neurot\u00f3xico; sin embargo, el metabolismo del etilmercurio es diferente del metilmercurio. En realidad se quiso inferir que la toxicidad del metilmercurio era similar al etilmercurio presente en el timerosal. [Provada amb \u00e8xit en cabres una nova vacuna contra la tuberculosi](https://www.openaire.eu/search/publication?articleId=od______1404::4dfcdb9afa501d98d59e07e37c0dec1f) P\u00e9rez del Val, Bernat 2014-01-01 Investigadors del CReSA proven per primer cop i amb \u00e8xit una nova vacuna contra la tuberculosi que millora la protecci\u00f3 de i la resposta immunol\u00f2gica a la infecci\u00f3 tuberculosa activa en humans i que, pel fet de ser hostes Salvador, Brasil, sobre la vacuna antisarampionosa](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891997001200001) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Moreira Luiza A. Cabus 1997-01-01 Full Text Available El \u00e9xito de las iniciativas internacionales para la erradicaci\u00f3n del sarampi\u00f3n depende en gran medida del grado de conocimiento sobre la vacunaci\u00f3n. En 1992 se evaluaron mediante un estudio transversal los conocimientos sobre la vacuna antisarampionosa de los pediatras de la ciudad brasile\u00f1a de Salvador, Bahia. Del total de 506 pediatras residentes en la ciudad, 299 (59% pudieron ser localizados y respondieron a un cuestionario de 15 preguntas en las que se planteaban situaciones hipot\u00e9ticas sobre indicaciones y contraindicaciones de esta vacuna. El promedio de aciertos fue de 9,3 preguntas de las 15, lo que muestra el poco conocimiento de los pediatras sobre la vacunaci\u00f3n antisarampiososa. Situaciones comunes en la pr\u00e1ctica pedi\u00e1trica brasile\u00f1a -desnutrici\u00f3n, infecci\u00f3n de v\u00edas respiratorias altas, diarrea y estado prematuro- fueron a menudo err\u00f3neamente consideradas como contraindicaciones para la inmunizaci\u00f3n. M\u00e1s de la mitad (62% de los pediatras no conoc\u00edan la v\u00eda correcta de administraci\u00f3n de la vacuna. Los conocimientos sobre la vacuna no variaron en funci\u00f3n del tiempo transcurrido desde la formaci\u00f3n universitaria del pediatra o de su trabajo en centros sanitarios de la Secretar\u00eda Estatal de Salud. Los profesores universitarios, los pediatras con maestr\u00eda y los que cursaban estudios de posgrado tuvieron una media de aciertos ligeramente superior a la del resto. Estos resultados indican la necesidad de reforzar la ense\u00f1anza sobre la vacunaci\u00f3n antisarampionosa en las facultades de medicina y en los programas de formaci\u00f3n continuada para pediatras. [Conocimientos de los pediatras de Salvador, Brasil, sobre la vacuna antisarampionosa](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49891997001200001&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Luiza A. Cabus Moreira 1997-12-01 Full Text Available El \u00e9xito de las iniciativas internacionales para la erradicaci\u00f3n del sarampi\u00f3n depende en gran medida del grado de conocimiento sobre la vacunaci\u00f3n. En 1992 se evaluaron mediante un estudio transversal los conocimientos sobre la vacuna antisarampionosa de los pediatras de la ciudad brasile\u00f1a de Salvador, Bahia. Del total de 506 pediatras residentes en la ciudad, 299 (59% pudieron ser localizados y respondieron a un cuestionario de 15 preguntas en las que se planteaban situaciones hipot\u00e9ticas sobre indicaciones y contraindicaciones de esta vacuna. El promedio de aciertos fue de 9,3 preguntas de las 15, lo que muestra el poco conocimiento de los pediatras sobre la vacunaci\u00f3n antisarampiososa. Situaciones comunes en la pr\u00e1ctica pedi\u00e1trica brasile\u00f1a -desnutrici\u00f3n, infecci\u00f3n de v\u00edas respiratorias altas, diarrea y estado prematuro- fueron a menudo err\u00f3neamente consideradas como contraindicaciones para la inmunizaci\u00f3n. M\u00e1s de la mitad (62% de los pediatras no conoc\u00edan la v\u00eda correcta de administraci\u00f3n de la vacuna. Los conocimientos sobre la vacuna no variaron en funci\u00f3n del tiempo transcurrido desde la formaci\u00f3n universitaria del pediatra o de su trabajo en centros sanitarios de la Secretar\u00eda Estatal de Salud. Los profesores universitarios, los pediatras con maestr\u00eda y los que cursaban estudios de posgrado tuvieron una media de aciertos ligeramente superior a la del resto. Estos resultados indican la necesidad de reforzar la ense\u00f1anza sobre la vacunaci\u00f3n antisarampionosa en las facultades de medicina y en los programas de formaci\u00f3n continuada para pediatras. [Milk from Brazilian of the Reoviridae and are recognized as the single most significant cause of severe gastroenteritis, malnutrition and diarrhea in young children. Each year rotavirus causes the death of about 440.000 children <5 years of age (313). The [Ensayo precl\u00ednico de la vacuna candid #1 producida en Argentina la Fiebre Hemorr\u00e1gica assay of Candid Argentina](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802005000400008) of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Ana M. Ambrosio 2005-08-01 Full Text Available Se compar\u00f3 en cobayos la seguridad, inmunogenicidad y eficacia protectora de un lote de vacuna Candid #1(C#1 fabricada en Estados Unidos de Am\u00e9rica (EE.UU. y distintos lotes de la misma vacuna fabricados en Argentina (Arg. El lote TSI 5-1-92 (EE.UU. y los lotes Exp N\u00ba 3, 7A y 8A (Arg fueron inoculados (0.5 ml, IM en cobayos de 250-400 g. Para cada ensayo diez animales recibieron soluci\u00f3n fisiol\u00f3gica y sirvieron como control. Todos fueron desafiados con la cepa pat\u00f3gena P23790 de virus Junin. Se registr\u00f3: a temperatura rectal, b peso corporal, c presencia de anticuerpos neutralizantes (AcNT pre y post-vacunaci\u00f3n, d respuesta al desaf\u00edo. Todos los animales vacunados desarrollaron AcNT anti virus Junin (rango = 40- 81920 y sobrevivieron al desaf\u00edo. En cada grupo control 8/10 animales murieron (d\u00eda 23.3 \u00b1 5.4 post-desaf\u00edo. Los cobayos resultaron id\u00e9nticamente protegidos de una descarga letal de virus Junin por la vacuna importada y los diferentes lotes de C#1 producidos en Argentina.Candid #1 vaccine against Argentine Hemorrhagic Fever produced in USA versus lots of the same vaccine made in Argentina were compared in guinea pigs regarding safety, immunogenicity and protective efficacy a challenge with pathogenic Junin Lots N\u00ba Exp 3, 7A and Argentine origin as well as lot TSI 5-1-92 from USA were inoculated in guinea pigs of 250-400 g in two consecutive assays. Ten animals inoculated with gained weight and remained normothermic to the to challenge whilst animals auf varies 6.2 authors semipolar (11 anti 22) AlGaN layers that C in H2 atmosphere. The layers are preferably (11 anti 22) oriented. The sample show a surface roughness between 15 and 2 nm. The Al content of the smoothest samples is about 60% determined by transmission experiments. Below 60% Al content a (GaN) of preparation. of of VLPs administered to were in all vaccinated and control rabbits before and after oral challenge with 103 50% infective doses of live P[14], G3 ALA lapine rotavirus. serum and intestinal G not intestinal IgA antibodies. infection were observed in individual VLPs administered parenterally to adjuvant is a better adjuvant than QS-21. The use of the rabbit model may further our understanding of the critical rotavirus proteins pentavalent rotavirus vaccine into its national immunization program in 2012. To determine the long-term impact of rotavirus vaccine on years following rotavirus vaccine introduction. We used data from an active surveillance system, from a review of pediatric ward registries, and from the Health Management Information System to describe trends in rotavirus and all-cause rotavirus genotypes in children younger than 5 years of age before the introduction of a universal rotavirus vaccination program: report of acute gastroenteritis among children less than of age throughout the This sentinel surveillance study was aimed to obtain baseline data on the rotavirus G and P genotypes across Turkey before the Turkish Rotavirus Surveillance in commercial serological the 13 to 24 month age group, followed by children in the age group of 25 to 36 months (28.3%. A total of eight different G types, six different P types, and 42 different G-P combinations were obtained. Four common G types (G1, G2, G3, and G9 and two common P types (P[8] and P[4] 95.1% and 98.8% the of tested in this study. rate of uncommon CONCLUSION: in Younger than 5 Years of Age before the Introduction of a Universal Rotavirus the most common causative agent of acute gastroenteritis among children less than of age throughout the This sentinel surveillance study was aimed to obtain baseline data on the rotavirus G and P genotypes across Turkey before the Turkish Rotavirus Surveillance in commercial serological the 13 to 24 month age group, followed by children in the age group of 25 to 36 months (28.3%). A total of eight different G types, six different P types, and 42 different G-P combinations were obtained. Four common G types (G1, G2, G3, and G9) and two common P types (P[8] and P[4]) 95.1% and 98.8% the of tested in this study. rate of uncommon Conclusion of severe and diarrhea in infants and young children less than 5 years of age. Potential impact of breast-feeding on the efficacy and immunogenicity of human rotavirus G1P[8] vaccine was examined = 3994) doses of human vaccine/placebo according to a 0-1 or 0-2 against any and severe rotavirus gastroenteritis was analyzed according to the infants high breast-fed and exclusively formula-fed children in the first season efficacy follow-up period, rotavirus 76.2% (95% CI: breast-fed and exclusively formula-fed infants was small. efficacy was equally high in breast-fed and exclusively formula-fed children in the first season. Breast-feeding seemed to reduce slightly the efficacy in the second season. [An\u00e1lisis econ\u00f3mico de las vacunas 10-valente y 13-valente 2014-01-01 Introducci\u00f3n: Las vacunas cl\u00e1sicamente han representado un m\u00e9todo econ\u00f3mico y eficaz para el control y prevenci\u00f3n de m\u00faltiples enfermedades infecciosas. En los \u00faltimos a\u00f1os se han introducido nuevas vacunas contra neumococo a precios elevados, y los diferentes an\u00e1lisis econ\u00f3micos a nivel mundial de estas vacunas no muestran tendencias. El objetivo de este trabajo era resumir la evidencia existente a trav\u00e9s de los diferentes estudios econ\u00f3micos evaluando las dos vacunas de segunda generaci\u00f3n c... [Rotavirus Immunization in Africa: history of rotavirus vaccine in Africa has not been good. The earlier rotavirus vaccine candidates, based on bovine A infection is a common cause of hospitalisation of children. However, in our laboratory almost 30% of rotavirus positive samples are from adults. Due to this an study into the riskfactors for rotavirus infection dogs, cattle, horses, and birds. There is some data suggesting direct transmission between animals and humans. Rotavirus typing is carried out...... in Denmark as the EuroRotaNet vaccine study. Samples trial conducted in infants in South Africa and Malawi. This paper examines rotavirus efficacy in three groups to receive either two (10 and 14 weeks) or three doses of Rotarix (together forming the pooled Rotarix group) or three doses of placebo at a 6,10,14-week schedule. Weekly home visits were conducted to gastroenteritis caused by the circulating G and P types from 2 weeks post-last dose until one year of age and the corresponding vaccine efficacy was calculated with 95% CI. Overall, were vaccinated and 4417 (pooled Rotarix = 2974; placebo = 1443) were included in the per protocol efficacy cohort. G1 wild-type was detected in 23 (1.6%) severe episodes from the placebo group. This was followed in order of detection by G12 (15 [1%] in placebo) and G8 types (15 [1%] in placebo). Vaccine efficacy against G1 wild-type, G12 and G8 types detected in 38 (2.6%) severe rotavirus gastroenteritis cases in placebo group. The remaining circulating P types comprised of P[4] (20 [1.4%] in placebo) and P[6] (13 [0.9%] in placebo). Vaccine against -6 [Vacunas y timerosal: no hay evidencias cient\u00edficas que muestren riesgo de autismo y desordenes neurol\u00f3gicos](https://www.openaire.eu/search/publication?articleId=od______3056::c178bdb2747b8762099be70feeaa7237) Cabezas, C\u00e9sar 2008-01-01 El timerosal es un compuesto org\u00e1nico que contiene etilmercurio, el cual ha sido usado como preservante de algunas vacunas, sobre todo en la presentaci\u00f3n de multidosis, desde los a\u00f1os 30. El etilmercurio es diferente delmetilmercurio, este \u00faltimo s\u00ed se conoce que es neurot\u00f3xico; sin embargo, el metabolismo del etilmercurio es diferente del metilmercurio. En realidad, se quiso inferir que la toxicidad del metilmercurio era similar al etilmercurio presente en to lead to the emergence of vaccine escape mutants. While multiple African countries have introduced a rotavirus vaccine, there are few data describing the evolution of rotaviruses that circulated before and after vaccine introduction. atypical DS-1-like in doctor. your the family](http://www.biomedcentral.com/1471-2431/9/11) Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Kelly Claudia M 2009-02-01 Full Text Available Abstract Background Rotavirus is the leading cause of severe diarrhea in young little is available regarding the emotional, social, and economic impact of rotavirus gastroenteritis on the family of a sick child. The objectives of this study were to: 1 assess the family impact of rotavirus parents to rank the importance of various factors associated with a case of rotavirus Methods The study enrolled parents and children (2-36 months of age brought to one of the study sites (outpatient clinic or ER if the child experienced 3 watery or looser-than normal stools and/or forceful vomiting within any period clinical invited group or individual interviews and subsequently completed questionnaire regarding diarrhea associated with rotavirus gastroenteritis, and noted that family life was impacted in several ways including loss of sleep, missed work, and an inability to complete normal household tasks. They expressed frustration at the lack of that confers a high medical and economic burden in more developed countries and can be fatal in less developed countries. Two vaccines with high efficacy and good safety profiles were approved and made available in Europe in 2006. We present an overview of the status of rotavirus vaccination in Europe. We discuss the drivers (including of universal rotavirus vaccination in Europe. By February, 2014, national universal rotavirus had been implemented in Belgium, Luxembourg, Austria, Finland, Greece, Luxembourg, Norway, and the UK. Four other German states have issued recommendations and reimbursement is provided by funds. universal 2014 Elsevier All rights reserved. [Desarrollo de un m\u00e9todo de CLAR-IR para la determinaci\u00f3n de etanol residual en vacuna Development of a HPLC-IR method for determination of residual ethanol in (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Matilde Cuevas Valdespino 2009-08-01 Full Text Available Los ingredientes farmac\u00e9uticos activos de la vacuna antimeningoc\u00f3cica cubana VA-MENGOC-BC TM (ves\u00edculas de membrana externa serogrupo C son conservados en etanol, de ah\u00ed que dicha vacuna posea un contenido de etanol residual, cuya concentraci\u00f3n real no se conoc\u00eda hasta el momento. Las regulaciones internacionales plantean que los productos biofarmac\u00e9uticos y sus ingredientes farmac\u00e9uticos activos deben tener bien caracterizadas todas sus impurezas, por lo que el objetivo de este trabajo fue el desarrollo de un m\u00e9todo de determinaci\u00f3n de etanol mediante cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n-\u00edndice de refracci\u00f3n para estos fines y su comparaci\u00f3n con un m\u00e9todo utilizado frecuentemente para cuantificar este solvente, como es la cromatograf\u00eda gaseosa. El m\u00e9todo evaluado result\u00f3 ser \u00fatil y con una buena robustez para la determinaci\u00f3n de este solvente org\u00e1nico en esta vacuna antimenigoc\u00f3cica. No se detectaron diferencias estad\u00edsticamente significativas entre los resultados obtenidos al evaluar las mismas muestras de vacuna mediante ambos m\u00e9todos cromatogr\u00e1ficos (cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n y cromatograf\u00eda gaseosa, lo que indica la posibilidad del uso de la cromatograf\u00eda l\u00edquida de alta resoluci\u00f3n en sustituci\u00f3n de la cromatograf\u00eda gaseosa para esta determinaci\u00f3n.Active pharmaceutical ingredients of has residual ethanol content, of which real concentration is not known just now. International regulations propose that the biopharmaceutical products and its active pharmaceutical ingredients must to have well defined all impurities, thus [Rotavirus vaccines Text Available Worldwide, account for more than 125 million cases of infantile gastroenteritis and nearly 1 deaths per year, developing countries. Rather than other control measures, vaccination is most to have a major impact on disease incidence. The peak 24 months however, months. G serotypes 1 to 4 are responsible for most disease, but there are indications that in Brazil that G type 5 is of emerging epidemiological importance. Both dehydrating diarrhea, many approaches to rotavirus vaccine development One vaccine, the United States of America, introduced to the market, and later withdrawn. A number of studies have found in developed countries than in developing (PFU RRV-TV have been carried out in two countries in Latin America, Brazil and Peru. Those trials yielded protective efficacy rates against all rotavirus diarrhea 18% to 35%. Data from a large catchment trial in Venezuela with a higher RRV-TV dose, of 4 X 10(5 PFU/dose, does not compromise the efficacy of RRV-TV if three doses of the vaccine are administered. Similarly, possible interference of oral poliovirus vaccine with the rotavirus vaccine can be [Rotavirus vaccines and in Latin Text Available Worldwide, account for more than 125 million cases of infantile gastroenteritis and nearly 1 deaths per year, developing countries. Rather than other control measures, vaccination is most to have a major impact on disease incidence. The peak 24 months however, months. G serotypes 1 to 4 are responsible for most disease, but there are indications that in Brazil that G type 5 is of emerging epidemiological importance. Both dehydrating diarrhea, many approaches to rotavirus vaccine development One vaccine, the United States of America, introduced to the market, and later withdrawn. A number of studies have found in developed countries than in developing (PFU RRV-TV have been carried out in two countries in Latin America, Brazil and Peru. Those trials yielded protective efficacy rates against all rotavirus diarrhea 18% to 35%. Data from a large catchment trial in Venezuela with a higher RRV-TV dose, of 4 X 10(5 PFU/dose, does not compromise the efficacy of RRV-TV if three doses of the vaccine are administered. Similarly, possible interference of oral poliovirus vaccine with the \"take\" of the rotavirus vaccine can be [Efectividad y duraci\u00f3n de la inmunidad de la vacuna frente al meningococo serogrupo A y C](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::079e97a5d510c0250481d9007f374dfc) Garc\u00eda Comas Luis; Ram\u00edrez Fern\u00e1ndez Rosa; Casta\u00f1eda L\u00f3pez 2000-01-01 FUNDAMENTO: La Comunidad de Madrid detect\u00f3 a partir de 1995 un incremento del n\u00famero de casos de enfermedad meningoc\u00f3cica por serogrupo C. En 1997 se realiz\u00f3 una campa\u00f1a de inmunizaci\u00f3n masiva sobre la poblaci\u00f3n de 18 meses a 19 a\u00f1os. El objetivo de este estudio es conocer la respuesta inmunitaria producida por la vacuna y su relaci\u00f3n con la edad. M\u00c9TODOS: Se seleccion\u00f3 una muestra de 1.003 ni\u00f1os vacunados durante la campa\u00f1a. Se extrajo una muestra de sangre antes de la vacunaci\u00f3n y tras uno,... [Incidence and cost of and rotavirus vaccine into the western market, we used modeling of national hospital registry data to determine the incidence and direct medical costs of annual and into the western market, we used modeling of national hospital registry data to determine the incidence and direct medical costs of annual marked winter peak similar to rotavirus-associated by 2...... different models, which indicated 2.4 and 2.5 (for children rotavirus-associated admissions per 1,000 children per year, respectively. These admissions amount to associated direct medical costs of US $1.7-1.8 per year. Using 2 was undertaken in Dunedin, between January Healthy, full-term ( 36 weeks old were randomly assigned (1:1:1) to receive 3 doses of oral RV3-BB vaccine with the first dose given at 0-5 d after birth (neonatal schedule), or the first dose given at about 8 weeks after birth (infant schedule), or to receive placebo (serum immune response or shedding of vaccine virus after any dose) was detected after 3 doses of RV3-BB vaccine in >90% of participants when the first dose was administered in the neonatal and infant schedules. The aim of the current study was to characterize RV3-BB shedding and virus replication following and schedule. Shedding was as polymerase of rotavirus was highest following vaccination at 8 weeks of age in both neonatal and infant schedules (19/30 and 17/27, respectively). Rotavirus was detected 3-7, at least one of RV3-BB, in 70% (21/30) of who shed RV3-BB, the result of replication rather than passage through to rotavirus vaccination R 2013-12-17 Conflicting evidence links malnutrition dams with 3-day-old pups to a diet (CD) isocaloric, multideficient regional basic diet (RBD) that produces PEM. At 3 weeks of age, we weaned CD and RBD pups to their dams' diet weanlings either live oral rotavirus vaccine (RRV) or PBS. At 6 weeks of age, we orally challenged all groups and RBD mice equally (Pvaccination and infection, does not impair rotavirus vaccine exacerbate infection in this mouse model of protein-energy Authors. Published by Elsevier Ltd.. All rights reserved. [Administraci\u00f3n de vacunas y casos de muerte s\u00fabita del lactante en el Per\u00fa, 2001: \u00bfasociaci\u00f3n o coincidencia temporal?](http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342006000100007&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Javier Vargas H Full Text Available Objetivos: Describir las caracter\u00edsticas cl\u00ednicas, socioecon\u00f3micas, y patol\u00f3gicas de nueve casos de lactantes que fallecieron horas despu\u00e9s de administr\u00e1rseles vacunas antipolio y DPT junto con anti Haemophilus influenzae b o asociada con antihepatitis B o BCG. Materiales y m\u00e9todos: Revisi\u00f3n de la historia cl\u00ednica, entrevista con el equipo de salud a cargo de la vacunaci\u00f3n y con los padres del lactante fallecido. Revisi\u00f3n de los informes del protocolo de autopsia e informes de anatom\u00eda patol\u00f3gica y entrevista con los m\u00e9dicos legistas y pat\u00f3logos. Evaluaci\u00f3n de control de calidad de las vacunas administradas. Realizaci\u00f3n de ex\u00e1menes de inmunohistoqu\u00edmica de tejidos pulmonares para el diagn\u00f3stico de virus. Resultados: Entre agosto y diciembre de 2001 se notificaron en el Per\u00fa, nueve casos de fallecimiento de lactantes entre ocho horas y tres d\u00edas despu\u00e9s de la aplicaci\u00f3n de vacunas DPT y antipolio. Despu\u00e9s de la vacunaci\u00f3n, los s\u00edntomas iniciaron entre 30 minutos a tres horas y la muerte se produjo entre ocho a 78 horas. Los s\u00edntomas m\u00e1s frecuentes fueron irritabilidad 8/9, llanto persistente 6/9, somnolencia 5/9, sangrado por nariz y boca 5/9. Todos los casos procedieron de familias pobres o muy pobres. El control de calidad se corrobor\u00f3 que las vacunas cumplieron con los est\u00e1ndares establecidos por la OMS. Las causas de la muerte reportadas en las necropsias fueron neumon\u00eda en dos casos y edema pulmonar en cinco casos, los informes de anatom\u00eda patol\u00f3gica mostraron una neumonitis intersticial y meningitis linfocitaria. No se observaron efectos citop\u00e1ticos virales en los tejidos pulmonares y los estudios toxicol\u00f3gicos fueron negativos. Conclusiones: No existe evidencia de una asociaci\u00f3n causal entre los eventos fatales y la administraci\u00f3n de las vacunas. [Rotavirus and the Vaccine (Drops) to Prevent It](https://www.cdc.gov/vaccines/parents/diseases/child/rotavirus.html) ... Immunization Resources and the Vaccine Prevent It Language: ... the vaccine. Why the The lower than in developed countries. The cause for this has been associated with several host and maternal factors including poor water sanitation and to poor vaccine uptake and response. The aim of this study was to examine the association between serological biomarkers of EED and seroconversion rotavirus vaccine in infants.This was a retrospective cohort study of 142 infants who had been fully immunized with Rotarix, and had known seroconversion status. Seroconversion was as or more rotavirus-specific titres 395.1, 21.5 (IQR = 21.5, 21.5, 0.3 (IQR = 0.3, 0.3, and (IQR = 6.4, In independent effect of other biomarkers confounders (i.e. age of child at vaccination, breast-milk anti-rotavirus IgA, infant serum anti-rotavirus IgG, and IgA seropositivity at baseline, there was strong evidence of about in seroconversion due to doubling Zonulin concentration (Adjusted risk to1.37; p<0 [Centers rotaviruses, of severe gastroenteritis in children less than five years of age. Essentially, all children around the world get the disease during the first few years of 2012-09-01 Full Text Available Abstract Background Rotaviruses are the most important cause of trial conducted in infants in South Africa and Malawi. This paper examines rotavirus efficacy in three groups to receive either two (10 and 14 weeks or three doses of Rotarix (together forming the pooled Rotarix group or three doses of placebo at a 6,10,14-week schedule. Weekly home visits were conducted to gastroenteritis caused by the circulating G and P types from 2 weeks post-last dose until one year of age and the corresponding vaccine efficacy was calculated with 95% CI. 4417 (pooled Rotarix = 2974; placebo = 1443 were included in the per protocol efficacy cohort. G1 wild-type was detected in 23 (1.6% severe episodes from the placebo group. This was followed in order of detection by G12 (15 [1%] in placebo and G8 types (15 [1%] in placebo. Vaccine efficacy against G1 wild-type, G12 and G8 types detected in 38 (2.6% severe rotavirus gastroenteritis cases in placebo group. The remaining circulating P types comprised of P[4] (20 [1.4%] in placebo and P[6] (13 [0.9%] in placebo. Vaccine against rotavirus vaccines observed children IgA or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. At the time of the study rotavirus vaccines had not been introduced in New Zealand of colostrum and breast milk samples collected 4 weeks, 20 weeks and 28 weeks after birth were measured. Infants were randomized to receive the first dose of vaccine at 0-5 d (neonatal schedule) or 8 weeks (infant schedule). Breast feeding was with-held for 30 minutes before and after vaccine administration. The relationship between rotavirus specific IgG and SNA levels in cord blood and IgA in colostrum and breast milk at the time of first active dose of RV3-BB vaccine and level of IgA response and stool excretion after 3 doses of RV3-BB rotavirus vaccine and were included in the analysis of the neonatal and infant groups. Rotavirus specific IgA in colostrum (neonatal schedule group) and breast milk at 4 weeks (infant schedule group) was identified in 14/21 (67%) and 14/17 (82%) of infants respectively. There was little evidence of an association between IgA in colostrum or breast milk IgA at 4 weeks, or between cord IgG or SNA level, and IgA response or stool excretion after 3 doses of RV3-BB, or after one dose (neonatal schedule) (all p>0.05). Conclusions: The level of IgA in colostrum or breast milk and level of placental and rotavirus vaccines observed children IgA or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. At the time of the study rotavirus vaccines had not been introduced in New Zealand burden of colostrum and breast milk samples collected 4 weeks, 20 weeks and 28 weeks after birth were measured. Infants were randomized to receive the first dose of vaccine at 0-5 d (neonatal schedule) or 8 weeks (infant schedule). Breast feeding was with-held for 30 minutes before and after vaccine administration. The relationship between rotavirus specific IgG and SNA levels in cord blood and IgA in colostrum and breast milk at the time of first active dose of RV3-BB vaccine and level of IgA response and stool excretion after 3 doses of of RV3-BB rotavirus vaccine and were included in the analysis of the neonatal and infant groups. Rotavirus specific IgA in colostrum (neonatal schedule group) and breast milk at 4 weeks (infant schedule group) was identified in 14/21 (67%) and 14/17 (82%) of infants respectively. There was little evidence of an association between IgA in colostrum or breast milk IgA at 4 weeks, or between cord IgG or SNA level, and IgA response or stool excretion after 3 doses of RV3-BB, or after one dose (neonatal schedule) (all p>0.05). The level of IgA in colostrum or breast milk and level of placental IgG and SNA did not impact on the serum IgA response or Alejandro Roque Vald\u00e9s 2004-01-01 El presente trabajo es un art\u00edculo de revisi\u00f3n que pretende abordar un tema tan controvertido como actual: la posible asociaci\u00f3n causal que se ha querido establecer entre el autismo y las vacunas infantiles. A partir de la \u00faltima d\u00e9cada del siglo XX se producen una serie de cambios en la clasificaci\u00f3n, nomenclatura y criterios diagn\u00f3sticos del autismo. Los hallazgos de estudios epidemiol\u00f3gicos llevados a cabo bajo estos nuevos ponderados han revelado que las tasas de prevalencia del autismo s... [Estimating rotavirus gastroenteritis hospitalisations by using hospital episode statistics before and after the a substantial early impact from the rotavirus vaccination program that commenced in 2007 in Australia. However, these assessments are affected by the validity and hospital coding measure the true incidence of hospitalised disease. The aim of this study was to assess the validity of these data sources for disease estimation, both before and after, vaccine introduction. All hospitalisations at a major paediatric centre in children aged <5 years from 2000 to 2009 containing acute gastroenteritis (AGE) ICD 10 AM diagnosis codes were linked to hospital laboratory stool testing data. The validity of the rotavirus-specific diagnosis and the hospitalisations by direct with adjustments for non-testing and miscoding were calculated for pre- and post-vaccination periods. A laboratory record of stool testing was available for 36% of all AGE hospitalisations (n=4948) the rotavirus code had positive hospitalisations only a third had a rotavirus average similar percentage reductions in annual average rotavirus hospitalisations of over 65%. Due to the limited use of stool testing and poor sensitivity of the rotavirus-specific diagnosis code routine hospital discharge hospitalisations and impact. However, this data can still be used to monitor vaccine impact as the effects of drop og has increased, however, all the reports had not been done accurate surveillance are essential for improving children 5 years Hasan Sadikin Hospital, Bandung because of diarrhea, from January 2006 through March 2007 were enrolled in a surveillance study and had stool dehydration (61% vs [Human rotavirus Available Evolution and Bioagents Department, Institute of Biology, State University of Campinas, Campinas, S\u00e3o Paulo, BrazilAbstract: Accounting for an estimated 600,000 deaths acute gastroenteritis among children five years. In Brazil, until rotavirus vaccination was established in the public health system in 2006, acute gastroenteritis striking children under five years and caused by these viruses was clearly associated with 3.5 million each year. After the introduction of the rotavirus vaccine in Brazil in March 2006, studies all over the country have been comparing rotavirus genotypes circulating in the recent pre- and postvaccination Most of these studies have reported a high prevalence of also a decrease in rotavirus detection all over Brazil after the introduction of the vaccine. So far, these are preliminary studies, as a longer period of time is necessary to establish if this high prevalence of G2P[4] is due to selective pressure by the vaccine on the circulating viruses or to a normal genotype fluctuation, and if it will have any impact on vaccine efficacy in the future. This review describes results from the most Available Abstract major cause of infantile gastroenteritis and each year causes 611 000 deaths worldwide. virus infects the mature enterocytes of the a watery diarrhea. Diarrhea can occur visible histological can transport. Maldigestion of carbohydrates and their accumulation in the intestinal lumen as well as malabsorption of nutrients and a concomitant lead to a malabsorption the NSP4 enterotoxin, diverse hypotheses have been proposed in favor in but mechanisms appear to be quite different from origin of net Cl- secretion. A solution to this riddle was that intestinal villi do in fact secrete chloride as dehydration, especially, in children under 5 years old. In Russia, the incidence of rotavirus infection is of IgM, IgG, and, notably, IgA antibodies. Due to absence of market drugs with direct action against rotavirus, a rational vaccination is considered the human animal origin, which replicate in Their implementation result with introduction of a complete virus into humans. In this paper, we studied protective activity flexible bridges. Efficiency of the candidate vaccine was studied in animal model using Balb/c mice. We have shown high level of the candidate vaccine is administered of animals mouse rotavirus EDC after intramuscular immunization with a candidate vaccine was associated with arising rotavirus-specific IgA and IgG antibodies in serum and intestine of immunized animals. conjugadas Text Available Las autoridades regulatorias recomiendan el uso de t\u00e9cnicas de Resonancia Magn\u00e9tica Nuclear o t\u00e9cnicas serol\u00f3gicas para la determinaci\u00f3n de la identidad de los ant\u00edgenos presentes en las vacunas conjugadas. Con la aparici\u00f3n de las vacunas conjugadas multivalentes, se ha hecho necesario recurrir a t\u00e9cnicas inmunoqu\u00edmicas con la utilizaci\u00f3n de anticuerpos monoclonales para aumentar la sensibilidad en la determinaci\u00f3n de la identidad de los ant\u00edgenos en dichas vacunas conjugadas. El objetivo del presente trabajo fue establecer las condiciones \u00f3ptimas de trabajo que permitieran utilizar la t\u00e9cnica del Dot Blot para determinar la identidad de los ant\u00edgenos en vacunas conjugadas de Streptococcus pneumoniae serotipo 19F. Para ello se estudiaron los tiempos de incubaci\u00f3n, la influencia del reactivo en la soluci\u00f3n de bloqueo; tambi\u00e9n las concentraciones \u00f3ptimas del anticuerpo monoclonal y de los ingredientes farmac\u00e9uticos activos, as\u00ed como los vol\u00famenes de aplicaci\u00f3n \u00f3ptimos para estos y vacunas. Se utiliz\u00f3 un anticuerpo monoclonal contra el polisac\u00e1rido capsular del serotipo 19F de neumococo. Las muestras empleadas en este trabajo fueron lotes de ingredientes farmac\u00e9uticos activos de conjugados de polisac\u00e1rido capsular 19F y lotes de un candidato vacunal cubano conjugado heptavalente contra neumococos. Los resultados mostraron que para la determinaci\u00f3n de la identidad antig\u00e9nica fueron suficientes 10 \u00b5L de muestras de los principios activos a una concentraci\u00f3n de 125 \u00b5g/mL e igual volumen para las vacunas heptavalentes. Qued\u00f3 demostrado que una concentraci\u00f3n de 1 \u00b5g/mL para el anticuerpo monoclonal y tiempos de incubaci\u00f3n de 30 min a 37 \u00b0C fueron suficientes para la determinaci\u00f3n. Estos resultados permiten concluir que quedaron establecidas las condiciones \u00f3ptimas de trabajo para determinar la identidad antig\u00e9nica por Dot Blot del polisac\u00e1rido capsular de 19F las Rotavirus gastroenteritis in a patient with Available Rotavirus most common cause of severe gastroenteritis in infants and young children. Reports about the clinical relevance of rotavirus in immunocompromised children rare. We herein presented a case of life-threatening Rotavirus gastroenteritis in an infant with acute the most common cause of children worldwide. Two internationally licensed rotavirus to be high-income countries and they could potentially be valuable tools for the prevention of rotavirus....... There is also a need for political commitment to prevent rotavirus infections as well as a need for an overall strengthening of the health systems in low-income countries. If these challenges were met, rotavirus child health survival from [Evaluaci\u00f3n de los programas de vacunaci\u00f3n mediante estudios serol\u00f3gicos vacunas distribuidas Full Text Available Antecedentes: El objetivo del estudio fue comparar las coberturas vacunales en escolares para la vacuna triple v\u00edrica (sarampi\u00f3n-rub\u00e9ola-parotiditis, DTP (difteria-t\u00e9tanos-tos ferina y poliomielitis, obtenidas a partir de las vacunas distribuidas a los centros de vacunaci\u00f3n, las vacunaciones declaradas y el an\u00e1lisis serol\u00f3gico de anticuerpos. M\u00e9todos: La cobertura vacunal se obtuvo a partir de los antecedentes de vacunaci\u00f3n recogidos en un cuestionario y mediante el an\u00e1lisis serol\u00f3gico de anticuerpos frente al sarampi\u00f3n para la vacuna triple v\u00edrica, y el t\u00e9tanos para la vacuna DTP en una muestra representativa de escolares en 2001. La cobertura vacunal por registros se obtuvo dividiendo el n\u00famero de individuos que pod\u00edan haber completado la vacunaci\u00f3n por la poblaci\u00f3n objetivo. Se evalu\u00f3 la concordancia entre los antecedentes de vacunaci\u00f3n y los resultados serol\u00f3gicos mediante el \u00edndice kappa. Resultados: En los escolares de 6-8 y 9-11 a\u00f1os de edad se obtuvo una cobertura vacunal por cuestionario del 85,5 y el 87,6% para la vacuna DTP, del 89,9 y el 89,6% para la vacuna triple v\u00edrica, y del 90,4 y el 89,4% para la vacuna poliomiel\u00edtica, respectivamente, mientras la cobertura vacunal por an\u00e1lisis serol\u00f3gico fue del 100 y el 99,6% para la vacuna DTP, y del 85,5 y el 93,3% para la vacuna triple v\u00edrica, respectivamente. La cobertura vacunal por registros fue significativamente mayor que la obtenida mediante estos 2 m\u00e9todos: un 93,5 y un 100% para la vacuna DTP, un 96,3 y un 98,8% para la vacuna triple v\u00edrica, y un 100% para la vacuna poliomiel\u00edtica. La concordancia obtenida entre los antecedentes de vacunaci\u00f3n y los resultados serol\u00f3gicos fue muy baja ( Background: The objective of this study was Un grup d'investigadors de la Unitat de Tuberculosi Experimental de la Fundaci\u00f3 Institut Germans Trias i Pujol ha creat una vacuna que permet reduir la durada del tractament de la infecci\u00f3 de nou mesos collaboration with ARSP the Australian Government Department of Health and Ageing evaluated the program for its utility and effectiveness of the rotavirus vaccines recently introduced into the was described using ARSP annual reports and staff interviews. The system were assessed by adapting standard guidelines for evaluating a surveillance system. Email surveys or face to face interviews were conducted with staff of ARSP, participating laboratories, rotavirus vaccine manufacturing companies and representatives of the Communicable Diseases Network Australia. The ability representativeness and sensitivity of the system are needed for the data to remain useful in the public health context. Methods for transferring data between the program and state and territory health departments need to be developed. [Vacunas y autoinmunidad: una rara asociaci\u00f3n bajo debate Vaccines and autoimmunity: a strange association under debate](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342012000200017) [Directory of Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Alexander Batista-Duharte 2012-06-01 Full Text Available La posible asociaci\u00f3n entre vacunas y enfermedades autoinmunes es un tema controversial. Existen elementos a favor de esta relaci\u00f3n basados en modelos te\u00f3ricos, ensayos de laboratorio y varios casos cl\u00ednicos publicados. En cambio, los estudios epidemiol\u00f3gicos no han confirmado esta asociaci\u00f3n y, de ellos, puede inferirse que las vacunas no constituyen una causa demostrada de enfermedades autoinmunes. En este trabajo se analizan las evidencias a favor y en contra de esta controversial asociaci\u00f3n, adem\u00e1s, se aborda un nuevo s\u00edndrome asociado con la administraci\u00f3n continuada de adyuvantes vacunales. Se concluye que debido al gran impacto en beneficio de la salud logrado con las vacunas, es necesario continuar desarrollando esta tecnolog\u00eda, pero tambi\u00e9n se debe seguir perfeccionando los dise\u00f1os de las nuevas formulaciones y profundizando estudios b\u00e1sicos, precl\u00ednicos, ensayos cl\u00ednicos y farmacovigilancia de los nuevos candidatos vacunales para establecer el riesgo real de desarrollo de un evento autoinmune posvacunaci\u00f3n.The occurrence sources including theoretical contrast, several epidemiological studies don't and at least indicates that vaccines are not a major cause of autoimmune diseases. We analyzed current scientific data concluded that vaccines bring a positive impact on public health, this rotavirus vaccines observed children IgA or stool excretion of vaccine virus after any dose of an oral rotavirus vaccine, RV3-BB, in Phase IIa clinical trial conducted at Dunedin Hospital, New Zealand. At the time o... [Vacunas para la prevenci\u00f3n de la gripe en personas de edad avanzada](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::9f9342f04c4ecfc6206eb357ddd593ea) Antecedentes: Durante las \u00faltimas cuatro d\u00e9cadas, las vacunas han sido la principal arma global para disminuir la repercusi\u00f3n de la gripe en las personas de edad avanzada, y a nivel mundial se recomiendan para los individuos de 65 a\u00f1os o m\u00e1s de edad. El objetivo principal de la vacunaci\u00f3n contra la gripe en las personas de edad avanzada es reducir el riesgo de complicaciones en quienes son m\u00e1s vulnerables. Objetivos: Evaluar la efectividad de las vacunas sobre la prevenci\u00f3n de la gripe, la... [Rotavirus vaccination within the South African Expanded ranked the third major cause of childhood mortality in South African children less than 5 years, where the majority and has documented in South Africa. As the preventive strategy to control rotavirus diarrhoea, South Africa became the first country in the WHO African Region to adopt the rotavirus vaccine in the national childhood immunisation programme in August 2009. The rotavirus vaccine in use, Rotarix, GSK Biologicals, is given at 6 and 14 weeks of age, along with other vaccines as part of Expanded Programme on Immunisation (EPI). Studies which facilitated the introduction of rotavirus vaccine in South included burden assess the safety and efficacy of vaccine candidates. This paper reviews the epidemiology of rotavirus in South Africa, outlines some of the steps followed to introduce rotavirus vaccine in the EPI, and highlights the early positive Dr George Mukhari hospital, a sentinel site at University of Limpopo teaching hospital in Pretoria, South Africa, which has conducted rotavirus surveillance for >20 years. Copyright \u00a9 2012 reserved. [Eficacia de la vacuna meningoc\u00f3cica de polisac\u00e1rido capsular del grupo C](https://www.openaire.eu/search/publication?articleId=doajarticles::665616b0e79abcde2883f393f494e02c) Gonz\u00e1lez Enr\u00edquez Jes\u00fas; Garc\u00eda Comas Luis; Alcaide Jim\u00e9nez Juan Francisco; S\u00e1enz Calvo Antonio; Conde Olasagasti Jos\u00e9 1997-01-01 FUNDAMENTO: Este trabajo consiste esencialmente en una revisi\u00f3n sistem\u00e1tica de la literatura cient\u00edfica sobre los efectos, intensidad y duraci\u00f3n de la respuesta serol\u00f3gica, as\u00ed como sobre la eficacia, efectividad y seguridad de la vacuna meningoc\u00f3cica de polisac\u00e1rido capsular del grupo C. M\u00c9TODOS: B\u00fasqueda en repertorio MEDLINE en el periodo 1970-1996. B\u00fasqueda espec\u00edfica de ensayos cl\u00ednicos aleatorizados y estudios de intervenci\u00f3n prospectivos en humanos con vacunas de polisac\u00e1ridos capsular... [Immunogenicity placebo-controlled efficacy trial conducted a 2007 through 2009. 2036 infants were randomly assigned, in a 1:1 ratio, to receive three oral doses of PRV or placebo approximately at 6, 10, and 14 weeks of age. Concomitant use of EPI vaccines, in accordance to the local EPI schedule. A total of 303 infants were evaluated for immunogenicity and blood samples were collected the first dose and two countries combined. When analyzed separately, the the individual serotypes tested ranged from 10 (G3) 50 (G1) the 37.3% (95% CI: 50.0), the G3 response rate in developed countries. Three oral immunogenic in two GAVI-eligible Asian countries: Bangladesh and Vietnam. The GMTs of both the serum anti-rotavirus IgA and SNA responses were generally higher in Vietnamese than in Bangladeshi children. The SNA with We of rotavirus from contacts diarrhea controls and healthy controls following presentation of the index child to health Rotavirus of contacts household contacts, infection attack rates (iAR were 55%, 8% and 2%, (n = 137, 130, 137 respectively. iARs were higher from index cases with vomiting, and amongst siblings. Disease ARs were higher when the index child was <18 months and had vomiting, with household contact <10 years and those sharing a room with the index case being more susceptible. We found no evidence of asymptomatic infections leading to disease transmission.Transmission rates of rotavirus are in households with an infected child, while background infections are rare. We have identified factors associated with transmission (vomiting/young age of index case and susceptibility (young age/sharing a room/being a sibling of the by an unknown mechanism, escape the gastrointestinal tract and cause viremia. The neonatal rat model of rotavirus infection was used to determine the phosphate-buffered saline. Blood following and that detecting rotavirus antigen in the than diarrhea. inflammatory in terms compliance vaccine same visit. Recently, we sought to generate a vaccine vector multiple epitopes into the rotavirus group antigenic protein, VP6. In the present study, a foreign epitope presenting a system using VP6 as a vector was created with six sites on the outer surface of the vector that could be used study contributes to a better understanding of the use of VP6-based vectors as multiple-epitope delivery vehicles and the epitopes displayed form be vaccines against rotavirus and poliovirus. [Comportamiento reactog\u00e9nico de la vacuna cubana contra la hepatitis B en ni\u00f1os f\u00edsica y mentalmente discapacitados](https://www.openaire.eu/search/publication?articleId=doajarticles::cd2d869696f88a55899ab58f2ce979f2) Pl\u00e1cido Pedroso Flaquet; Manuel D\u00edaz Gonz\u00e1lez 2000-01-01 Se estudi\u00f3 la reactogenicidad de la vacuna recombinante cubana contra el virus de la hepatitis B, derivada de c\u00e9lulas de levadura (Heberbiovac-HB), al aplicar dosis de 5 y 10 mg y emplear el esquema de inmunizaci\u00f3n 0, una segunda dosis al mes y la tercera a los 6 meses a 2 grupos de ni\u00f1os f\u00edsica y mentalmente discapacitados de 5 a 14 a\u00f1os de edad. Los s\u00edntomas observados en el total de la poblaci\u00f3n estudiada fueron de 5,1 %, mientras que en los grupos vacunados con 10 y 5 mg, la sintomatolog\u00ed... [Comparative analysis of pentavalent rotavirus vaccine the vaccine efficacy over a 2-year follow-up was lower against the genotypes contained in against the into the high level of cross-protection by RotaTeqTM against these G8 strains. Phylogenetic analysis the presence of a high number of bovine rotavirus gene segments in these human G8 strains. In addition, we performed an in depth analysis on the individual amino acid level which showed that G8 rotaviruses were more strains might be partially explained by the fact May, 2012, Rwanda became the first low-income African country to introduce pentavalent rotavirus vaccine into the global deaths from rotavirus, concerns remain about performance settings. for non-bloody diarrhoea in children younger than 5 years in Rwanda between Jan 1, 2009, and Dec 31, 2014, using monthly discharge data from the Health Management Information System. Additionally, we reviewed the registries in the paediatric wards at six hospitals from 2009 to 2014 and abstracted the number of total admissions and admissions for children younger than 5 by studied trends in admissions specific to rotavirus at one hospital that had undertaken active rotavirus surveillance from 2011 to 2014. We assessed changes in rotavirus epidemiology by use of data Information fell 17-29% from a pre-vaccine median of 4051 to in and was recorded in age-eligible to be vaccinated, but we noted a decrease in the proportion of children with diarrhoea testing positive for rotavirus in almost every age group. The number of admissions to hospital for diarrhoea and brasileira contra hepatite B em rec\u00e9m-nascidos Eficiencia y seguridad de la vacuna brasilera contra hepatitis B en reci\u00e9n-nacidos Efficacy and safety of the Brazilian vaccine against Hepatitis B in newborns](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0034-89102009000600013) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Expedito Jos\u00e9 de Luna 2009-12-01 Full geral do Guarulhos, entre 2002 e 2005. A vacina contra os rec\u00e9m-nascidos foram alocados aleatoriamente ao grupo refer\u00eancia. Os rec\u00e9m-nascidos receberam tr\u00eas doses das vacinas, uma em at\u00e9 24 h ap\u00f3s o nascimento e as subseq\u00fcentes 30 e 180 dias ap\u00f3s. No primeiro ensaio 538 rec\u00e9m-nascidos completaram o Considerou-se crit\u00e9rio de equival\u00eancia a diferen\u00e7a grupo experimental, comparada a 98,5% (267/271 no grupo controle (p = 0,001. Com este VrHB-IB n\u00e3o atingiu 25\u00bcg, a soroprote\u00e7\u00e3o no segundo ensaio foi de 100% no grupo experimental e 99,2% no grupo controle. Nenhum evento adverso grave foi registrado. A foi considerada seu uso recomendado \u00e0 vacina\u00e7\u00e3o de rec\u00e9m-nascidos.OBJETIVO: Analizar la eficiencia y seguridad de vacuna recombinante contra hepatitis B en reci\u00e9n-nacidos. M\u00c9TODOS: El estudio fue conducido en hospital general del municipio de Guarulhos, Sureste de Brasil, entre 2002 y 2005. La vacuna recombinante contra hepatitis B del Instituto Butantan (VrHB-IB fue analizada en dos ensayos cl\u00ednicos. En ambos ensayos, los reci\u00e9n-nacidos fueron distribuidos aleatoriamente en el grupo experimental o control (vacuna de referencia. Los reci\u00e9n-nacidos recibieron tres dosis de las vacunas, una en m\u00e1ximo 24 h posterior al nacimiento y las subsecuentes 30 y 180 d [Seguridad, reactogenicidad e inmunogenicidad de una nueva vacuna de polisac\u00e1ridos meningoc\u00f3cicos en adultos cubanos](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2017000100003&lng=es&nrm=iso&tlng=es) [Directory Rossana Estruch-de la 2017-04-01 Full Text Available Se realiz\u00f3 un estudio aleatorizado, controlado y a doble ciegas, en 352 adultos j\u00f3venes cubanos entre 18 y 35 a\u00f1os de edad, con el objetivo de evaluar la seguridad, reactogenicidad y la inmunogenicidad de una nueva vacuna de polisac\u00e1ridos de Neisseria meningitidis serogrupos A, C y W135, producida por el Instituto Finlay de Vacunas (La Habana, Cuba, con respecto a su similar comercial Mencevax\u00ae ACW de Glaxo Smith Kline. Se tomaron muestras de suero antes y 28 d\u00edas despu\u00e9s de la vacunaci\u00f3n. La reactogenicidad de ambas vacunas fue similar. Los s\u00edntomas y signos, tanto locales como generales fueron leves y aparecieron principalmente durante las primeras 48 h despu\u00e9s de la vacunaci\u00f3n. Ning\u00fan sujeto present\u00f3 eventos adversos graves durante los 28 d\u00edas del per\u00edodo de vigilancia. La vacuna en estudio mostr\u00f3 ser segura y poco reactog\u00e9nica; sus porcentajes de seroconversi\u00f3n a los 28 d\u00edas posteriores a la vacunaci\u00f3n fueron de: 92,19 % para el serogrupo A, 88,89 % para C y 90,06 % para W135. No se detectaron diferencias con respecto a la seroconversi\u00f3n. La seroprotecci\u00f3n alcanzada con la vacuna en estudio fue de 98,44 %, 91,81 % y 95,32 % para los serogrupos A, C y W135 respectivamente y no fue inferior con respecto a la vacuna control para los tres serogrupos estudiados. [Impact of and young children in low and middle-income countries (LMICs). Many of these countries have adopted the into their routine immunization, whereas others are considering introduction. This article provides update the rotavirus vaccines less than 5 years, and their cost-effectiveness. The WHO, updated its recommendation to of the decreased efficacy of the vaccines in LMICs, Sub-Saharan Africa have age the vaccine. Even with improvements in sanitation, nutritional status in children, and other health-related indices in LMICs, the use of rotavirus vaccines will play an important in preventing and public health impact.](https://www.ncbi.nlm.nih.gov/pubmed/21668823) Gray, J 2011-09-01 Rotaviruses are the cause of acute gastroenteritis, and disease is widespread amongst infants and young with significant mortality in developing countries with more than 500 000 children dying each year as a result of the severe dehydration associated rotavirus disease. Efforts been for use in many countries throughout the world following safety effectiveness approximately 40-59% in developing countries, their could significantly mortality associated rotavirus disease that is concentrated in these countries. \u00a9 2011 The Association for the Publication of the Journal of Internal Medicine. [Identification of the two rotavirus gene segments serotype-specific neutralization. determined with radioactively parental authors found that two gene segments serotype-specific neutralization. determined with radioactively parental authors found that two results in approximately half million hospitalizations young children. As in many countries, the infection dynamics of rotavirus in the Netherlands are characterized by an annual winter peak, which was notably low in 2014. Previous study suggested an association between weather factors and both rotavirus transmission and incidence. From epidemic theory, we know that the proportion of susceptible individuals can affect disease transmission. We investigated how these factors are associated with rotavirus transmission in the Netherlands, and their impact on rotavirus transmission in 2014. We used available and proportion to primary infection. Weather data were directly available from a the effective reproduction number from most parsimonious with low autocorrelation. Higher proportions of susceptible individuals and lower temperatures were associated with increases in rotavirus findings susceptible contributed to lower rotavirus transmission in the Netherlands. However, our model, which overestimated the magnitude of the peak, suggested that other factors were likely instrumental in reducing the incidence that year. virus is a double stranded RNA (dsRNA) virus with 11 segments. 4-2-3-2 The I and II exist. This work was carried out to study the prevalence of rotavirus infection among 0-5 shape HPV vaccine introduction strategies in Peru Investigaci\u00f3n formativa relacionada con el dise\u00f1o de estrategias para introducir la vacuna contra el VPH en Per\u00fa](http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342010000300007) [Directory of Open Access Full Text the to prevent cancer. Community-level concerns regarding safety and quality of services will need to be addressed. The immunization system in Peru is strong and has capacity for including the HPV an effective program for HPV vaccine introduction.OBJETIVO: Comprender el contexto sociocultural, las capacidades del sistema de salud y las condiciones pol\u00edticas vinculadas al c\u00e1ncer cervical y a la vacuna contra el VPH para dise\u00f1ar una estrategia apropiada de introducci\u00f3n de la vacuna contra el VPH. MATERIAL Y M\u00c9TODOS: Investigaci\u00f3n formativa usando t\u00e9cnicas cualitativas y cuantitativas. Los participantes incluyeron ni\u00f1os, padres, l\u00edderes, funcionarios del sector salud y educaci\u00f3n, y dise\u00f1adores de pol\u00edticas. RESULTADOS: Generalmente se apoya la introducci\u00f3n de la vacuna contra el VPH, dado que se aprecian los beneficios de la vacunaci\u00f3n y se desea prevenir el c\u00e1ncer. En la comunidad se encontraron preocupaciones sobre seguridad, confianza y calidad de atenci\u00f3n. El sistema de inmunizaciones en el Per\u00fa es eficiente y tiene la capacidad para incluir la vacuna contra el VPH. CONCLUSIONES: La investigaci\u00f3n formativa permite comprender elementos clave que ayudan a dise\u00f1ar un programa efectivo para la introducci\u00f3n de la vacuna contra el VPH. [Estudios de inmunogenicidad, seguridad y eficacia de la Vacuna Q frente a la leishmaniosis canina](https://www.openaire.eu/search/publication?articleId=od_______296::4dfda7f2f3e4339756541268672e7022) Fern\u00e1ndez Cotrina, Javier 2016-01-01 Se analizaron la seguridad, inmunogenicidad y eficacia protectiva de cuatro dosis de la vacuna Q de Leishmania infantum (VQ). Para ello, cincuenta perros beagle (10 por grupo) fueron vacunados con una dosis \u00fanica de 200, 100, 50 y 25 \u00b5g de VQ. A los perros del grupo control se les inyect\u00f3 el diluyente de la vacuna. Los datos muestran que la vacunaci\u00f3n con VQ indujo una respuesta humoral temprana y espec\u00edfica dependiente de la dosis. Adem\u00e1s, durante el per\u00edodo post-vacunaci\u00f3n no se detect\u00f3 rea... [Effectiveness rotavirus vaccines in 2006, rotavirus was the of gastroenteritis among European children rotavirus vaccines in Europe following first of Four findings from post-marketing studies from the US and Latin America. We confirm the significant public health benefit of rotavirus vaccination in Europe and provide further evidence to universal rotavirus all European countries. Copyright \u00a9 2015 Live-attenuated lower efficacy in low income countries, and additionally are associated with a rare but severe adverse event, intussusception. We have been (IM administration in mice. The aim of this study was to evaluate the response and with virulent Wa G1P[8] human doses of 5 g IRV when administered intradermally and 5 index and in sera of the piglets. This study demonstrated that the ID and IM administrations of IRV are immunogenic and protective against low income countries, and additionally are associated with a rare but severe adverse event, intussusception. We have been (IM) administration in mice. The aim of this study was to evaluate the response and with virulent Wa G1P[8] human doses of 5 g IRV when administered intradermally and 5 index and in sera of the piglets. This study demonstrated that the ID and IM administrations of IRV are immunogenic and protective against in producing potentially be used. In order to develop such an alternative therapy, the effectiveness of Lactobacillus produce to surface was investigated. L. rhamnosus GG is one of probiotic and from sources, only GG (UT) was able to display ARP1 on the bacterial surface. The genomic analysis of strain GG (UT) showed that the genes welE and welF of the EPS cluster are inactivated, which causes a defect in exopolysaccharide (EPS) its surface. Finally, GG to confer a level of protection against rotavirus-induced diarrhea similar to that of wild-type GG (NCC 3003) in a mouse pup model, indicating that the EPS may not be involved in the intrinsic antirotavirus activity. Most BL23. American Society for Microbiology. All Rights Reserved. [Desarrollo de vacunas contra el virus de la inmunodeficiencia humana tipo 1: Relevancia de la inmunidad celular contra subtipos](https://www.openaire.eu/search/publication?articleId=doajarticles::3941e408f16fd779b922d875bd01b15f) Ana Mar\u00eda Rodr\u00edguez; Gabriela Turk; Mar\u00eda Fernanda Pascutti; Juliana Falivene; Mar\u00eda Magdalena Gherardi 2010-01-01 Han pasado casi 30 a\u00f1os de la detecci\u00f3n de los primeros casos de infecci\u00f3n con HIV-1 y a\u00fan no se ha conseguido desarrollar una vacuna efectiva y segura. A pesar del impacto positivo sobre la pandemia que se ha conseguido gracias a los avances en la terapia antirretroviral (TARV), el HIV/sida sigue constituyendo un grave problema para la salud p\u00fablica, especialmente en los pa\u00edses en desarrollo, donde es dif\u00edcil el acceso al tratamiento. En el mundo, 33 millones de personas viven con el virus d... [Effectiveness of 1000 child-years among children age less than 5 and it imposes a substantial burden to the healthcare system in (RV1) (RV5) rotavirus vaccines are licensed in Japan, neither has been incorporated in the national infant immunization programme. In this study, we estimated vaccine effectiveness (VE) in Japan. This study was conducted in Yuri-Kumiai General Hospital located in a city in the north-western part of Japan. Age-eligible children for rotavirus vaccination were enrolled if they were hospitalized for rotavirus gastroenteritis between September 2013 and August 2016. Rotavirus gastroenteritis was defined by the detection of rotavirus antigen by immunochromatography. \"Vaccinated\" was defined modelling the year of birth, year of admission, residence of the children and vaccination status, and by matching the age of cases with that of test-negative controls. The adjusted odds ratio of the vaccinated over unvaccinated was then used to calculate VE in the formula of (1 - adjusted odds ratio) \u00d7 100. Out of the 189 test-negative controls vaccinated. During the study period, the vaccine uptake rate in the controls increased from 36.2% to 61.8%. On the other hand, the vaccination coverage over the three years was 64.2% in Yuri-Honjo city (three quarters of the catchment), and 91.4% in Nikaho city (one quarter of the catchment). The VE was calculated to be 70.4% (95% confidence interval: 36.0-86.4%, P = 0.002). The point estimate of the VE was lower but its 95% confidence interval overlaps those of the efficacies obtained of the leading causes of death in children under 5, and an estimated 39% of these deaths are attributable to rotavirus. Currently two live, immunity effect associated rotavirus vaccine not yet been quantified. The purpose of this meta-analysis was a systematic literature review of articles published between 2008 and 2014 that measured the impact of rotavirus vaccine on severe gastroenteritis (GE) We assessed the quality published immunity one of across all years presented studies. studies reporting a rotavirus-specific GE outcome, four of five of which were conducted in the United States, the median herd effect across all study years studies reporting an all-cause GE outcome, all of were Latin America, the median herd effect a herd immunity effect in children under one year of age in the United States and Latin American countries. Given the high variability in vaccine efficacy Published by Elsevier All rights reserved. [Prevalence among Saudi children with gastroenteritis. This study was conducted at the Department of Medical Laboratories, Qassim University during the winter seasons of the years 2004 and 2005. A total of 284 diarrhoeal fecal specimens collected from children using enzyme immunoassay. Of the 284 specimens, to be positive for viruses gastroenteritis. Rotavirus to A. Eight specimens were found positive by two viruses. The introduction of simple and rapid tests for diagnosis of viruses causing gastroenteritis in patients. (author) [Mortalidad por enfermedad diarreica en menores, antes y despu\u00e9s de la introducci\u00f3n de la vacuna contra el rotavirus Analysis of the mortality due to diarrhea in younger children, before and after the introduction of of Text Available OBJETIVO: Analizar la mortalidad por diarrea en menores de cinco a\u00f1os en M\u00e9xico, antes y despu\u00e9s de la vacunaci\u00f3n contra el rotavirus. MATERIAL Y M\u00c9TODOS: Se compararon defunciones y mortalidad por diarrea mediante diferencias porcentuales anuales por grupo etario, antes (2000-2005 y despu\u00e9s (2006-2007 de la vacunaci\u00f3n. RESULTADOS: Entre 2000 y 2007 la mortalidad por diarrea disminuy\u00f3 42%. En los estados con vacunaci\u00f3n, la mortalidad se redujo 15.8 y 27.7% en menores de uno y de uno a cuatro a\u00f1os, respectivamente, en el periodo de 2006 a 2007. DISCUSI\u00d3N: La reducci\u00f3n observada en la mortalidad por diarrea en menores de cinco a\u00f1os despu\u00e9s de 2005 puede atribuirse en parte a la vacunaci\u00f3n contra el rotavirus.OBJECTIVE: To analyze the mortality due to acute diarrhea in children younger than five years old, before and after the introduction of rotavirus vaccine in Mexico. MATERIAL AND METHODS: states' vaccine status using annual percentage differences before (2000-2005 and after (2006-2007 the introduction of the HRV. RESULTS: From 2000-2007, deaths due to acute diarrhea in children under five years of age dropped 42%. In those states that received the HRV early in 2006, diarrhea mortality decreased between 2006-2007 15.8% in children younger than one year old and 22.7% in children 1-4 years old. DISCUSSION: The observed reduction in mortality due to acute diarrhea in children under five years of age after 2005 can be, in part, attributed to the HRV. [Presencia de rotavirus en adultos con diarrea en Asunci\u00f3n, Paraguay Incidence of rotavirus in adults with in Asunci\u00f3n, of Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) M. Mart\u00ednez 2005-06-01 Full Text Available Desde octubre de 2001 a marzo de 2004 se analizaron 533 heces de individuos mayores de 18 a\u00f1os con cuadros de diarrea, identific\u00e1ndose rotavirus en 92 (17,3% de ellas. La infecci\u00f3n por rotavirus en adultos no mostr\u00f3 un grupo et\u00e1reo m\u00e1s afectado y se present\u00f3 a lo largo de todo el a\u00f1o sin diferencias significativas en las frecuencias trimestrales. En Paraguay, en los ni\u00f1os menores de 5 a\u00f1os, presenta un pico estacional entre los meses de junio y octubre. Los datos presentados refuerzan la necesidad de tener en cuenta a rotavirus en el diagn\u00f3stico diferencial de las diarreas en adultos.From October 2001 to March 2004, 92 out of 533 (17.3% fecal samples of patients over 18 years of age were positive for rotavirus. There were not differences of rotavirus incidence between age Although in Paraguay, rotavirus infections in children less than 5 years old present a seasonal peak pattern (since June to October, in adults rotavirus was present throughout the year adults. [La Expedici\u00f3n Filantr\u00f3pica de la vacuna (1803 - 1810](http://scielo.isciii.es/scielo.php?script=sci_arttext&pid=S0465-546X2007000400010) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Jorge Veiga de Cabo 2007-12-01 Full Text Available La Expedici\u00f3n Filantr\u00f3pica de la vacuna supuso una de las empresas sanitarias realizadas en el Siglo XVIII de mayor envergadura, por su complejidad, dificultad y sobre todo, por constituir una de las misiones de Salud P\u00fablica m\u00e1s importantes realizadas en la Historia. Supone el resultado de un proceso en el que una serie de acontecimientos hist\u00f3ricos, sanitarios y sociales confluyen para generar uno de los primeros programas de intervenci\u00f3n en salud p\u00fablica a escala internacional y de expansi\u00f3n de la vacuna de la viruela. Se crean Centros de producci\u00f3n, almacenamiento y distribuci\u00f3n de la vacuna, y programas de capacitaci\u00f3n t\u00e9cnica enfocados a mantener campa\u00f1as de vacunaci\u00f3n poblacional.One of the most important medical achievements made in the eighteenth century was the Philanthropic Expedition of the Vaccine. Due to its complexity and difficulty it was one of the most important Public Health undertakings in history. It was the outcome of a series of historical, social and health advances that converged in creating one of the earliest international programs for the expansion of the smallpox vaccine, creating centres for the production, storage and distribution of the vaccine together with technical training programs cause of severe gastroenteritis and mortality in young children and animals. Due to segmented nature of dsRNA genome and caprine samples collected from organized rotavirus were The latex agglutination test showed 25 newborn positive of ovine, bovine and human origin. Only two Sheep22/Hisar/2013) showed vp4 A rotavirus (GAR) specific primer. However, they did not >98/97% and vp7 nt/aa identity different of Based on nucleotide with human from different regions of the world. Earlier, higher prevalence of human rotaviruses was reported analysis strongly transmission of human GAR to sheep. Vaccines: a of success with 2017-01-01 Approximately 40 years have passed since the discovery of the rotavirus and 10 years since the introduction and progressive and four additional vaccines have been licensed and are being used in defined regions. In this context, one main issue that remains unsolved is the lower review. The imperative challenge ahead is to fulfill the of severe gastroenteritis in children less than five years of age. Essentially, all children around the world get the disease during the first few years of life. Infectious Diseases. Date Released: Text medical problem young children, caused by different microbial including Cryptosporidium spp. and rotavirus, which are usually stool test. This aimed and children Erbil.Methods: Fecal specimens were 400 children (boys and girls, aged one month to five years old, who attended Hospital in Erbil higher among boys (6.25% vs 5.55% and 2 The peak infection higher among males (34.4% vs 30.0% and in children between one to three years old (39.3%. The of rotavirus infection. [Estudio de toxicidad por dosis \u00fanica y tolerancia local de una vacuna antimeningoc\u00f3cica tipo B en ratas Sprague Dawley](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200004&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Juan F. N\u00fa\u00f1ez 2006-08-01 Full Text Available La vacuna antimeningoc\u00f3cica tipo B, objetivo de este estudio, contiene ves\u00edculas purificadas de la membrana externa del meningococo del serogrupo B de la cepa (Cu- 385 - 83 B:4:P1.19,15. El esquema de vacunaci\u00f3n propuesto en humanos consiste en tres dosis de 0,5 mL, separadas por un intervalo \u00f3ptimo de ocho semanas. El objetivo de este estudio de toxicidad en ratas Sprague Dawley (SD fue determinar la toxicidad potencial, letalidad, \u00f3rganos, sistemas susceptibles y otros eventos adversos, as\u00ed como la toxicidad en el sitio de inoculaci\u00f3n despu\u00e9s de la administraci\u00f3n de una dosis de la vacuna en estudio. Los resultados indicaron que, bajo las condiciones del estudio y seg\u00fan los criterios establecidos para evaluar los resultados, la vacuna antimeningoc\u00f3cica tipo B, no produce efectos t\u00f3xicos en el modelo animal usado. Todo lo que se observ\u00f3 fueron formaciones granulomatosas a nivel del punto de inoculaci\u00f3n. Estas formaciones han sido reportadas como pertenecientes a los adyuvantes de dep\u00f3sito, como el hidr\u00f3xido de aluminio, usado en otras vacunas parenterales. Se concluye que la vacuna antimeningoc\u00f3cica tipo B result\u00f3 satisfactoria en las pruebas de toxicidad por dosis\u00fanica y tolerancia local realizadas en la especie rata. [Effectiveness of Pentavalent Rotavirus Vaccine Under Conditions countries than in high-income countries. Rwanda was one of first low-income countries in sub-Saharan Africa to introduce rotavirus vaccine into its national immunization program. We sought to evaluate rotavirus vaccine effectiveness (VE) using a case-control design. Cases and controls were children who presented with a diarrheal illness to 1 of 8 sentinel district hospitals and 10 associated health centers and had a stool specimen that tested positive (cases) or negative (controls) for enzyme immunoassay. Due to high vaccine coverage almost immediately after vaccine introduction, the analysis was restricted to children 7-18 weeks of age at time of rotavirus vaccine introduction. VE was calculated as (1 - odds ratio) \u00d7 100, where the odds ratio was health center visit and was 65% (95% CI, -80% to 93%) in children 6-11 months of age and 81% (95% CI, 25%-95%) in children 12 months of age. Rotavirus vaccine is in in Rwandan children who began their rotavirus vaccine series from 7 to 18 weeks of age. Protection from vaccination was sustained after the first year of life. Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US. [Etiolog\u00eda y manejo de la gastroenteritis aguda infecciosa en ni\u00f1os y adultos](http://www.sciencedirect.com/science/article/pii/S071686401470063X) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) A. Yalda Lucero, DRA 2014-05-01 Full Text Available La Gastroenteritis Aguda (GEA infecciosa es una patolog\u00eda frecuente y de alto impacto, especialmente en ni\u00f1os menores de cinco a\u00f1os y adultos mayores. En nuestro medio, la causa m\u00e1s frecuente es viral (rotavirus y norovirus seguido de Salmonella, Shigella, E.coli diarreog\u00e9nicas y Campylobacter. Habitualmente son cuadros autolimitados que no requieren estudio de laboratorio espec\u00edfico y cuyo manejo debe centrarse en la reposici\u00f3n hidro-electrol\u00edtica de acuerdo al grado de deshidrataci\u00f3n. Existe evidencia sobre beneficio sintom\u00e1tico del uso de probi\u00f3ticos (Lactobacillus GG y S.boulardii; racecadotrilo en cuanto a la diarrea; y ondasetr\u00f3n para los v\u00f3mitos. En caso de sospecha de agente invasor (bacteria o par\u00e1sito debe realizarse un estudio etiol\u00f3gico e iniciar terapia antimicrobiana de acuerdo al microorganismo identificado. La prevenci\u00f3n de contagio mediante medidas de saneamiento y adecuada manipulaci\u00f3n de agua y alimentos es fundamental. Actualmente se dispone de vacunas efectivas contra algunos de los agentes involucrados (ej. rotavirus, que deben recomendarse en grupos de riesgo. [Rotavirus Infection in the Auckland Region After the Implementation of Universal Infant Rotavirus Vaccination: Impact on Hospitalizations L; Drinkovi, Dragana; Roberts, Sally A; Wilson, Elizabeth M; Best, Emma J 2018-01-01 In July 2014, New Zealand introduced universal infant vaccination with RotaTeq (Merk & Co.) administered as 3 doses at 6 weeks, 3 and 5 months of age. We sought to assess the impact of rotavirus vaccination on gastroenteritis (GE) hospitalizations in the greater Auckland region and analyze changes in rotavirus testing in the period around vaccine introduction. Hospitalizations, laboratory testing rates and methods period (2009-2013), post-vaccine period (January 2015 to December 2015) and year of vaccine introduction (2014). There was a 68% decline in rotavirus hospitalizations human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: Kathleen M 2014-01-01 cause of morbidity and mortality among African infants and young children. A phase III, placebo-controlled, multi-centre clinical trial of a live, oral G1P[8] human rotavirus vaccine (RIX4414) undertaken in Malawi significantly reduced the incidence of severe rotavirus gastroenteritis in the first year of life. We now report on vaccine efficacy in the Malawi cohort of children who were followed into the second year of life. A total of 1,773 healthy infants were enrolled in Blantyre, Malawi into three groups. Two groups received three doses of RIX4414 or placebo at age 6, 10, and 14 weeks and the third group received placebo at 6 weeks and RIX4414 at age 10 and 14 weeks. Subjects were followed by weekly home visits for episodes of gastroenteritis until 1 year of age, and were then re-consented for further follow-up to 18-24 anti-rotavirus was determined on a subset of children by using ELISA on pre- and post-vaccine blood samples. Rotavirus and VP4 RT-PCR. A total of 70/1030 (6.8%, 95% CI 5.3 - 8.5) subjects in the pooled (2 dose plus 3 severe rotavirus gastroenteritis in the entire follow-up period (Vaccine Efficacy 38.1% (9.8 - 57.3). The point estimate of efficacy in the second year of life (17.6%; 59.2 - 56.0) was lower than in the first year of life (49.4%; 19.2 - 68.3). There were non-significant trends towards a higher efficacy in the second year life among children who received the three-dose of human rotavirus vaccine against severe gastroenteritis in Malawian children in the first two years of life: Kathleen M 2012-04-27 cause of morbidity and mortality among African infants and young children. A phase III, placebo-controlled, multi-centre clinical trial of a live, oral G1P[8] human rotavirus vaccine (RIX4414) undertaken in Malawi significantly reduced the incidence of severe rotavirus gastroenteritis in the first year of life. We now report on vaccine efficacy in the Malawi cohort of children who were followed into the second year of life. A total of 1773 healthy infants were enrolled in Blantyre, Malawi into three groups. Two groups received three doses of RIX4414 or placebo at age 6, 10, and 14 weeks and the third group received placebo at 6 weeks and RIX4414 at age 10 and 14 weeks. Subjects were followed by weekly home visits for episodes of gastroenteritis until 1 year of age, and were then re-consented for further follow-up to 18-24 anti-rotavirus was determined on a subset of children by using ELISA on pre- and post-vaccine blood samples. Rotavirus and VP4 total CI the entire follow-up period (vaccine efficacy 38.1% (9.8-57.3)). The point estimate of efficacy in the second year of life (17.6%; -59.2 to 56.0) was lower than in the first of life (49.4%; 19.2-68.3). There were non-significant trends towards a higher efficacy in the second year life among children who received the three-dose the G1P[8 a group A rotavirus was isolated from the brain of a fox with encephalitis and neurologic signs, detected by rabies surveillance reported that detected year round Brazil suggest a seasonal behavior of the infection. On the other hand, some studies link infection with climatic variables such as rainfall. according to the seasonal pattern, estimates the age of greatest risk for infection. The analysis of the rotavirus temporal series and accumulated precipitation was performed with the SPSS. The events (73.8% 573/779) for those born in the period with a low incidence of the virus was recorded at an earlier age (mean age 6.5 +/- 2.0 months) when compared with those born in the station of high incidence (63.5% 568/870, mean age 11.7 incidence and rainfall was demonstrated. In addition, it was found that the period of birth determines the age and risk of infection. This information generated during the preaccine period will be helpful to measure the impact of the vaccine against the rotavirus. [Effect rotavirus examined. time the one-hit The effect studied with respect to two phenomena, viz. the RNA-protein linkage and the formation of uracil dimers. To number of the purified 3 H-uridine-labelled rotavirus was exposed to UV radiation, and the RNA was extracted and analyzed by paper chromatography in the ascending mode. The formation of photodimers was found to be only. (author). 3 Text Available The objective of this study to design a delivery system resistant to the gastrointestinal environment for oral vaccine against porcine Lactococcus lactis in Materials for Disease Control DATES: Written comments is the leading cause of severe diarrhea in children. The aims of the present study were to determine the neutralizing activity of VP6-specific llama-derived single associated diarrhea administration of comparable levels of porcine IgG Abs only protected 4 out of 6 of the animals from human RVA diarrhea but significantly when nor induced detectable host Ab responses to the treatment in serum or intestinal contents. This study shows that the oral administration of rotavirus VP6-VHH nanoAb as a treatment that can complement or be used as an alternative to the current strain-specific RVA Celina G Vega Full Text Available Group A Rotavirus (RVA is the leading cause of severe diarrhea in children. The aims of the present study were to determine the neutralizing activity of VP6-specific llama-derived single associated diarrhea administration of comparable levels of porcine IgG Abs only protected 4 out of 6 of the animals from human RVA diarrhea but significantly when nor induced detectable host Ab responses to the treatment in serum or intestinal contents. This study shows that the oral administration of rotavirus VP6-VHH nanoAb as a treatment that can complement or be used as an alternative to the current strain-specific RVA diarrhea. model\"](http://www.biomedcentral.com/1471-2334/13/54) [Directory Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Tu Hong Anh T 2013-01-01 Full Text Available Abstract Background To update a cost-effectiveness analysis of rotavirus vaccination in the Netherlands previously published in 2011. burden of disease total vacuna of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Jos\u00e9 Moreno 2009-03-01 Conclusiones. Los an\u00e1lisis sugieren la vacunaci\u00f3n como medida masiva de control para influenza en adultos mayores de 65 a\u00f1os. Existe un importante vac\u00edo de conocimiento en la efectividad de la vacuna en ni\u00f1os menores de dos a\u00f1os y madres gestantes. [Molecular Epidemiology of Rotavirus in Rotaviruses are leading causes of gastroenteritis in the young of many species. Molecular epidemiological studies in few. risk factors for infection, and genetic housed within rescue tray fecal samples were collected during the winter and summer in 2012 from all pens containing kittens and a random sample of those housing A was associated with season (odds ratio, 14.8 [95% CI, 1.1 to 200.4]; P = 0.04) but not age or diarrhea. It was higher during the summer (4.7%; 95% CI, 1.2 to 8.3%) than in winter (0.8%; 95% CI, 0.2 to of detected characterized for 19 (33.3%) of the 57 rotavirus-positive and identified, G3P[9] G6P[9]. the first population-based study of rotavirus in cats and the first report feline G6P[9], which questions the previous belief Journals Javier 2010-08-01 Full Text Available Abstract Background Rotavirus is the most common cause of gastroenteritis in young children worldwide. The aim of the study was to assess the health outcomes and the economic impact of rotavirus vaccination Methods A birth cohort was followed up to the age 5 using a cohort model. Epidemiological parameters were prospective epidemiological study conducted in Spain, 2004-2005 and from the literature. Direct and indirect costs were assessed from the national costs sources. RotaTeq per protocol efficacy data was taken from a large worldwide rotavirus clinical trial (70,000 children. Health outcomes included costs from both perspectives: \u20ac22 million from the national health system perspective and from Jim P 2017-04-03 Rotavirus gastroenteritis is a leading global cause of mortality and morbidity in young children due to diarrhea and dehydration. Over of deaths occur contrast, same offers the possibility to save many more lives of children under the age of 5. The reduced efficacy of rotavirus vaccines in developing settings may be related to well as host immune factors. This review examine under study to target the issue of effectiveness Full Text Available Abstract are the single most important cause of severe diarrhea in young children worldwide. The once daily with Gastrogard-R\u00ae from the age of 4 to 10 days, and were inoculated with rhesus rotavirus (RRV at 7 days of age. secondary inoculation with epizootic-diarrhea infant-mouse (EDIM virus was days of age. Disease symptoms were scored daily and viral samples the responses. In intervention be before and after vaccine introduction among children 5 years of age. Rotarix \u00ae rotavirus vaccine is currently licensed for infants in and was introduced in 2012. The vaccination course consists of two doses. The first dose is administrated at 6 weeks of age and the second dose is completed by 10 weeks. Based on a longitudinal observational study, we assessed the impact vaccination on rotavirus hospitalization before and after vaccination among children 5 years of age at the Yemeni-Swedish Hospital (YSH in Taiz, Yemen. old. covered diarrhea was reduced by 75.93%. Vaccine coverage increased from 23% in 2012 to 72% in 2014. Also, the results showed that the program in will rely upon efficient vaccine delivery systems and sustained evolving tres arbovirosis transmitidas por mosquitos Aedes, se han propagado en las \u00faltimas d\u00e9cadas en zonas tropicales y subtropicales h\u00famedas. El dengue es epid\u00e9mico en \u00e1reas subtropicales de la Argentina. Despu\u00e9s de la infecci\u00f3n por DENV hay inmunidad duradera contra el serotipo infectante, pero aumenta el riesgo de enfermedad grave por los otros tres. La vacuna recombinante tetravalente, Dengvaxia\u00ae previene el dengue grave y la hospitalizaci\u00f3n en s... [Bovine rotavirus pentavalent G9 has been developed by the Serum Institute of India Ltd, in collaboration with the National Institute of Allergy and Infectious Diseases USA. The vaccine and II studies adults, and infants. It has been found safe and immunogenic and will undergo a large Phase III study to assess efficacy against severe rotavirus gastroenteritis. Copyright \u00a9 2014. (Sweden)](https://doaj.org/search#.V6PA8bgrK70) 2011-04-01 Full Text Available Abstract Background Diarrhea mortality remains a leading cause of child death and rotavirus vaccine an effective tool for preventing severe rotavirus diarrhea. data efficacy may by region. Methods We reviewed published vaccine efficacy trials to estimate We assessed the a standard protocol and conducted meta-analyses where more than Latin America, 42.7% of episodes in high-mortality Asia, of episodes in sub-Saharan Africa, 88% of episodes low-mortality Asia vaccine on diarrhea mortality. The strains peculiar to this environment should be introduced. ..... Safety and efficacy of an against severe rotavirus ... prevalence and 41, astrovirus, and rotavirus. [Eficacia y seguridad de una vacuna contra la leptospirosis humana en Cuba Efficacy and safety of a vaccine against human leptospirosis in Cuba](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004000400005) [Directory of Open 2004-04-01 Full Text Available OBJETIVOS: Evaluar la eficacia de la vacuna cubana contra la leptospirosis vax-SPIRAL y aportar informaci\u00f3n adicional acerca de la seguridad de esta vacuna. M\u00c9TODOS: Ensayo de eficacia (fase III controlado, aleatorizado y con doble enmascaramiento de la vacuna cubana contra la leptospirosis vax-SPIRAL (Instituto Finlay, Cuba. Como control se utiliz\u00f3 la vacuna recombinante contra la hepatitis B Heberbiovac-HB (Heber Biotec, Cuba. Como unidad de aleatorizaci\u00f3n para la asignaci\u00f3n al grupo de estudio o al grupo testigo se emplearon los 523 consultorios de los m\u00e9dicos de familia existentes en los municipios seleccionados. El estudio abarc\u00f3 a toda persona de 20 a 64 a\u00f1os de edad de uno u otro sexo que resid\u00eda en los municipios de Ranchuelo, Quemado, Santo Domingo, Encrucijada, Corralillo, Cifuentes y Camajuan\u00ed, en la provincia de Villa Clara, ubicada en la regi\u00f3n central de Cuba, que acept\u00f3 participar voluntariamente en el ensayo. La vacunaci\u00f3n se efectu\u00f3 en los consultorios de los m\u00e9dicos de familia entre febrero y julio de 1998, con un intervalo de 6 semanas entre las dos dosis. El per\u00edodo de seguimiento fue de 12 meses. Se consider\u00f3 positivo un caso si hab\u00eda recibido las dos dosis de la vacuna asignada y hab\u00eda enfermado de leptospirosis, con diagn\u00f3stico confirmado mediante m\u00e9todos serol\u00f3gicos y microbiol\u00f3gicos, despu\u00e9s de 21 d\u00edas de aplicada la segunda dosis. Se calcularon la eficacia de la vacuna y el riesgo relativo (RR de enfermar de leptospirosis despu\u00e9s de la vacunaci\u00f3n. Para el estudio de seguridad se escogi\u00f3 a dos personas al azar entre las personas vacunadas en cada uno de los consultorios que participaron en el estudio de eficacia. El seguimiento de las reacciones adversas locales y sist\u00e9micas lo realizaron los m\u00e9dicos de familia durante los siete d\u00edas posteriores a la aplicaci\u00f3n de cada dosis. El nivel de significaci\u00f3n se fij\u00f3 en 0,05. RESULTADOS: En total se vacun\u00f3 a 101 832 personas, de las cuales 50 [Global Impact of all-cause acute gastroenteritis (AGE) the first 10 years since vaccine licensure, including recent evidence from countries with were reduced by a median of 67% overall and 71%, 59%, and 60% in countries with low, medium, and high and all-cause Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US. [Impact and mortality globally, and rotavirus is responsible for decreases, the number of rotavirus deaths in children under five was 215,000 per year in 2013. Of these deaths, approximately 41% occurred in Asia and 3% of those in Bangladesh. While Bangladesh has yet to introduce rotavirus vaccination, the country applied for Gavi support and plans to introduce it in 2018. This analysis evaluates the impact and cost-effectiveness of rotavirus vaccination in provides estimates of costs of the vaccination program to help inform decision-makers and international partners. This analysis used Pan American Health Organization's TRIVAC model scenario. With a Gavi $142/DALY averted. Without a Gavi ranged from is to be cost-effective. of vaccination de vacunas y casos de muerte s\u00fabita del lactante en el Per\u00fa, 2001. \u00bfAsociaci\u00f3n o coincidencia temporal?](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::e53e6396d7036924ac4edb136005a9b2) Vargas H, Javier; Centro Nacional de Salud P\u00fablica, Instituto Nacional de Salud. Lima, Per\u00fa.; Su\u00e1rez J, Magna; Centro Nacional de Salud P\u00fablica, Instituto Nacional de Salud. Lima, Per\u00fa.; Llamoga S, Alejandro; Centro Nacional de Salud P\u00fablica, Instituto Nacional de Salud. Lima, Per\u00fa.; Quispe T, Neyda; Centro Nacional de Salud P\u00fablica, Instituto Nacional de Salud. Lima, Per\u00fa.; Alva R, Fernando; Chu C, Julia; Centro Nacional de Producci\u00f3n de Biol\u00f3gicos, Instituto Nacional de Salud. Lima Per\u00fa.; Pereyra S, H\u00e9ctor; Oficina General de Epidemiolog\u00eda, Ministerio de Salud. Lima, Per\u00fa.; Ticona Z, Mar\u00eda; Oficina General de Epidemiolog\u00eda, Ministerio de Salud. Lima, Per\u00fa.; Medrano G, Jorge; Direcci\u00f3n General de Salud de las Personas, Ministerio de Salud. Lima, Per\u00fa.; Cerna D, Carolina; Direcci\u00f3n General de Salud de las Personas, Ministerio de Salud. Lima, Per\u00fa. 2006-01-01 Objetivos: Describir las caracter\u00edsticas cl\u00ednicas, socioecon\u00f3micas, y patol\u00f3gicas de nueve casos de lactantes que fallecieron horas despu\u00e9s de administr\u00e1rseles vacunas antipolio y DPT junto con anti Haemophilus influenzae b o asociada con antihepatitis B o BCG. Materiales y m\u00e9todos: Revisi\u00f3n de la historia cl\u00ednica, entrevista con el equipo de salud a cargo de la vacunaci\u00f3n y con los padres del lactante fallecido. Revisi\u00f3n de los informes del protocolo de autopsia e informes de anatom\u00eda patol\u00f3... [Epidemiology of rotavirus diarrhea in [African Journals Online (AJOL)](http://www.ajol.info/index.php) Background: Rotavirus still remains the major cause of diarrhea in children below 5 years. No data on rotavirus epidemiology is available in the Northern regions of Cameroon. aimed to determine the prevalence of group A rotavirus (RVA) in children below 5 years with of (aged 0-12 admitted acute diarrhea in our 2011. the 839 pentavalent was conducted in 4 hospitals from January 2012 to August 2013. Vaccine status was compared between case patients (children with laboratory-confirmed rotavirus nondiarrhea diarrhea models. We 213 case patients, 657 hospital controls, and 334 test-negative controls. Effectiveness of 2-3 doses of a rotavirus vaccine against rotavirus requiring emergency interval [CI], 58%-84%) with hospital controls, and 52% (95% CI, 26%-69%) with test-negative controls. Using hospital controls, of age (71% [95% CI, 44%-85%]) (P= .85), from Published by Oxford University Press for the Infectious Diseases Society of America 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US. [Streptococcus pneumoniae aislados durante 2002-2006: serotipos y resistencia antibi\u00f3tica. Correlaci\u00f3n las vacunas existentes](http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1025-55832008000100006&lng=en&tlng=en) of Open Jos\u00e9 Mar\u00eda Guevara-Duncan 2008-03-01 Full Text Available Objetivos: Identificar los serotipos de S. pneumoniae aislados, correlacion\u00e1ndolos con los incluidos en las vacunas existentes y su resistencia antimicrobiana. Dise\u00f1o: Estudio descriptivo, observacional y longitudinal. Lugar: Instituto de Medicina Tropical Daniel A. Carri\u00f3n, Facultad de Medicina, UNMSM. Material biol\u00f3gico: Cepas Intervenciones: Cuarenta Streptococcus pneumoniae de nuestro cepario, aislados entre el 2002 y 2006, fueron serotipificados en el Instituto de Salud Carlos III en Madrid -Espa\u00f1a; 15 fueron invasivos, 11 aislados de infecciones localizadas, 6 de portadores y 8 eran multiresistentes. Principales medidas de resultados: Protecci\u00f3n de las vacunas existentes en nuestro medio a las infecciones causadas por Streptococcus pneumoniae. Resultados: Hubo 14 serotipos diferentes y los serogrupos m\u00e1s identificados fueron 23, 19 y 6. El 28,6% estaba contenido en la vacuna 7-valente, 42,9% en la 9-valente, 50% en la 11-valente y el 71,4% en la 23-valente; 57,5% fue resistente a la penicilina y 30% a eritromicina. El grupo de Streptococcus invasivo result\u00f3 m\u00e1s sensible a los antibi\u00f3ticos que los otros grupos. Los serotipos asociados a multirresistencia fueron 19F y 23F. Conclusiones: Ninguna de las vacunas protege a todas las infecciones causadas por Streptococcus pneumoniae, en nuestro medio. [Study on Xuerong; bottle-feeding ones (45.2%). rate buffalo calves in Bangladesh was carried out to detect its association with diarrhoea. An overall 28% incidence in buffalo calves below month (7%) calves. Rotavirus infection in diarrhoeic in winter (16.7%), followed 21 refs, tabs [Estudio histopatol\u00f3gico entre ratones infectados con Salmonella typhi sin vacunar y vacunados por diferentes v\u00edas con las vacunas polisacar\u00eddica y de c\u00e9lulas enteras](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2000000400004&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Juan F. Infante 2000-12-01 Full Text Available La fiebre tifoidea constituye una enfermedad propia del hombre. La misma es causada por Salmonella typhi y produce una respuesta inflamatoria en el tracto intestinal. Con el fin de establecer su control por vacunaci\u00f3n el Instituto Finlay ha desarrollado una vacuna a partir del polisac\u00e1rido capsular Vi. Para su estudio experimental no existe un modelo animal que reproduzca los s\u00edntomas y la patogenia de la enfermedad. El desarrollo de modelos experimentales y los estudios histopatol\u00f3gicos aportan informaciones al conocimiento de la enfermedad y a la interpretaci\u00f3n de los procesos inmunol\u00f3gicos. Nos propusimos caracterizar el cuadro histopatol\u00f3gico en los ratones utilizados en las pruebas de potencia de la vacuna antitifo\u00eddica basada en polisac\u00e1rido Vi purificado y su comparaci\u00f3n con la vacuna de c\u00e9lulas enteras. Se utilizaron 240 ratones de ambos sexos pertenecientes a la l\u00ednea C57BL/6 procedentes del Centro Nacional para la Producci\u00f3n de Animales de Laboratorio (CENPALAB, con un peso comprendido entre 18 y 22 g. Se evalu\u00f3 la protecci\u00f3n comparativa entre las v\u00edas intraperitoneal y subcut\u00e1nea utilizando dos inmun\u00f3genos, a partir del polisac\u00e1rido Vi y con la variante de c\u00e9lulas enteras. Se logr\u00f3 una considerable eficacia en rat\u00f3n C57BL/6 para reproducir las lesiones compatibles con Salmonella typhi en h\u00edgado y bazo. La sobrevivencia del grupo no vacunado fue de un 15%. La sobrevivencia de los ratones correspondientes al grupo vacunado con polisac\u00e1rido Vi oscil\u00f3 entre 90% y 100% para ambas v\u00edas, mientras que los vacunados con c\u00e9lulas enteras variaron entre 50% y 100% para la v\u00eda subcut\u00e1nea y entre 60% y 100% para la v\u00eda intraperitoneal todo lo cual evidencia la superioridad de la vacuna a partir del polisac\u00e1rido capsular Vi sobre la variante de c\u00e9lulas enteras en la especie rat\u00f3n C57BL/6 [Desarrollo de una vacuna probi\u00f3tica para el tratamiento del c\u00e1ncer c\u00e9rvico-uterino](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::1ea3de1bdf059dfdef615fb2bb624b84) Cort\u00e9s P\u00e9rez, Naima Gisela; Berm\u00fadez Humar\u00e1n, Phillipe; Luna Leal, Roberto Montes de Oca 2003-01-01 Dado que el virus del papiloma humano tipo 16 (HPV- 16) es la principal causa del c\u00e1ncer c\u00e9rvicouterino, hay una gran necesidad de desarrollar una vacuna profil\u00e1ctica y/o terap\u00e9utica. La oncoprote\u00edna E7 es constitutivamente producida por neoplasias cervicales y, por tanto, considerada como un blanco potencial para dirigir el desarrollo de una vacuna terap\u00e9utica contra el c\u00e1ncer c\u00e9rvico-uterino. En este trabajo desarrollamos un sistema inducible para expresar la prote\u00edn... [Inactivation of human and human human clearly both virus types were rapidly inactivated by ozone concentrations of Comparison oral rotavirus that are effective in and high in serum and breast milk, severe malnutrition, and interference by other flora and viruses in the gut. We have pursued development of an alternative parenteral rotavirus vaccine with the goal of inducing comparable levels of immunogenicity and efficacy in populations throughout the world regardless of their income levels. In the present study, we the protection of of and (G1P[8]). Our findings demonstrate the proof of concept for an IRV in a large animal model and provide evidence and justification for further clinical development as an alternative candidate vaccine. by Ltd. [Rotavirus epidemiology and vaccine demand: considering the major cause of gastroenteritis in children throughout the world. Every year, a large number of situation leads to economic loss and health problem. searched attenuated vaccines are throughout the world. Many countries have included rotavirus vaccines in national immunization program to reduce the disease burden. However, due to low efficacy of the available has not yet been achieved in developing countries such as Bangladesh. Poor economic, public health, treatment, and sanitation status of the low-income countries necessitate the need effective rotavirus vaccine. this regard, inactivated rotavirus of child mortality worldwide. Rotavirus is one of the most common causes severe and dehydration in of rotavirus This of Pediatrics, Division of Infectious Diseases, Louisiana State University Health Sciences Center, New Orleans, LA, USAAbstract: Until recently, rotavirus was the most common cause of diarrhea in infants and young children with over 100 million cases and 400,000 deaths every year worldwide. Yet, its epidemiology is changing rapidly with the introduction of two in 2000s. result of others being immunized - was not expected to be a benefit of rotavirus vaccination programs since the vaccines were thought to Studies in a variety of settings than expected detect this phenomenon - the consistency of the evidence is compelling. These studies are reviewed and described here. While is needed, clarifying the presence of herd immunity not exercise but for the incidence of the disease is highest the direct vaccine, M : Rotavirus is the most common cause of severe gastroenteritis among young children worldwide. Data are needed to assess the efficacy of the rotavirus vaccine in African children. : We conducted a randomized, placebo-controlled, multicenter trial in South Africa (3166 infants; 64.1% of the total) and Malawi (1773 infants; 35.9% of the total) to evaluate the efficacy of a live, oral rotavirus vaccine severe rotavirus has vaccines on disease burden of the introduction of pentavalent rotavirus vaccination an age-structured model of rotavirus transmission calibrated to 6 years of French gastroenteritis incidence and vaccine clinical trial data. We evaluated the the financial benefits will be recouped within the first 5 years following vaccination implementation. From third-party the burden of rotavirus and could be cost-effective under plausible conditions. Copyright \u00a9 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by [Suspected 2012-01-01 Group A rotaviruses infect humans and a variety of animals. In July a rare rotavirus strain with G8P[14] specificity two patients with diarrheoa, who the same sequences of the and these human G8... [Biennial pattern of rotavirus gastroenteritis in the Netherlands and a the Netherlands. Rotavirus detections were however similar in 2015 and lower in 2016 compared with 2010-2013. Gastroenteritis consultations rates were also age-distribution shifted to older [Determinants of rotavirus transmission young children. As in many countries, the infection dynamics of rotavirus in the Netherlands are characterized by an annual winter peak, which was notably low in 2014. Previous work suggested an association between weather factors and [Rotavirus in the Republic of Ireland by using national data on the number of hospitalizations for diarrhea children by ICD-9-CM for the period January, 1997, to We collated data on laboratory-confirmed detections nationally for the same period among children years old. We calculated the overall contribution of rotavirus to laboratory-confirmed intestinal disease children old INFOSCAN, disease bulletin for one-third of the population. sources and estimated the proportion of diarrheal hospitalizations that are likely the result of rotavirus in children <5 years old. RESULTS: In children <5 years old, 9% of all hospitalizations are for diarrheal illness. In this age group 1 in 8 are hospitalized for a diarrheal illness, and 1 in 17 are hospitalized for rotavirus by 5 years of age. In hospitalized children <2 years old, 1 in 38 have a Access to comprehensive national databases may have contributed to the high hospitalization rates, as well as a greater tendency to with diarrhea Ireland. Available has traditionally as a hemostatic agent, while the aerial part of the plant consisting of leaf and stem is known to exhibit anti-diarrheal properties and has been widely used a remedy in many parts of China. As rotavirus is one of the most commonly associated diarrhea-causing pathogen, this study the And the representative components of aqueous extract were isolated and shown that both the viability of MA-104 cells and the viral load were the cause the low cell viability and viral load, an effect which was accelerated with incubation in the aqueous identified be el desarrollo de vacunas contra la neosporosis bovina Advances in the development of vaccines Full Text Available La neosporosis es una enfermedad que ocasiona abortos en bovinos y est\u00e1 causada por un protozoo intracelular obligado denominado Neospora caninum. Las graves p\u00e9rdidas econ\u00f3micas que provoca en los sistemas de producci\u00f3n de bovinos justifica la necesidad de avanzar en el desarrollo de vacunas. La resistencia a par\u00e1sitos Apicomplexa est\u00e1 asociada a una respuesta inmune T helper 1 mediada por linfocitos T CD4 citot\u00f3xicos y a la producci\u00f3n de interfer\u00f3n-gamma, interleuquina-12, factor de necrosis tumoral e inmunoglobulina G2. La disminuci\u00f3n de la transmisi\u00f3n vertical en las sucesivas pre\u00f1eces y el bajo nivel de repetici\u00f3n de abortos en animales infectados sugieren la existencia de mecanismos inmunitarios de protecci\u00f3n. Hasta el momento se conoce que la inoculaci\u00f3n pre-servicio con taquizo\u00edtos vivos protege contra la infecci\u00f3n y el aborto. Los antecedentes de desarrollo de vacunas vivas contra otros protozoos estimulan a los investigadores a continuar en la b\u00fasqueda de una vacuna de este tipo contra N. caninum de buena eficacia. Por otra parte, una vacuna inactivada, aun con una baja eficacia, es \u00fatil en la prevenci\u00f3n del aborto en aquellos establecimientos donde la enfermedad es epizo\u00f3tica. Una vacuna contra la neosporosis deber\u00eda evitar el aborto, la transmisi\u00f3n transplacental y la persistencia de la infecci\u00f3n. Este trabajo menciona los diversos tipos de vacunas que han sido evaluados hasta el momento, incluyendo inmun\u00f3genos inactivos, taquizo\u00edtos vivos, ant\u00edgenos recombinantes y interferon-gamma, interleukin-12, tumor necrosis [VARIABILIDAD EN LA NOTIFICACI\u00d3N DE REACCIONES ADVERSAS A LAS VACUNAS DE LA GRIPE PAND\u00c9MICA Y ESTACIONAL. TEMPORADAS 2009-2010 Y 2010-2011, COMUNITAT VALENCIANA](https://www.openaire.eu/search/publication?articleId=doajarticles::6f322a77ce0bd5fd88c95f861a1a0782) Ana Mar\u00eda Alguacil Ramos; Jos\u00e9 Antonio Lluch Rodrigo; Antonio Portero Alonso; Rosa Mart\u00edn Ivorra; Eliseo Pastor Villalba 2012-01-01 Fundamentos: La p\u00e9rdida de confianza en la seguridad de las vacunas derivada de situaciones de alarma, como en el caso de la gripe pand\u00e9mica, puede afectar tanto a las coberturas vacunales como a la sensibilidad frente a la notificaci\u00f3n de las sospechas de reacciones adversas asociadas a vacunas (SRAAV). El objetivo del trabajo es describir los efectos adversos a la vacuna frente a la gripe pand\u00e9mica notificados en la temporada 2009-2010 y comparar si existen diferencias con los descritos con... [Simian rhesus rotavirus is virus (>10(8) p.f.u.) productively infect but not 10(3) p.f.u. Horizontal transmission of RRV to one of three mock-inoculated rabbits occurred 4-5 days after onset of virus antigen in RRV-infected rabbits. challenge. These that RRV of the unusual replication efficacy of RRV in rabbits, the sequence of gene encoding the lapine non-structural protein NSP1 was three lapine rotaviruses revealed a high cause severe diarrhea in young Korean children. Rotavirus data acquired from uninterrupted surveillance studies between 1989 and 2009 in South Korea were analyzed to better understand the genetic diversity and G9P[8] has the is necessary to evaluate the efficacy of these vaccines for their sustained use in South Korea. The present study provides comprehensive and up-to-date information regarding the epidemiology, genetic diversity, and evolution of the circulating rotaviruses in Korea. Crown Copyright \u00a9 2014. B.V. All rights reserved. [Unexpectedly burden of rotavirus very of Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Reilly Available Abstract Background highest incidence of rotavirus gastroenteritis has generally been reported in children 6-24 months of age. Young infants are to be protected by maternal antibodies acquired transplacentally or via breast milk. The purpose of our study was to assess the age distribution of children with confirmed community-acquired rotavirus gastroenteritis presenting to an urban referral hospital. Methods Children presenting to The Children's Hospital of Philadelphia with acute gastroenteritis have been monitored for the presence of rotavirus antigen in the stool by ELISA since epidemic season. Results Over the last 12 rotavirus seasons prior to the introduction of the pentavalent rotavirus in or not recorded in 6 and 5 cases, respectively. Overall, 58% of the cases occurred in boys. G1 was the predominant VP7 serotype, accounting for 72% The median (IQR age was 11 (5-21 months. A total of 790 (48% cases occurred in children outside the commonly quoted peak age range, with 27% in infants 24 months of age. A total of 220 (13% cases occurred during the first 3 months of life, and the number of incidence of community-acquired rotavirus gastroenteritis monitored over 12 seasons in the prevaccine era at a major university hospital was nearly constant for each month of age during the first year of of symptomatic rotavirus disease [Perspectivas de vacunas e inmunoterapia contra [Directory of Text Available El c\u00e1ncer cervicouterino representa un grave problema de salud p\u00fablica, debido a la asociaci\u00f3n de la neoplasia con el virus del papiloma humano; actualmente se realizan estudios usando estrategias dirigidas a combatir este pat\u00f3geno, mediante vacunas, que podr\u00edan ser de gran utilidad para el control de la progresi\u00f3n de la enfermedad. El estudio tanto de la inmunolog\u00eda humoral como celular ha servido para el desarrollo de vacunas. As\u00ed, la utilizaci\u00f3n de part\u00edculas virales sint\u00e9ticas para el estudio de anticuerpos neutralizantes y el uso de prote\u00ednas tempranas virales, entre otras, para la inducci\u00f3n de inmunidad mediada por c\u00e9lulas, han sido la pauta para realizar estudios que dirijan la respuesta inmune para prevenir la infecci\u00f3n celular tanto hacia c\u00e9lulas infectadas no transformadas como hacia c\u00e9lulas transformadas viralmente con resultados favorables. [Comparison of two recombinant hepatitis B vaccines and their interchangeability in Argentine infants Comparaci\u00f3n de dos vacunas recombinantes contra la hepatitis B y su intercambiabilidad en lactantes argentinos](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892004000100006) [Directory of Open Access dos vacunas pedi\u00e1tricas recombinantes contra la hepatitis B -Euvax-B y la vacuna de referencia Engerix-B- en cuanto a su inmunogenicidad y reactogenicidad, e investigar su intercambiabilidad, es decir, si el esquema de vacunaci\u00f3n contra la hepatitis B de tres dosis comenzado con una primera dosis de Engerix-B puede completarse con dos dosis de Euvax-B. M\u00c9TODOS: Este estudio se llev\u00f3 a cabo en la ciudad de C\u00f3rdoba, Argentina, entre marzo de 1999 y febrero de 2000. Se vacun\u00f3 contra la hepatitis B a tres grupos de 100 lactantes argentinos a los 0, 1 y 6 meses de edad. El grupo A recibi\u00f3 tres dosis de Euvax-B; el grupo B, tres dosis de Engerix-B; y el grupo C, una dosis de Engerix-B seguida de dos dosis de Euvax-B. Para evaluar la reactogenicidad se utiliz\u00f3 la informaci\u00f3n brindada por los padres acerca de determinados fen\u00f3menos locales o sist\u00e9micos solicitados por los investigadores que hubieran ocurrido durante los siete d\u00edas posteriores a la vacunaci\u00f3n. Para establecer si eran id\u00e9nticas cl\u00ednicamente las vacunas Euvax-B y Engerix-B se utilizaron las tasas de seroprotecci\u00f3n -es decir, t\u00edtulos de anticuerpos contra el ant\u00edgeno de superficie de hepatitis B (anti-HBsAg > 10 miliunidades internacionales por mililitro (mUI/mL- alcanzados dos meses despu\u00e9s de la tercera dosis. RESULTADOS: La reactogenicidad fue baja en los tres grupos de estudio. A los 5 meses de la segunda dosis (es decir, inmediatamente antes de la tercera dosis, las tasas de seroprotecci\u00f3n fueron 95,9%, 94,7% y 90,2% en los grupos A, B y C, respectivamente. Dos meses despu\u00e9s de la tercera dosis, todos los lactantes se encontraban protegidos, con concentraciones medias geom\u00e9tricas de anti-HBsAg de 2 468,1 mUI/mL en el grupo A, de 1 714,8 mUI/mL en el grupo B y de 2 075,3 mUI/mL en el grupo C. CONCLUSIONES: Las dos vacunas recombinantes contra la hepatitis B estudiadas fueron bien toleradas y altamente inmunog\u00e9nicas. La vacuna Euvax-B fue cl\u00ednicamente id\u00e9ntica (no inferior a la [Rotavirus I in feces of a cat with metagenomics in the feces of a cat to the only two currently sequenced members of that species other nor were this DR. AMINU ABSTRACT. The study was carried out to determine the molecular characteristics of the rotavirus strains associated with diarrhea among children in Kwara state, Nigeria. A total of 150 stool samples were collected from (AJOL)](http://www.ajol.info/index.php) study was carried to determine the molecular characteristics of the rotavirus strains associated with diarrhea among children in Kwara state, Nigeria. A total of 150 stool samples were collected from severe gastroenteritis in children <2 years of age in South Africa and worldwide. Most endemic neonatal nursery strains are thought to be asymptomatic. However, rotavirus infection, such as ... [Caracter\u00edsticas de los v\u00eddeos en espa\u00f1ol publicados en YouTube sobre la vacuna contra el virus del papiloma humano](http://www.redalyc.org/articulo.oa?id=17033372012) [Directory of Open Full Text Available Fundamentos: Internet constituye un recurso de b\u00fasqueda de informaci\u00f3n relacionada con la salud. El objetivo de este trabajo fue conocer las caracter\u00edsticas de los v\u00eddeos en idioma espa\u00f1ol de YouTube relacionados con la vacuna contra el virus del papiloma humano (VPH. M\u00e9todos: Se realiz\u00f3 un estudio observacional a partir de una b\u00fasqueda en YouTube el 26 de julio de 2013, con las palabras establecieron categor\u00edas por tipo, fuente de publicaci\u00f3n y predisposici\u00f3n favorable o no hacia la vacuna. Se registr\u00f3 el n\u00famero de visitas, tiempo de duraci\u00f3n de los videos y origen de los 20 v\u00eddeos m\u00e1s visitados. Resultados. Se encontraron 1.080 videos registrados, 170 fueron seleccionados y clasificados como: noticias locales (n=39; 37 favorables, 2 internacionales (n=3; 3/0; 0:11:33; 1667 visitas. De los 20 videos m\u00e1s reproducidos predominan los favorables a la vacunaci\u00f3n (n=12; 0:43:43; 161.789 visitas frente a los desfavorables (n=8; 2:44:14; 86.583 visitas. Conclusiones. Predominan los videos que tiene una opini\u00f3n favorable hacia la vacuna contra el VPH, aunque los videos de contenido negativo son los m\u00e1s extensos y reproducidos- [Implementation of Rotavirus Surveillance and Vaccine Introduction - World Health Organization African Region, 2007-2016.](https://www.ncbi.nlm.nih.gov/pubmed/29095805) Mwenda, (3), coverage (4), and impact on pediatric diarrhea hospitalizations the WHO African Region. By December 2016, 31 (66%) of 47 countries in the WHO African Region had introduced rotavirus vaccine, including 26 that vaccine pediatric hospitalizations that introduction. These of rotavirus in the countries in the and of B H; Pickering, K; DuPont, H L; Woodward, W E 1983-01-01 Previously, we demonstrated that children in day care centers experience diarrhea outbreaks. and teachers hands at a care center, 4 (16%) were positive for rotavirus antigen when SA-11 type 1, and bacteriophage 12 on similar environmental surfaces in a laboratory. Poliovirus type 1 more a dry surface. Rotavirus SA-11 could be detected for 30 min. All three viruses survived longer when they were suspended in fecal material than when they were suspended in water. surfaces be transmitted to susceptible children. This finding helps explain why rotavirus shows a mode of spread like that of parasitic and bacterial agents within day care center settings. was The 2-day meeting included invited lectures as well as original oral and poster presentations and brought together experts from unvaccinated children and neonates too young vaccinated have been observed in many European countries. Early evidence now also suggests that rotavirus attention should be given infants, who may age out of the vaccination window before hospital discharge and to HIV infected children who are at increased risk of severe rotavirus AGE. There is a small but increased following improve protection by vaccination, in vaccines discussed mortality in the developing years of age to rotavirus diarrhea annually, with 145 000 occurring in sub-Saharan Africa. Human astroviruses have been identified as one of the most frequent causes of rotavirus disease, an important cause of gastroenteritis. Since there are no data on the incidence and antigenic diversity of rotavirus infection in remains a leading cause of acute gastroenteritis in children worldwide with an estimated 2000 deaths each day in developing countries. Due scourge in Kenya, it is possible that rotavirus-related gastroenteritis has been aggravated in adults. The Global Alliance for Immunizations has common cause of severe diarrhea in infants and young children is rotavirus which is associated with significant morbidity, use, administered in rotavirus was compared with no universal rotavirus vaccination program. There was a high degree of variability in base-case results across studies even when the same country, often reflecting differences in the selection of data sources used to populate the models. In addition, results were sensitive to plausible changes in a number of key input parameters. As such, it is to whether a universal rotavirus analyses this is the case. In addition, international guidelines advocate universal vaccination of infants and children against rotavirus. It is also difficult to draw conclusions regarding the cost effectiveness of vaccine RIX4414 relative to that of the pentavalent rotavirus vaccine, which administered as cost-effectiveness each vaccine was compared with no universal rotavirus vaccination program, results were generally sensitive to vaccine [Epidemiology of rotavirus-associated hospital admissions in the for rotavirus gastroenteritis in children 0 to 14 years of age were reviewed in the period 2003-2005 in the province of Ferrara. A total of 4,238 children were admitted to the pediatric departments; 151 patients were diagnosed with gastroenteritis. The annual rate of hospitalization for rotavirus was countries, efficacy of a pentavalent rotavirus vaccine against severe disease in Ghana, Kenya, and Mali between April, 2007, and March, 2009. In our multicentre, double-blind, placebo-controlled trial, undertaken in rural areas of Ghana and Kenya and an urban area of Mali, we randomly assigned infants aged 4-12 weeks without symptoms of gastrointestinal disorders in a 1:1 ratio to receive three oral doses of pentavalent rotavirus vaccine 2 mL or placebo at around 6 weeks, 10 weeks, and 14 weeks of age. Infants with HIV infection were not excluded. Randomisation was done by computer-generated randomisation sequence in blocks of six. We obtained data for gastrointestinal symptoms from parents on days or more after the third dose of placebo or vaccine to end of study (March 31, 2009; around 21 months of age). Analysis was per protocol; infants who received scheduled doses occurring rotavirus disease earlier than third dose and had complete clinical and laboratory results were included in the analysis. This study is vaccine and 2348 assigned to placebo were included in the per-protocol analysis. 79 cases of severe rotavirus gastroenteritis were reported in 2610.6 person-years in the vaccine group, compared with 129 cases in 2585.9 person-years in the with postvaccine introduction (2015 and the hospitals. We examined monthly acute diarrhea hospitalizations by Care during 2012-2016. Active surveillance data among children 0-11 months of age and by 21% and 33% among children 12-23 months of age in 1 X 106 pfu/ml of rotavirus, group B chicks were inoculated with 1 X 106 cfu/ml of Salmonella pullorum, group C chicks were inoculated with 1 X 106 pfu/ml of rotavirus and 1 X 106 cfu/ml of Salmonella pullorum, while group D birds were given 1ml of PBS alone. Birds in all groups were ... [Estimates of economic burden of providing inpatient Nagaraj, Shyamala 2007-12-01 To estimate the cost of an episode of inpatient care and the economic burden of hospitalisation for gastroenteritis (GE) hospital-based study on children less than 14 years of age with rotavirus GE, admitted to University of Malaya Medical Centre, Kuala Lumpur, was conducted in 2002. Data on human resource expenditure, costs of for rotavirus GE in Malaysia was estimated by multiplying the cost of each episode of hospital admission for rotavirus GE with national rotavirus incidence in Malaysia. In 2002, the per capita by Malaysian Government was US$71.47. Rotavirus was positive in the 393 patients with acute GE admitted during the study period. The median cost of providing inpatient care for an episode of rotavirus GE was US$211.91 (range US$68.50-880.60). The estimated average cases of children rotavirus GE in Malaysia (1999-2000) was 8571 financial of providing care for GE in be US$1.8 rotavirus in Malaysia a novel VP4 of a recombinant rotavirus vaccine because it mediates the attachment and penetration Due the explored past years. In previous studies, found that addition, it should the was higher than that of VP8 and VP5. In this study, it was found that when the N-terminal 25 could be expressed in soluble form in E. purified to trimers. was diarrhea rotavirus shedding in enhanced and could be considered as a viable candidate for further development and has the potential to parenterally administered rotavirus of child mortality worldwide. Rotavirus is one of the most common causes severe and dehydration in of rotavirus This children with rotavirus diarrhea are included in the study. The majority boys (74.4%) and children aged 0 - 12 months (82.75%). Mean age of children in the study was 16.38 months. Almost every third child in the study was hypotrophic (29.2%). More than half of the infants (55.2%) were on mixed food, somewhat more than was breast feeding (36.45%), and every twelfth (8.33%) was on artificial milk (animal or formula). Apart from diarrhea, present in all patients, vomiting presentation of the represent a considerable cost, particularly for countries that do not qualify for any external financial support. This study aimed to evaluate the cost-effectiveness of introducing rotavirus vaccination into Albania's national immunization program and to inform decision-making by improving national capacity to conduct was to assess vaccine impact cost-effectiveness. The model economic data used in the model were based on national cost studies, and surveillance data, as well as estimates from the scientific literature. Cost-effectiveness was the uncertainty around the incremental cost-effectiveness ratios (ICERs). With 3% discounting of costs and health benefits over to no vaccination, the discounted cost per averted US$ 2008 US$ both perspectives, introduction highly the per less than three times gross domestic of severe gastroenteritis and fatal dehydration in human infants and and electrolytes into the intestinal lumen. Fluid absorption in the small intestine is driven by Na + -coupled transport mechanisms at the luminal membrane, including DNA Vaccines: Induction of the immune (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Javier Mota-S\u00e1nchez 2009-01-01 Full Text Available La efectividad de las vacunas y la inmunizaci\u00f3n en la prevenci\u00f3n de las enfermedades infecciosas es uno de los grandes avances de la medicina. En la actualidad, el acceso a la tecnolog\u00eda de punta en el \u00e1rea de la gen\u00f3mica y la prote\u00f3mica ha hecho posible acelerar el desarrollo de nuevos modelos de vacunas con caracter\u00edsticas mejoradas en aspectos fundamentales, como la inmunogenicidad y la seguridad. A casi dos d\u00e9cadas del primer informe, en el cual se demostr\u00f3 que un gen puede expresarse mediante la inyecci\u00f3n directa de ADN desnudo, las vacunas de ADN han probado ser eficientes para inducir una respuesta inmunitaria protectora contra par\u00e1sitos, virus y bacterias en diversos modelos animales. Esta revisi\u00f3n tiene por objetivo presentar un panorama general de las vacunas de ADN y los mecanismos mediante los cuales la inmunizaci\u00f3n con ant\u00edgenos insertados en vectores de ADN (pl\u00e1smidos inducen una respuesta inmunitaria.The effectiveness of vaccines and immunization in the prevention of infectious diseases is one of the greatest successes in medicine. In recent years, with access to cutting edge genomic and proteomic technology, it is possible to accelerate the development of new and improved vaccines with better immunogenicity and safety characteristics. Since the first report almost two decades ago, where it was demonstrated that gene expression is possible by directed injection of naked DNA, proven induce protective immune virus in diverse disease models. This review aims to present an overview about DNA vaccines and the mechanisms by which incidence and impact of zoonotic rotavirus are not well defined, and one reason...... for this is a lack of data about strains circulating in suspected reservoir animal hosts. In this study we report the incidence, genetic diversity, and swine in 6 European countries. From 2003 to 2007, 1101 and more than 2000 faecal specimens were...... collected nucleotide and phylogenetic of VP7 and genes. were detected Palomares, Laura Rotavirus is the most common cause of severe diarrhea in many animal species of economic interest. A simple, safe and cost-effective vaccine is required for the control and prevention of rotavirus in animals. In this study, we evaluated use of Saccharomyces cerevisiae extracts containing rotavirus-like as a vaccine in doses of 1mg of yeast extract containing rotavirus proteins capable in all mice groups diminished in comparison with the control group when challenged with vaccines against of human G20P[28] rotavirus rotaviruses are the major cause of severe gastroenteritis in the young of mammals and birds. This describes characterization Rotavirus Classification Three of the 11 gene segments (VP7, VP4, VP6) were similar rotavirus of strain strain BatLi09 detected in Cameroon in 2014 are monophyletic. The NSP1 gene was found to be most closely related to human strain A. Grechukha 2013-01-01 Full Text Available The the burden of rotavirus disease. Rotavirus infection is the leading cause of mortality among children under 5 years of age and is a major problem for a public healthcare. The world is actively engaged in the prevention of rotavirus infection since 2005. There is a lot of data on the efficacy and safety of this vaccine. Different foreign investigations have shown the herd immunity of the vaccine. The authors present data about effectiveness and safety detergents rotavirus](http://www.etde.org/etdeweb/details.jsp?query_id=1&page=0&osti_id=5157012) [Energy Technology Data Exchange Ashley, for effect. A result was ionic rotavirus and reovirus were very different, and rotavirus was found to be extremely sensitive to several of detergents. However, associados \u00e0 cobertura vacinal em adolescentes Factores asociados a la cobertura por vacunas en adolescentes Factors associated to the vaccination covering in adolescents](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-21002010000600013) [Directory of Access Journals entre adolescentes de uma \u00e1rea da Estrat\u00e9gia Sa\u00fade da Fam\u00edlia de Teresina - PI. M\u00c9TODOS: Estudo de natureza quantitativa e do tipo seccional. A foi constitu\u00edda por 261 adolescentes e de para a contra de 15 anos (Raz\u00e3o da Preval\u00eancia (RP = 2,85; \u00cdndice de Confian\u00e7a (IC 95% = 1,63-4,99; o sexo masculino (RP = 2,04; IC95% =1,15-3,62.OBJETIVO: Analizar los factores asociados a la condici\u00f3n de estar vacunado entre adolescentes, en un \u00e1rea de la Estrategia Salud de la Familia, en la ciudad de Teresina, en el estado de Piau\u00ed. M\u00c9TODOS: Estudio de naturaleza cuantitativa y de tipo seccional. La muestra fue constituida por 261 adolescentes y el an\u00e1lisis fue realizado por medio de la estad\u00edstica descriptiva. RESULTADOS: La cobertura por vacuna contra rub\u00e9ola, sarampi\u00f3n e caxumba fue de 5,4%; para la vacuna contra la difteria y t\u00e9tano, fue de 22,9%; para la vacuna contra hepatitis-B, fue 27,2% y de 35,2% para la vacuna contra la fiebre amarilla. CONCLUSI\u00d3N: La baja cobertura por vacunaci\u00f3n encontrada en este estudio est\u00e1 relacionada a: 1 las oportunidades perdidas de vacunaci\u00f3n (65,5%; a la deficiencia de conocimiento sobre las vacunas, al intervalo de edad mayor de 15 a\u00f1os [Raz\u00f3n de la Prevalencia (RP = 2,85; \u00cdndice de Confianza (IC 95% = 1,63-4,99]; al sexo masculino (RP = 2,04; IC95% =1,15-3,62.OBJECTIVE: To analyze the factors J. Bolpe 1991-02-01 Full Text Available Se examin\u00f3 una vacuna dise\u00f1ada para inmunizar al hombre, preparada con extracto de fenol insoluble, para determinar si proteg\u00eda a cobayos contra el desaf\u00edo con la cepa virulenta B. abortus 2308. Se incluyeron en el experimento las vacunas vivas atenuadas B. abortus cepa 19 y B. melitensis Rev. 1, para comparar los resultados. Se vacunaron 93 animales en cada grupo, que fueron subdivididos en subgrupos de 31 y se los desafi\u00f3 con 10(4, 10\u00b3 y 10\u00b2 unidades formadoras de colonias de la cepa B. abortus 2308 virulenta. El an\u00e1lisis global de los resultados demostr\u00f3 una protecci\u00f3n del 11.9% en animales vacunados con el extracto de fenol insoluble, 65% en los vacunados con B. abortus cepa 19 y 95% en el grupo que recibi\u00f3 vacuna B. melitensis Rev. 1.A phenol insoluble for its B. melitensis Rev. 1 were included in the experiment for comparison. Ninety three animals were vaccinated in each group and subdivided in subgroups of units of the results showed protection of 11.9%, 65% insoluble the M. Background Rotavirus (RV) is the leading cause of diarrhea-related death in children worldwide, and ninety-five percent of RV deaths, but have low-income settings where they are most needed. [ROTAVIRUS REALLY PROTECT Open 2013-01-01 Full Text Available According to the statistics of the recent 5 years, the share of rotavirus gastroenterites is 44-47% of all acute intestinal infections in children under 5 years of age in the Russian Federation. Up to 5% of mortality rate in children under 5 years of age is connected with rotavirus gastroenteritis. Rotavirus gastroenteritis takes an especially severe course in of months method of preventing this infection is on the rotavirus strains dominant in Russia and abroad, efficacy and safety of immunization with a pentavalent vaccine and the recommended schemes of its administration. This vaccine is registered in the Russian Federation; it is to be first used in the nearest future. [Hospitalizations due to rotavirus gastroenteritis in Catalonia, Spain, 2003-2008](https://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=3212997) 2011-01-01 Background Rotavirus is the most common cause of severe gastroenteritis among young children in Spain and worldwide. We evaluated hospitalizations due to estimated related costs in children under 5 years old in Catalonia, Spain. Results We analyzed hospital discharge data from the Catalan Health Services regarding hospital admissions coded as infectious gastroenteritis in children under 5 for the period 2003-2008. In order to estimate admission incidence, we used population estimates for each study year published by the Statistic Institut of Catalonia (Idescat). The costs associated with hospital admissions due to rotavirus diarrhea were estimated for the same years. A decision tree model was used to estimate the threshold cost of rotavirus vaccine to achieve cost savings from the healthcare system perspective in Catalonia. From 2003 through 2008, 10655 children under 5 years old were admitted with infectious gastroenteritis (IGE). Twenty-two percent average annual incidence of 104 RVGE hospitalizations per 100000 children in for RVGE occurred during December through March. The mean hospital stay was 3.7 days, 0.6 days longer than for other IGE. An additional 892 cases of presumed nosocomial RVGE were detected, yielding an incidence rotavirus hospitalization costs due to community acquired RVGE 2008 result in health system cost savings if the cost of the vaccine was 1.93 \u20ac or less. At a vaccine cost of 187 \u20ac the incremental cost per hospitalization prevented be lower in [Influence of oral polio vaccines on performance of the in and both vaccines are now recommended by the World Health Organization for all children worldwide. Both immunogenicity and efficacy of these rotavirus vaccines has been lower in developing compared to industrialized reviewed the effect of trivalent OPV on immunogenicity and efficacy of currently recommended with OPV. Limited data suggests that the interference is greater after the first dose of OPV, presumably because the first dose is associated with greatest intestinal replication of vaccine polio virus strains, and this interference is largely overcome with subsequent rotavirus vaccine doses. Despite the lower immunogenicity, one large efficacy study in middle income Latin American countries showed no decrease in rotavirus vaccine infants receiving concurrent OPV. While these administration rotavirus Rotavirus in shellfish prevalence of Rotavirus in shellfish from Southern Kerala. Materials and The shellfish samples after processing was concentrated the study. Rotavirus detected in 2 out of 60 brown mussels (3.33%, 2 out of 70 yellow clams (2.86% and 1 out of 70 black clams (1.43%. Conclusion: Low prevalence of Rotavirus was obtained in our study. A more extensive study need to be conducted to estimate the prevalence of enteric virus in shellfish. [La evidencia acerca de la controversia de las vacunas que contienen timerosal y su asociaci\u00f3n con el autismo](https://www.openaire.eu/search/publication?articleId=doajarticles::9f083d9cb2b9e06dbceeb1cf2c0fabe3) Lisset Garc\u00eda-Fern\u00e1ndez; Adri\u00e1n Hern\u00e1ndez; V\u00edctor Su\u00e1rez Moreno; Fabi\u00e1n Fiestas 2013-01-01 La vacunaci\u00f3n es una de las medidas de mayor impacto en la salud p\u00fablica para la reducci\u00f3n de la morbimortalidad infantil. El timerosal es un compuesto org\u00e1nico del mercurio utilizado como preservante de los frascos multidosis. Eventualmente, en el Per\u00fa, surgen olas de controversia acerca de la seguridad de estas vacunas, asoci\u00e1ndolas especialmente con el autismo. Como resultado de estas controversias, se han propuesto, incluso, leyes que proh\u00edben este tipo de vacunas, lo que tendr\u00eda un impor... [Rotavirus vaccine response correlates with the infant Rotavirus (RV) is the leading cause of diarrhea-related death children worldwide and ninety-five percent of RV deaths, but have efficacy in low-income settings where they are most needed. The of Available in low-income countries. Recently the World Health Organization (WHO has released global recommendation that all countries include infant rotavirus vaccination in their national immunization programs. Our objective was to provide information on the expected health, economic and financial consequences rotavirus 72 the support by the GAVI Alliance (GAVI-eligible countries in order to estimate the health with rotavirus vaccination programs. The primary international dollars per disability-adjusted life year scenarios. Results incremental per 5 in the poorest parts of the world, depending on vaccine outpatient scarce. In this a hospital-based mortality surveillance, conducted over 7 years, in the Ciudad Hospitalaria Dr. Enrique Tejera, Valencia, Venezuela. Rotavirus was identified in stool samples that rotavirus (21%; 21/100) is the leading cause of death due to diarrhea among children causes in this age group. Shigella spp. (19%; 13/69) was the second most For Venezuela, it is estimated that approximately 300 children cause of death due to diarrhea, which supports previous estimations. This is the first study to present data of cause-specific mortality due to conjugate vaccination in Brazil, and Uruguay Impacto econ\u00f3mico de la vacuna antineumoc\u00f3cica conjugada en Brasil, Chile y Uruguay](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892008000800004) pneumococcal 7-valent conjugate vaccine Brazil, and analytic model was constructed to compare pneumococcal vaccination of children 0-5 years old with no vaccination in Brazil, Chile, and Uruguay. Costs and health outcomes were analyzed from the societal perspective. Vaccine, demographic, epidemiologic, and cost data were incorporated into this economic analysis. RESULTS: At the rate of diphtheria-tetanus-pertussis (DTP vaccine coverage and a vaccine price US$ 53 per dose, PCV7 was projected to prevent 23 474 deaths per year in children under 5 years old in the three countries studied, thus averting 884 US$ 613.9 million. At US$ 53 per averted from a societal perspective would range from US$ 664 (Brazil to US$ 2 019 (Chile. At a cost of US$ 10 per dose, vaccine cost is lower than the overall cost of illness averted (US$ 125 050 497 versus US$ 153 965 making it cost effective and cost-saving. CONCLUSIONS: The results of this study demonstrate that the of PCV7 vaccine at US$ 53 per dose extra costs. It is unclear whether vaccination at the current price is affordable to these countries.OBJETIVOS: Evaluar el impacto econ\u00f3mico de la aplicaci\u00f3n de la vacuna antineumoc\u00f3cica conjugada heptavalente (PCV7 en Brasil, Chile y Uruguay. M\u00c9TODOS: Se elabor\u00f3 un modelo anal\u00edtico de decisiones para comparar la vacunaci\u00f3n antineumoc\u00f3cica de los ni\u00f1os de 0-5 a\u00f1os de edad con la no vacunaci\u00f3n, en Brasil, Chile y Uruguay. Los costos y los desenlaces para la salud se analizaron desde el punto de vista de la sociedad. Al an\u00e1lisis econ\u00f3mico se incorporaron los costos y los datos demogr\u00e1ficos, epidemiol\u00f3gicos y de la vacuna. RESULTADOS [Frequency Rotaviruses major cause of gastroenteritis and diarrhea in infants and young children worldwide. Basic epidemiological data concerning rotaviruses among infants and children are care providers in gastroenteritis (RVGE), but rotavirus Central Asia, is considering the introduction of rotavirus vaccination into its national immunization We performed a cost-effectiveness analysis of rotavirus vaccination spanning 20 years by using synthesis of dynamic transmission models accounting for herd protection. We found that a 90% coverage would prevent 880 rotavirus deaths and save an average of 54,784 life-years for children vaccine cost at be entirely offset. To by vaccination warrant further de un ELISA tipo inhibici\u00f3n para cuantificar polisac\u00e1rido Vi en la vacuna antitifo\u00eddica cubana vax-TyVi](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200002&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Esther Mar\u00eda Fajardo 2006-08-01 Full Text Available Se describe la validaci\u00f3n de un ELISA tipo inhibici\u00f3n, reportado por primera vez en la literatura cient\u00edfica para cuantificar un ant\u00edgeno vacunal: el polisac\u00e1rido Vi de Salmonella Typhi, para ser empleado en el control de la calidad de la vacuna antitifo\u00eddica cubana vax- TyVi\u00e2. El ensayo consta de seis pasos: 1 Recubrimiento de placa de reacci\u00f3n con poli-L-lisina y posteriormente polisac\u00e1rido Vi; 2 Bloqueo con leche descremada; 3 Inhibici\u00f3n o neutralizaci\u00f3n en tubos de suero anti-Vi de conejo, respectivamente, con polisac\u00e1rido Vi de Curva de Calibraci\u00f3n (concentraciones desde 1-32 g/mL, control positivo y muestras de vacuna (3 diluciones; 4 Neutralizaci\u00f3n de anticuerpos anti-Vi libres, presentes en las mezclas anteriores, por el Polisac\u00e1rido de Recubrimiento; 5 Reconocimiento de anticuerpos anti-Vi unidos a la placa (conjugado anti-IgG de conejo-fosfatasa alcalina y 6 Revelado por reacci\u00f3n enzima-sustrato. Los par\u00e1metros de validaci\u00f3n estudiados y sus resultados fueron: 1 Precisi\u00f3n, expresada como coeficiente de variaci\u00f3n a tres niveles de concentraci\u00f3n de polisac\u00e1rido, comprendidos en el rango de su especificaci\u00f3n (35, 50 y 70 g/mL y evaluada en t\u00e9rminos de repetibilidad; precisi\u00f3n intraensayos (cuatro analistas y L\u00edmite de detecci\u00f3n: 0,5 g/mL; 4 Exactitud (recuperaci\u00f3n para las tres diluciones de la muestra: entre 100 y 118%, y 5 Robustez: no influye 1,5 h de bloqueo (p = 0,52 ni \u00b1 5 min para leer placa (p = 0,56; influye grandemente la calidad del agua (p = 0,026, a favor del agua para inyecci\u00f3n. El ensayo es adecuado para los fines propuestos y es una medida de la inmunogenicidad in vitro del polisac\u00e1rido Vi. [Sunlight-induced inactivation of human Wa and of exogenous OSU solutions were irradiated with simulated solar UV and visible light in the presence of different photosensitizers dissolved in buffered solutions. For human greater than the endogenous effects under irradiation with full spectrum and UVA and visible light at 25 C. For porcine rotavirus, the exogenous effects with UVA and visible light irradiation were only observed at high temperatures, >40 C. The results from and visible light irradiation of natural dissolved organic matter solutions were likely responsible (kexp) found in both 1 mM NaHCO3 and 1 mM phosphate-buffered solutions suggested that OH radical was a major surface Available WHO shows 113000 children in India succumb to death due to Rotavirus diarrhea. Lack of knowledge about pathogenesis of virus has led to lack of therapy for severely infected human rotaviruses also follows same path and this specificity of virus to host genetic predisposition for the the disease. children less 5 of viral were screened for fucosyltransferase of Histo Blood present study, to investigate possible association of the rotavirus with the intestine. The FUT2 and FUT3 gene has been found to show significant association with the rotavirus infection hence meeting a pre-defined case definition for acute gastroenteritis. Despite the use of this study design in low-income settings, the TND has not been evaluated to measure rotavirus vaccine effectiveness. This study builds upon prior methods to evaluate the use of the TND for influenza vaccine using to original RCT vaccine efficacy estimates (VE-RCTs). The core assumption of the TND (i.e., rotavirus has no effect rotavirus-negative rights [Hospitalization of Goh, A 2003-01-01 To determine the epidemiology of rotavirus gastroenteritis in children admitted to an urban hospital in a developing country from South-East Asia. Retrospective review of cases of acute gastroenteritis admitted to the children's ward of the University of Malaya Medical Centre, Kuala Lumpur, Malaysia, between 1996 and 1999. During the study period, 333 cases (24%) of 1362 stool samples, obtained from paediatric admissions each year. Of the 271 cases analysed, 72% of the affected population were less than 2 years of age. Peak incidence of admissions was between January to March, and September of diarrhoea admission Central Asia, is considering the introduction of rotavirus vaccination into its national immunization We performed a cost-effectiveness analysis of rotavirus vaccination spanning 20 years by using synthesis of dynamic transmission models accounting for herd protection. We found that a 90% coverage would prevent 880 rotavirus deaths save an average for children <5 years of age. Indirect protection 40% reduction in severe mild rotavirus gastroenteritis, respectively. Cost per year gained was US $18,044 from a societal perspective and US $23,892 from a health care the 2 key parameters of cost-effectiveness, mortality rates vaccine cost at a A infection is a common cause of hospitalisation of children. In addition, almost 30% of diagnosed persons A dogs, cattle, horses, and birds. There is some data suggesting...... direct transmission between animals and humans. Rotavirus genotyping is carried out in Denmark as part of the EUROTAnet vaccine study. In 2006 a total of 180 samples were successfully typed, and to date 85 samples from 2007 have been typed. 19 samples from pigs and 31 samples from cattle (from 2006...... and 2007) have also been typed. For the human samples all common human G types (1-4 and 9), as well the emerging G12 were identified, and were found in combination with the common P types ([4], [6], and new vaccines have been licensed to prevent rotavirus, the cause of 20% to 50% of severe acute gastroenteritis in young children worldwide. These vaccines have been implemented in national immunization programs in about 30 high- and middle-income countries, including the United States, and vaccine use has led to substantial decreases in diarrhea-related health care vaccines is expectedly lower in developing countries in Asia and Africa, the public health benefits of vaccination in these settings, where more than the estimated 453,000 annual to develop alternative rotavirus vaccines that could have a better efficacy and safety profile and may be less (10 and 17 weeks) and followed year. Intensive diarrhea surveillance was for association with risk of RVD and interactions with vaccine arm. Incidence of all RVD was 38.3 cases per zinc level (odds ratio [OR], 0.77; P = .002) and lack of rotavirus immunoglobulin A (IgA) seroconversion (OR, 1.95; P = .018) were associated with risk of RVD, independent of vaccination status. Water treatment and exclusive breastfeeding were of borderline significance. Factors not associated with RVD included height for age at 10 weeks, vitamin D, retinol binding protein, maternal education, household income, and sex. In an urban slum with high incidence of RVD, the Lower serum zinc level and lack of IgA seroconversion were associated with increased risk of RVD independent of vaccination. NCT01375647. \u00a9 The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail journals.permissions@oup.com. [Vacuna contra la fiebre hemorr\u00e1gica Candid#1 producida en Argentina: Inmunogenicidad y A. Enria 2010-06-01 Full Text Available Se realiz\u00f3 un estudio cl\u00ednico en 946 voluntarios humanos sanos, donde se compar\u00f3 la vacuna Candid#1 producida en Argentina con la elaborada en EE.UU., que hab\u00eda sido utilizada en estudios previos. Como objetivo primario se evalu\u00f3 la equivalencia en la eficacia utilizando como marcador subrogante a la inmunogenicidad medida por detecci\u00f3n de anticuerpos neutralizantes. Como objetivo secundario se evalu\u00f3 la equivalencia en inocuidad comparando las tasas de reacciones adversas. Ambas vacunas mostraron una tasa equivalente de inmunogenicidad ligeramente superior al 95.5%, que es la eficacia estimada para Candid #1 en estudios previos. No se observaron eventos adversos graves relacionados con la vacuna. Los eventos adversos generales considerados relacionados fueron de escasa significaci\u00f3n cl\u00ednica y de resoluci\u00f3n espont\u00e1nea o con tratamiento sintom\u00e1tico; se presentaron en los receptores de ambas vacunas en tasas equivalentes (29.9% para la vacuna fabricada en la Argentina y 35.0% para la fabricada en EE.UU., e incluyeron: cefalea, decaimiento, mialgias, plaquetopenia leve (A clinical study volunteers was done to compare Candid #1 vaccine manufactured in Argentina with the vaccine produced in USA that had been previously used. The efficacy severe vaccines. The general events (29.9% for the Argentine vaccine and 35.0% for the USA vaccine were found for both vaccines. These included: headache, weakness, myalgias, mild low blood [Estudio de tolerancia de la vacuna vax-TyVi\u00ae en ratas Sprague Dawley](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2005000100003&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Eligio Full Text Available La antitifo\u00eddica vax-TyVi\u00ae consiste en una preparaci\u00f3n de polisac\u00e1rido capsular Vi de Salmonella typhi, el cual es diluido en una soluci\u00f3n buffer isot\u00f3nica soluci\u00f3n amortiguador, a la que se le a\u00f1ade fenol como preservo. Cada dosis de 0,5 mL contiene 25 g de polisac\u00e1rido como sustancia activa. En nuestro pa\u00eds el esquema de vacunaci\u00f3n contra la fiebre tifoidea con vax- TyVi\u00ae se aplica a los alumnos de 9-10 a\u00f1os (5to grado, una 2da dosis a la edad de 12-13 a\u00f1os (8vo grado y una 3ra dosis a la edad de 16-17 a\u00f1os (11no grado. Adem\u00e1s, es vacunado el personal de riesgo de Salud P\u00fablica y el personal que manipula alimentos. En el presente trabajo se describe el ensayo de tolerancia local llevado a cabo con la vacuna vax-TyVi\u00ae durante su fase de estudios precl\u00ednicos, actualmente utilizada en la vacunaci\u00f3n contra la fiebre tifoidea en Cuba. Se emple\u00f3 un total de 170 ratas que fueron tratadas con la vacuna, su placebo (todos los componentes, excepto la materia prima activa, o que no recibieron tratamiento alguno (controles. Se realizaron observaciones cl\u00ednicas diarias durante todo el ensayo, se determin\u00f3 el consumo de agua y alimentos y se realizaron investigaciones anatomopatol\u00f3gicas a animales sacrificados 3, 7, 14, 21, 28, 35 y 42 d\u00edas despu\u00e9s de la inoculaci\u00f3n. No se observaron muertes ni s\u00edntomas de toxicidad; no se encontraron diferencias estad\u00edsticamente significativas entre los pesos vivos, el consumo de agua ni el de alimentos entre los grupos del ensayo. Tampoco se observaron lesiones anatomopatol\u00f3gicas que indicaran toxicidad por parte del producto inoculado. Los resultados permitieron concluir que la potencialidad de la vacuna vax-TyVi\u00ae para producir efectos adversos locales es baja. [La articulaci\u00f3n p\u00fablico-privada en la producci\u00f3n de vacunas en M\u00e9xico](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0103-11042016000400009&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Silvia Tamez Full Text Available RESUMEN El art\u00edculo analiza el proceso de privatizaci\u00f3n de la atenci\u00f3n a la salud: la Articulaci\u00f3n P\u00fablico-Privada (APP. Espec\u00edficamente estudia la producci\u00f3n de vacunas em M\u00e9xico, tomando como caso los Laboratorios de Biol\u00f3gicos y Reactivos de M\u00e9xico, S.A. de C.V. (Birmex, empresa paraestatal, responsable de producir, distribuir e investigar biol\u00f3gicos y reactivos en M\u00e9xico. Interesa destacar el comportamiento de Birmex durante el periodo de la pandemia de influenza de 2009, producida por el virus de la influenza A subtipo H1N1. Los resultados muestran que gracias al impulso de las pol\u00edticas de liberalizaci\u00f3n y desregulaci\u00f3n, existe una apertura de los servicios p\u00fablicos a las corporaciones supranacionales. [Modern Views and laboratory data characterizing the course of rotavirus infection in children of Zaporizhya region, there are provided the modern features of the disease. The authors of rotavirus infection in children is shown. [Los precios de la carne vacuna en Buenos Aires colonial. Una interpelaci\u00f3n historiogr\u00e1fica e hist\u00f3rica](https://revistas.utadeo.edu.co/index.php/TyE/article/view/945/984) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Andrea Dupuy 2014-12-01 Full Text Available En el \u00e1mbito de los estudios de mercado, los precios constituyen los principales indicadores del comportamiento de la econom\u00eda, aun los de Antiguo R\u00e9gimen. El objetivo del presente trabajo es abordar el an\u00e1lisis de los precios de la carne vacuna de la ciudad de Buenos Aires colonial partiendo de la idea de que este mercado, al igual que los de las distintas ciudades hispanoamericanas, present\u00f3 a lo largo de la etapa colonial una regularidad predominante. Y aun cuando estuvo atravesado por situaciones cr\u00edticas de escasez, estos factores no lograron modificar sustancialmente, desde una mirada de largo plazo, las caracter\u00edsticas del mismo. [Characterization of rotavirus strains detected study was based in hospitals the Gizan area. Stool samples were collected between (G and P genotyping). Rotavirus was detected in 54 of 454 (12%) subjects. The ages of those infected with rotavirus ranged from 15 days to 20 years, with a median age of 36 months. The highest (93%) a G- with prevent pathogen adhesion to the porcine specific and abundant milk G1P[8] and G2P[4] fluorescent monkey kidney epithelial cells (MA104 cells). Oligosaccharides were added at different time points in the infectivity assays. Infections in the absence reduction in G1P[8] infectivity was seen with 2'FL when added after the onset of infection (62% reduction, P rotaviruses in MA104 directly protected, addition \u00a9 Nutrition. [Evaluaci\u00f3n de dos equipos inmunocromatogr\u00e1ficos comerciales para el diagn\u00f3stico r\u00e1pido de la infecci\u00f3n por rotavirus Evaluation of two immunochromatography kits for rapid infections](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0325-75412008000300007) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) C. J. T\u00e9llez 2008-09-01 Full Text Available Se realiz\u00f3 un estudio prospectivo para evaluar dos equipos comerciales inmunocromatogr\u00e1ficos para el diagn\u00f3stico r\u00e1pido de infecci\u00f3n por rotavirus a partir de muestras fecales: VIKIA\u00ae Rota-Adeno, de bioM\u00e9rieux, y Simple Rota- Adeno, de Operon. Como m\u00e9todo de referencia se utiliz\u00f3 la transcripci\u00f3n reversa y reacci\u00f3n en cadena de la polimerasa (RT-PCR con cebadores espec\u00edficos del gen de la prote\u00edna VP7 de rotavirus del grupo A. La sensibilidad y la especificidad respecto de la RT-PCR fueron del 98,4% y 84,8% para el Simple Rota-Adeno, y del 100% y 24,2% para el VIKIA\u00ae Rota-Adeno. Es de destacar la baja especificidad de este \u00faltimo equipo diagn\u00f3stico, que present\u00f3 un elevado n\u00famero de falsos positivos, por lo que el valor predictivo de un resultado positivo es s\u00f3lo del 71,6%. Asimismo, se identificaron los genotipos de las cepas de rotavirus detectadas; la mayor\u00eda de ellas correspondieron al genotipo G9P(8 (65%, seguido de los genotipos G1P(8 (25,4% y VP7 rotavirus used as the reference method. The sensitivity and specificity of ICG the and respectively, Rota-Adeno which result is the leading cause of severe diarrhea worldwide in young children. Although rotavirus vaccine efficacy is high in developed countries, efficacy is lower in developing countries. Here, we investigated heterogeneity of rotavirus infant characteristics in post hoc analysis of the Africa either 3 doses of vaccine/placebo and were followed for up to 2 years. Within subgroups, vaccine efficacies and 95% confidence intervals regression. We at first dose, gender, breastfeeding status and nutrition status. African children at efficacy (23.7%; 95% CI: status in Ghana and gender in Asian countries. Heterogeneity of efficacy was observed for age at first dose in African countries. This was an exploratory validate heter\u00f3logos](http://www.revistabiomedica.org/index.php/biomedica/article/view/1056) of Open Access serotipo Typhi, es el agente etiol\u00f3gico de la fiebre tifoidea de los habitantes de las regiones m\u00e1s pobres del mundo y es, adem\u00e1s. el centro de atenci\u00f3n de muchos investigadores dados sus fascinantes mecanismos de invasi\u00f3n, multiplicaci\u00f3n intracelular y diseminaci\u00f3n intercelular que expresa in vivo e in vitro. Aunque estos mecanismos se asocian directamente con la patogenicidad y la severidad de la enfermedad, las mutaciones definidas en el cromosoma de Salmonella han permitido que estos mecanismos de virulencia se puedan utilizar en beneficio del hospedero. Las mutantes atenuadas de Salmonella son capaces de invadir las c\u00e9lulas M de la mucosa intestinal y de migrar a las c\u00e9lulas linfoides del sistema reticuloendotelial donde, en lugar de causar enfermedad, activan eficazmente las respuestas inmunes humoral y celular no s\u00f3lo contra el microorganismo mismo sino tambi\u00e9n contra aquellos antigenos heter\u00f3logos recombinantes que la bacteria pueda expresar y transportar. En la presente revisi\u00f3n, se discutir\u00e1n los avances m\u00e1s recientes en el campo de las vacunas vivas atenuadas de Salmonella, su evaluaci\u00f3n preclinica y clinica y, tambi\u00e9n, su aplicaci\u00f3n como vector de antigenos. Se dar\u00e1n a conocer las t\u00e9cnicas biomoleculares de clonaci\u00f3n y expresi\u00f3n procari\u00f3tica de las toxinas dift\u00e9rica, tet\u00e1nica y de pertusis. as\u00ed como de los ant\u00edgenos de Helicobacterpylori y de Plasmodium falciparum. Finalmente, se propone el uso de Salmonella atenuada como vector de vacunas de ADN para expresi\u00f3n eucari\u00f3tica de los ant\u00edgenos recombinantes. Los continuos esfuerzos cientificos y tecnol\u00f3gicos en el campo de la vacunaci\u00f3n con vectores vivos atenuados sugieren que Salmonella es una herramienta potencialmente \u00fatil para enfrentar el constante reto de la fiebre tifoidea. Igualmente, los estudios precl\u00ednicos y cl\u00ednicos de fase I demuestran la eficacia de la vacuna de Salmonella viva atenuada como vector de ant\u00edgenos heter Fischer Black, Robert E 2011-01-01 Abstract Background Diarrhea mortality remains a leading cause of child death and rotavirus vaccine an effective tool for preventing severe rotavirus diarrhea. data efficacy may by region. Methods We reviewed published vaccine efficacy trials to estimate We assessed the a standard protocol and conducted meta-analyses where more an overview of the impact of universal rotavirus immunization with the pentavalent vaccine, RotaTeq, which was introduced in Israel in 2010. The vaccine is given free of charge at age 2, 4 and 6 months, with an 80% coverage that was shortly achieved during the universal immunization period. Compared to pre-universal immunization years (2008-2010), a reduction of 66-68% the central northern In southern a reduction of 80-88% in ineligible immunization. Vaccine effectiveness against RVGE hospitalization at Universal rotavirus was an impressive decrease in the burden of RVGE in young children in Israel, likely attributed to good vaccine coverage of and complex interaction with the host cell RNA in rotavirus infected independent resulting in a loss of RNA sensing machinery in the infected cell. To best of our knowledge, this is the first report on NSP1 functionality where a signaling virus orchestrates the cellular antiviral response to its own benefit by various back up strategies. [History of rotavirus research in children in Malawi: of a killer](https://www.ajol.info/index.php/mmj/article/view/45631) [African Journals Online spanning characteristics of rotavirus and tolerability of inactivated flu vaccine In high risk and healthy children Inmunogenicidad y tolerancia de la vacuna inactivada anti-influenza en ni\u00f1os en alto riesgo y en controles sanos](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802007000400005) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Maria Luisa Avila Aguero 2007-08-01 Full Text Available We conducted this open study to evaluate the immunogenicity and safety of the inactivated influenza vaccine, Imovax Gripe\u00ae in 154 children between 6 and 36 months of age at high risk of influenza- related complications, and in a reference group of 64 healthy children. The study was conducted over two flu seasons, in which the vaccine contained the same A strains but different B strains. The results for the A/H3N2 and A/H1N1 strains from the two flu seasons were pooled, but those for the B strains were not. Anti-hemagglutinin (HA antibody titers were determined before, each and safety any adverse event observed, included or not in list each group of and healthy with those observed in previous studies The equally well tolerated by all study groups. Reactogenicity was low and similar in both high-risk and healthy children. Overall from 9.5% to 15.4% of at-risk children and 12% of children at high-risk of influenza related complications.Se realiz\u00f3 un estudio cl\u00ednico abierto para evaluar la inmunogen\u00edcidad y la seguridad de la vacuna inactivada anti-influenza, Imovax Gripe\u00ae, en 154 ni\u00f1os entre 6 y 36 meses de edad con alto riesgo de complicaciones ligadas a la influenza, y en un grupo de referencia de 64 ni\u00f1os sanos. El estudio fue [Rotavirus - Global research and severe diarrheal disease and in infants and young children worldwide. An increasing number of related publications cause a crucial challenge to the relevant output. of the worldwide research activities on Rotavirus. Up to now, no in-depth global scientometric analysis relating to Rotavirus publications has been carried out. This study used scientometric tools and the method of density equalizing mapping visualize the differences of the worldwide research effort referring to Rotavirus. The aim of the study was to compare scientific output geographically and over time by using an in-depth data analysis and New quality and quantity indices in science (NewQIS) tools. Furthermore, a gender analysis was part of the data interpretation. We retrieved all Rotavirus-related articles, which were published on \"Rotavirus\" during the time period from 1900 to 2013, from the Web of Science by a defined search term. These items were analyzed regarding quantitative and qualitative aspects, and visualized with methods and the technique of density equalizing mapping to show the differences of the worldwide research efforts. This work aimed to the current NewQIS platform. 5906 Rotavirus associated articles were published in 138 countries from 1900 to 2013. The USA authored 2037 articles that equaled 34.5% of all published items followed by Japan with 576 articles and the United Kingdom - as the most productive representative of the European countries - with 495 articles. Furthermore, the USA established the most cooperations with other countries and was found to be in the center of an international collaborative network. We performed a gender analysis of authors per country (threshold was set at a publishing output of more than 100 articles by more Rotateq\u00ae and affordability of implementing rotavirus immunization based on the Global Alliance for Vaccines and Immunization (GAVI)-subsidized vaccine price in the context of Vietnamese health [Identification of co-infection by rotavirus and parvovirus in dogs with gastroenteritis in Mexico](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1517-83822017000400769&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Ariadna Flores Ortega Full Text Available ABSTRACT This is the first report on circulating canine rotavirus in Mexico. Fifty samples 7% of dogs were infected rotavirus exclusively, 14% were co-infected with both rotavirus and clinical signs in co-infected dogs were [Effect is the most common cause of severe gastroenteritis among young children worldwide. Data are needed to assess the efficacy of the rotavirus vaccine in African children. We conducted a randomized, placebo-controlled, multicenter trial in South Africa (3166 infants; 64.1% of the total) and Malawi (1773 infants; 35.9% of the total) to evaluate the efficacy of a live, oral rotavirus vaccine severe ratio to receive two doses of vaccine (in addition to one dose of placebo) or three doses of vaccine--the pooled vaccine group--or three doses of placebo at 6, 10, and 14 weeks of age. Episodes of gastroenteritis caused by wild-type rotavirus during the first year of life were assessed through active follow-up surveillance and were graded with the use of the Vesikari scale. A total of 4939 infants were enrolled and to one of the three groups; 1647 infants received two doses of the vaccine, 1651 infants received three doses of the vaccine, and 1641 received placebo. Of the 4417 infants included in the per-protocol efficacy analysis, severe rotavirus gastroenteritis occurred in 4.9% of the infants in the placebo group and in 1.9% of those in the pooled vaccine group (vaccine efficacy, 61.2%; 95% confidence interval, 44.0 to 73.2). Vaccine efficacy was lower in Malawi than in South Africa (49.4% vs. 76.9%); however, the episodes of severe gastroenteritis that were prevented was greater in Malawi than in South Africa (6.7 vs. 4.2 cases prevented per 100 infants vaccinated per year). Efficacy against all-cause gastroenteritis least one reported in 9.7% of the infants in the pooled vaccine group and in 11.5% of the infants in the placebo group. Human rotavirus significantly provides a A rotavirus the major pathogen causing gastroenteritis in animals. Its segmented RNA genome can lead to the emergence of new transmission and/or reassortment events. PMID:27462899 [Pagos por desempe\u00f1o para mejorar el estado nutricional infantil: impacto de los convenios de apoyo presupuestario en tres regiones peruanas con alta prevalencia de desnutrici\u00f3n cr\u00f3nica infantil, 2010-2014](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1726-46342017000300365&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Viviana Cruzado de la Vega Full Text Available RESUMEN Objetivos. Estimar el impacto de un esquema de pago por desempe\u00f1o, denominado convenios de apoyo presupuestario, aplicado por el Gobierno a las tres regiones con mayores tasas de desnutrici\u00f3n cr\u00f3nica infantil (DCI en 2008, Apurimac, Ayacucho y Huancavelica, sobre indicadores de cobertura de servicios de cuidado infantil (vacunaci\u00f3n, controles de crecimiento y desarrollo infantil, suplemento de hierro y del estado nutricional del ni\u00f1o (desnutrici\u00f3n, anemia, diarrea. Mediante estos convenios se transfer\u00edan recursos a los presupuestos de dichas regiones condicionados al cumplimiento de compromisos de gesti\u00f3n y metas de cobertura con el objetivo de mejorar el estado nutricional infantil. Materiales y m\u00e9todos. A partir de los datos de la Encuesta Demogr\u00e1fica y de Salud Familiar de 2008 a 2014, se compara la evoluci\u00f3n en los indicadores evaluados de una muestra de ni\u00f1os que residen en los \u00e1mbitos donde se suscribieron los convenios y una muestra de control, mientras los convenios estuvieron vigentes y en los a\u00f1os posteriores para reportar el estimador de diferencias en diferencias del impacto promedio de los convenios Resultados. se encuentran impactos positivos sobre el incremento de coberturas de vacunas del esquema b\u00e1sico y de la vacuna rotavirus y, a trav\u00e9s de ellos, en la reducci\u00f3n de la ocurrencia de diarrea y desnutrici\u00f3n. Conclusiones. el esquema habr\u00eda sido efectivo en activar la cadena mayor cobertura de vacunas y menor DCI, pero no parece mejorar la cobertura de otras prestaciones como las atenciones de crecimiento y desarrollo del ni\u00f1o y entrega de suplementos de hierro al ni\u00f1o y gestante. [Rotavirus Virus-Like Particles system, have as surrogates of mg of free chlorine (FC)/liter both the no differences were observed between tracers and infectious rotavirus at short contact times. However, from 30 min of contact with FC onward, the decay of infectious infectious rotavirus in fresh and marine water. exposure was more pronounced on pseudovirus than in GFP-VLPs. In all types of water, the UV dose to induce a 90% reduction the validation of virus Divina das Dores de Ana Maria Tavares; Costa, Paulo Sergio Sucasas da; Melga\u00e7o, Irene Angela 2009-11-01 Rotavirus is a major cause of gastroenteritis in children. Knowledge of rotavirus genotypes Alegre, Brazil. Stool samples were collected from children <5 years of age who had diarrhea and were screened by the Rotaclone polymerase chain reaction. A total of 510 samples collected. Of these, 221 (43.3%) were positive rotavirus. Overall, G9 was and G1; P[4] and and G1P[8] were distribution of rotavirus monitoring of rotavirus is burden to human and animal health. Interspecies transmission between livestock, domestic animals and humans is commonly but spread a direct or recent interspecies transmission from a cat to human. reserved. [Impacto de la vacuna conjugada en la incidencia de meningitis por Haemophilus influenzae en el Distrito Federal de Brasil: resultados de tres a\u00f1os de seguimiento Impact of anti-Hib conjugate vaccine on the [Directory Haemophilus influenzae del serotipo b (Hib es todav\u00eda un importante agente causal de procesos infecciosos. Su variante encapsulada es la causa de formas invasoras de enfermedad. En algunas poblaciones abor\u00edgenes, la incidencia de enfermedades causadas por Hib es mayor de 400 por 100 000 ni\u00f1os menores de 5 a\u00f1os. En los decenios de 1970 y 1980, tras la identificaci\u00f3n de anticuerpos protectores contra la c\u00e1psula de Hib, se desarrollaron vacunas contra este microorganismo. OBJETIVO: Estimar el impacto que ha tenido desde su introducci\u00f3n, en marzo de 1998, la vacunaci\u00f3n contra Hib en el Distrito Federal de Brasil. M\u00c9TODO: Con los datos de base poblacional del Sistema de Vigilancia de la Secretar\u00eda de Salud del Distrito Federal de Brasil, se compararon las tasas de incidencia de meningitis correspondientes a los tres a\u00f1os anteriores y posteriores a la introducci\u00f3n de la vacuna. Se compararon tambi\u00e9n los cambios en su tendencia. RESULTADOS: Al comparar los dos per\u00edodos se advierte una reducci\u00f3n de aproximadamente 90% en la incidencia de meningitis por Hib, cambio que no ocurre en el caso de las meningitis ocasionadas por otros agentes bacterianos. Se registr\u00f3 un aumento proporcional de los casos entre los ni\u00f1os de 6 meses de edad y menores, debido a la reducci\u00f3n de la incidencia entre los mayores de esa edad. CONCLUSI\u00d3N: La introducci\u00f3n de la vacuna conjugada en el Distrito Federal de Brasil redujo de 168 por 100 000 (1995-1997 a 15 por 100 000 (1999-2001 la incidencia de meningitis por Hib entre ni\u00f1os de 7 a 35 meses. Esto representa una reducci\u00f3n de 91,1%.INTRODUCTION: Type b Haemophilus influenzae Hib infections in children under five is greater than 400 per 100 000. In the seventies and eighties, vaccines against Hib of severe dehydrating diarrhea among children under 5. Over 80% of the approximate half a million child deaths every year occur in South Asia and sub-Saharan Africa alone. Although less explored than cholera spatio-temporal signatures and footprints and hydroclimatic drivers is yet to be developed. In this study, we evaluate the seasonality respect to regional hydroclimatic variables and their extremes in an endemic region in South Asia. Hospital-based surveillance data from different geographic locations allowed us to the detailed spatial and temporal characteristics of rotavirus propagation under the influence of climate variables in both coastal and inland areas. The rotavirus transmission patterns show two peaks in a year in the capital city of Dhaka, where winter season (highest in January) shows a high peak and the July-August monsoon season shows a smaller peak. strong A Full Text Available the commonest cause of diarrhea rotavirus disease in Uganda has remained unknown. This study was therefore done to determine the on this association disappeared on multivariate analysis. significant association was found between rotavirus infection and nutritional status, HIV status and attendance of or school. Conclusions meeting a pre-defined case definition for acute gastroenteritis. Despite the use of this study design in low-income settings, the TND has not been evaluated to measure rotavirus vaccine effectiveness. Methods This study builds upon prior methods to evaluate the use of the T... leading diarrhea. 33 African across of Ouagadougou, Burkina Methods Between November 2010, stool specimens from 447 children less than 5 years of age suffering from diarrhoea were for the presence in (33.8% of the patients. Most of the cases (94.2% were in children Conclusions The results of this study underscore the need to control rotavirus infections among young children in Burkina Faso and may argue a decision on the introduction of rotavirus vaccine in Burkina Faso. [Identification of co-infection by rotavirus and parvovirus in dogs with in Ortega, Ariadna Flores; Mart\u00ednez-Casta\u00f1eda, Jos\u00e9 Sim\u00f3n; Bautista-G\u00f3mez, Linda G; Mu\u00f1oz, Ra\u00fal Fajardo; Hern\u00e1ndez, Israel Quijano This is the first report on circulating canine rotavirus in Mexico. Fifty samples 7% of dogs were infected rotavirus exclusively, 14% were co-infected with both rotavirus and parvovirus; clinical signs 2017 Sociedade Brasileira de Microbiologia. Published Editora Ltda. All rights reserved. [Efficacy and immunogenicity of two or three dose rotavirus-vaccine regimen in South African children 56-88%) the first of established in African settings. This study reports on the efficacy of HRV against severe RVGE over two consecutive rotavirus seasons African children. A prospective, double-blind, placebo controlled multi-centered trial in South Africa and assigned infants in a 1:1:1 ratio to receive either two (10 and 14 weeks; HRV_2D) or three (6, 10 and 14 weeks; HRV_3D) doses of HRV or placebo. The of Vesikari scale. 1339 infants (447 in the HRV_2D group, 447 in the HRV_3D group and 445 in the placebo group) were enrolled in Year 2 of the study, including 1035 (77.3%) who were followed up over two consecutive rotavirus seasons Cohort seasons in the HRV_3D compared to HRV_2D arms of the study in Cohort subjects. Rotarix is associated with significant reductions in severe gastroenteritis episodes through 2 years of life among South African children. Further research is needed to Ltd. rights reserved. [Differences Text Available Rotaviruses are a major cause of acute gastroenteritis in infants and young children worldwide and in many other mammalian and avian host species. Since 2006, countries and are applied as part of program vaccination (EPI schemes childhood the cause of death in >200,000 children of <5 years of age worldwide in 2013, and the mortality is concentrated in countries of sub-Saharan Africa and S.E. Asia. Various factors that have been identified or suggested as being in the differences of vaccine effectiveness are reviewed here. Recognition of these factors will help achieve gradual worldwide improvement of rotavirus vaccine effectiveness. [B\u00fasqueda e identificaci\u00f3n de nuevos candidatos a vacuna contra la malaria producida por Plasmodium vivax](https://revistas.unal.edu.co/index.php/actabiol/article/view/27394) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Andr\u00e9s Mauricio Pinz\u00f3n Velasco 2004-07-01 bioinform\u00e1ticas, estableciendo diversos patrones de alineamiento, as\u00ed como niveles de similitud no menores al 40%. A pesar de un riguroso enmascaramiento tanto de las secuencias prot\u00e9icas de P. falciparum, como del genoma de P. vivax, en este \u00faltimo fue evidente una alta presencia de regiones repetitivas que no fueron enmascaradas por ninguna de las fuentes de ADN repetitivo presente en la base de datos de REPBASE, lo cual lleva a pensar que dichas regiones pueden ser espec\u00edficas de este tipo de organismos. Finalmente se encontraron coincidencias entre 76 secuencias proteicas con actividad antig\u00e9nica de P. falciparum y el genoma hasta ahora secuenciado de P. vivax, que cumpl\u00edan con los requisitos m\u00ednimos para establecer los niveles de coincidencia, entre las cuales se determin\u00f3 que cuatro constituyen importantes candidatos a una vacuna contra la malaria producida por P. vivax. [Decreased performance of live born path designing strategies for the vaccines' improvement. Areas covered: We accessed studies efficacy, and immunogenicity) and correlated performance with several risk factors. Here, we review the factors that might contribute to the low vaccine transfer research because the data about their interference with the efficacy of rotavirus vaccines are inconclusive and at times conflicting. [Rotavirus in the Netherlands : Background information for the Health Council](https://www.narcis.nl/publication/RecordID/oai%3Adspace.library.uu.nl%3A1874%2F349679/uquery/rotavirus/id/5/Language/EN) Verberk, can cause a gastrointestinal infection and is common in young children. There are two vaccines available; both have to be administered via the mouth. The Dutch Health Council will advise the Ministry of Health, Welfare and Sport on how childhood vaccination against rotavirus will be made [Desarrollo y pruebas de campo de la vacuna sint\u00e9tica contra la malaria SPf66](https://revistas.unal.edu.co/index.php/revfacmed/article/view/27236) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Mauricio Rojas 1993-04-01 Full Text Available De acuerdo a estad\u00edsticas recientes de la Organizaci\u00f3n Mundial de la Salud, se estima que 2100 millones de personas habitan en cerca de 100 pa\u00edses donde la malaria es una enfermedad end\u00e9mica, afectando cerca de 270 millones de individuos anualmente y siendo la causa directa de por 10 menos dos millones de muertos al a\u00f1o, especialmente de ni\u00f1os menores de cinco a\u00f1os de edad. Las medidas de control del vector y del par\u00e1sito con insecticidas y quimioterapia parec\u00edan ser suficientes para la erradicaci\u00f3n, pero a lo largo del tiempo se ha demostrado la poca eficacia de estas medidas, hacienda que el desarrollo de una vacuna sea esencial como un componente efectivo para el control y erradicaci\u00f3n de la malaria especialmente en los pa\u00edses del tercer mundo. [Distribution of rotavirus genotypes associated with acute diarrhoea in Zimbabwean less circulating genotypes among children under 5 years before and after vaccine introduction. The Zimbabwe Ministry of Health and Child Care introduced rotavirus vaccine in national immunization program in May 2014. Active hospital-based surveillance for diarrhoea was conducted at 3 2008 to 2016. Children aged less than 5 years, who presented with acute gastroenteritis as a primary illness and who were admitted to a hospital ward or treated at the emergency unit, were enrolled and had of which 3016 (46%) stools were During 3750 acute stools were collected, of which 937 (4%), (3%) and G8P[4] (3%). G1P[8] (30%) was most dominant two years after vaccine introduction followed by G9P[6] (20%), G2P[4] (15%), The decline in rate Ltd. [Influence of birth rates cause of mortality in developing countries, and yet the factors. By fitting a mathematical model of rotavirus transmission dynamics to published age distributions of cases from 15 countries, we obtain rotavirus seasonality observed in many tropical countries may be due to the high birth overall disease, it may increase the degree of seasonal the single most common cause of acute gastroenteritis in children under five years of age. Rotavirus gastroenteritis has a high morbidity and mortality in children in Kenya. Objectives: To determine the short term clinical outcome for children admitted to Kenyatta Wang, Guangzhou; Zhang, Changjun 2016-01-01 This study with lactose intolerance. cases of infants with diarrhea randomly collected from our hospital at the same period, which their rotavirus detection was negative. The observation group was 185 cases of infants with rotavirus, which was tested to be positive. Through the urine galactose determination, 62 cases of the control group were positive and 124 cases of the observation group were positive. Then 124 cases of combined with lactose intolerance were randomly divided into two groups. 60 cases in the control group were given rehydration, correction of acidosis, oral smecta, Intestinal probiotics treatment, then continued to the original feeding method. While, 64 cases in the treatment group, on the basis of routine treatment, applied the low lactose milk feeding. To observe the total effective rate for the two groups. The incidence of diarrhea (49.2%), which was tested to be negative. And statistically and could the duration of disease, and restored to normal E.; Mary K.; Peyer's patches. activation can induce B cells, one or more of the capsid proteins could be responsible for the initial RNA was were performed, which ruled out possible lipopolysaccharide contamination as source activation confirmed structural and Vegetation](http://www.mdpi.com/2073-4441/8/3/78) [Directory of Open Access (Sweden)](https://doaj.org/search#.V6PA8bgrK70) C. Davidson 2016-03-01 Full Text Available Soil vegetation are two for controlling the overland transport kinetics of pathogens in a natural environment. With livestock operations moving more towards concentrated animal operations, the need to dispose of a very large amount of manure in rotavirus, which may pose a threat of contamination of water resources. This study examined the kinetics of rotavirus in overland transport, with an overall objective spanning particles in surface by an average of 73%, in addition to delaying the time to peak recovery. The vegetation, in general, appeared to decrease the recovery leading cause of severe diarrhea in children under 5. In Argentina, the most affected regions are the Northeast and Northwest, where hospitalizations and deaths are more frequent. This study estimated the of adding either of two licensed vaccines the routine immunization schedule. The integrated TRIVAC vaccine cost-effectiveness model from the Pan American Health Organization's ProVac Initiative (Version 2.0) the health and societal perspectives. Two doses of monovalent (RV1) rotavirus vaccine of both national and sub-national analysis, discounting all costs and benefits 3% annually. Our base case results were to range alternative when compared to and perspective Northeast US$ 1470 US$ 636 for RV1, the Northeast compared to the whole country; and, in the Northwest, health service's costs saved outweighed the cost of introducing the vaccine. vaccine compared to no of US$ 9090. Key variables influencing results were annual loss of efficacy, of deaths, no [Safety, immunogenicity, and protective two doses of RIX4414 human rotavirus vaccine in healthy infants.](https://www.ncbi.nlm.nih.gov/pubmed/17380232) C; determine the safety, immunogenicity and efficacy of two doses of rotavirus Brazil, Mexico and Venezuela. Infants received two oral doses of vaccine or placebo at 2 and 4 months of age, concurrently with routine immunizations, except for vaccine (OPV). paper results from Bel\u00e9m, Brazil, where the number of subjects per group and the viral vaccine titers with a of 11 defined as severe GE. The rates of solicited general symptoms were similar in vaccine and placebo recipients. At 2 months after the second dose, a seen in the immunogenicity of routine vaccines. Vaccine against any John P. Utz Leadership Award Dr. Charles M\u00e9rieux Award for Achievement in Vaccinology and Immunology ... reliable way to should ... [Desarrollo de una vacuna profil\u00e1ctica de segunda generaci\u00f3n contra el papilomavirus humano Development of a second generation prophylactic vaccine against human papillomavirus](http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802011000500015) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Alonso Leonardo 2011-06-01 Full Text Available Los papilomavirus humanos (HPV son el agente etiol\u00f3gico del c\u00e1ncer cervical (CC, la segunda causa de muerte por c\u00e1ncer en mujeres. Se estima que medio mill\u00f3n de nuevos c\u00e1nceres se diagnostica cada a\u00f1o, ocurriendo la mayor\u00eda de ellos en pa\u00edses en v\u00edas de desarrollo debido a la ausencia o ineficiencia de los programas masivos de detecci\u00f3n temprana. Recientemente se han introducido en el mercado dos vacunas profil\u00e1cticas contra las principales cepas oncog\u00e9nicas de HPV, la cepa 16 y 18, responsables por el 80% de todos los CC. Estas vacunas se obtienen en forma recombinante y han demostrado ser extremadamente seguras y eficaces. Sin embargo, su impacto inmediato en la incidencia de la infecci\u00f3n por HPV en pa\u00edses en v\u00edas de desarrollo ser\u00e1 m\u00ednimo, debido principalmente al alto costo de las mismas. Existe la necesidad de contar con vacunas de segunda generaci\u00f3n, de bajo costo y de aplicaci\u00f3n masiva que permitan disminuir sensiblemente el n\u00famero de CC en la poblaci\u00f3n. Con este objetivo hemos desarrollado una plataforma de expresi\u00f3n recombinante que permite obtener part\u00edculas tipo virus (VLPs con las cuales es posible formular vacunas efectivas y accesibles contra la infecci\u00f3n por HPV.Human papillomaviruses (HPV are the etiologic agent for cervical cancer (CC, the second cause of cancer death in women worldwide. It is estimated that half a million new cases are diagnosed each year, mostly in developing countries due to the lack of massive programs for early detection of the virus. Recently, two prophylactic vaccines against the main oncogenic HPV types 16 and 18 (responsible for 80% of CC have been introduced into market. Both of these vaccines, obtained as recombinants, have been shown to be safe and effective; however, their high cost works against its impact incidence of HPV infection in developing and low-income countries. There is a need to have in hand second generation, low cost vaccines of massive use [Rotavirus Infection in Four States deaths worldwide and with 33,000 deaths in Nigeria in children < 5 years of age annually. However, limited data exit on particles (VLP from rotavirus, gut to deliver molecules capsid in baculovirus led to the auto assembly of VLP that display similar properties to rotavirus. In vitro experiments showed that VLP were MA104 and provide the first in vivo evidence of the potential of these nanoparticles as a promising safe candidate for drug delivery to intestinal cells. [Prospective study of the burden of rotavirus gastroenteritis in Danish first to characterize the total burden of rotavirus gastroenteritis (RVGE) at both hospital and general physician (GP) clinics in Denmark, and also the first to confirm rotavirus (RV) as the leading cause of acute gastroenteritis (GE) among children......This was the first study to characterize the total burden of rotavirus gastroenteritis (RVGE) at both hospital and general physician (GP) clinics in Denmark, and also the first to confirm rotavirus (RV) as the leading cause of acute gastroenteritis (GE) among children... [Rotavirus Text Available Approximately 40 years have passed since the discovery of the rotavirus and 10 years since the introduction and progressive and four additional vaccines have been licensed and are being used in defined regions. In this context, one main issue that remains unsolved is the lower review. The imperative challenge ahead is to fulfill the rotavirus detected in child with gastroenteritis in Rio de Janeiro, Brazil](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02761983000300002) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Text Available identical to rotaviruses were found in the faeces of a nine week-old child with gastroenteritis. Analysis of the viral RNA genome by polyacrylamine gel electrophoresis revealed 10 wich in migration those of the great majority of rotaviruses infecting man and other animal hosts. The virus was not detected by a highly sensitive the only strain with such behaviour among 230 rotaviruses of human origin examined in this laboratory since 1979. The implications of the de dois meses com gastroenterite. An\u00e1lise do genoma viral eletroforese em gel de poliacrilamida revelou 10 faixas (provavelmente quais diferem em velocidade de migra\u00e7\u00e3o das observadas na grande maioria de rotavirus de hospedeiros humanos e de diversas esp\u00e9cies v\u00edrus foi revelado o que sugere a aus\u00eancia do ant\u00edgeno de grupo que da rea\u00e7\u00f5es cruzadas entre a maioria dos rotavirus. O v\u00edrus descrito no presente trabalho foi o \u00fanico com tal comportamento entre 230 amostras analisadas por n\u00f3s desde 1979. A rotavirus n\u00e3o relacionados antigenicamente cause worldwide, and several vaccines have the burden and healthy mothers living in a rural area (n=145) and mothers living in an urban area (n=147) of Vietnam. Total IgA concentration was significantly higher in samples from mothers in the rural region than in samples from mothers in the urban region, whereas mothers had significantly higher forming up to or even at a milk-to-virus ratio of 1:8. An rotavirus in children hospitalised for acute gastroenteritis (AGE) in two urban hospitals in Malaysia. A 12-month prospective study (January to December in children younger 14 years with AGE hospitalised to the paediatric units of University of Malaya Medical Centre (UMMC), Kuala Lumpur; and Hospital Sultanah Aminah (HSA), Johor Bahru, Malaysia was conducted. In 2002, 399 and 1307 children with AGE were admitted to UMMC and HSA, samples Rotavirus the = hospitalisation in HSA were older than 5 years of outbreak within the communities served increase in admissions of rotavirus gastroenteritis was observed in both units from January to March 2002. The peak age group for rotavirus-related hospital admission in this study was much older, between 12 to 35 months. It is uncertain whether this was related to the outbreak of rotavirus gastroenteritis observed within two urban areas from January to March 2002 re-infection with rotavirus in Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Text Available ranges from >90% in high socio-economic settings (SES to 50% in low SES. With the imminent introduction of rotavirus vaccine in low SES countries, performance.We developed a mathematical model to predict rotavirus vaccine efficacy in high, middle and low SES based on data specific for each of severe rotavirus in high, middle and low SES, respectively. Also predicted was that vaccines are most effective against severe disease and efficacy declines with age in low but not high SES. Reduced immunogenicity of vaccination and reduced protection factors efficacy in low continued risk of severe disease in non-primary natural infections in low SES is key factor underpinning reduced efficacy of different SES, validating the model. The phenomenon of reduced vaccine efficacy can be predicted by factors of of the vaccine (e.g. improving immunogenicity in low SES and vaccination program (e.g. additional doses may bring improvements. in high socio-economic settings (SES) to 50% in low SES. With the imminent introduction of rotavirus vaccine in low SES countries, in these strategies to improve vaccine performance. We developed a mathematical model to predict rotavirus vaccine efficacy in high, middle and low SES based on data specific for each 51% of severe rotavirus in high, middle and low SES, respectively. Also predicted was that vaccines are most effective against severe disease and efficacy declines with age in low but not high SES. Reduced immunogenicity of vaccination and reduced protection are the main factors that compromise efficacy in low SES. The continued risk of severe disease in non-primary natural infections in low SES is key factor underpinning reduced efficacy of different SES, validating the model. The phenomenon of reduced vaccine efficacy can be predicted by factors of of the vaccine (e.g. improving immunogenicity in low SES) and vaccination program (e.g. the plasma and stool of rotavirus-infected children. We sought to determine the rotavirus vaccine could extend protection into the second year of life in low resource countries. We conducted an open-label, individual-randomized trial in assigned 600 9- to 11-month old infants to fever control difference, 0.1% CI, - 4.2). occurred in control group; 364 [95% CI, 294 to 450]) compared to controls (68 [95% CI, 50 to 92] and 153 [95% CI, 114 to 207]. PRV did not interfere with MV and MenAV; this rolls out vaccination against rotavirus-diarrhea, a major cause of child illness and death. As the vaccine covers a limited number of rotavirus variants, this study describes the molecular epidemiology of rotavirus among children under two years in Dar es Salaam, Tanzania, prior to implementation of vaccination. Methods Stool specimens, 690 children admitted to hospital due to diarrhea (cases) and 545 children without diarrhea (controls) during one year. Controls were inpatient or child was most frequently found in the age group of four to six months. The prevalence of rotavirus in cases was lower in stunted children (28.9%) than in non-stunted children (40.1%, opportunistic pathogen children infected HIV. PMID:24844631 [Pron\u00f3stico (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Mota-Hern\u00e1ndez Felipe 2001-01-01 Full Text Available Objetivo. Comparar la gravedad de la diarrea por rotavirus (RV y por no rotavirus. Material y m\u00e9todos. Estudio transversal en 520 lactantes con diarrea aguda, efectuado entre octubre de 1994 y marzo de 1995 en siete centros del primer nivel de atenci\u00f3n en cinco estados de M\u00e9xico. El diagn\u00f3stico de RV se realiz\u00f3 con ensayo inmunoenzim\u00e1tico o por electroforesis. El an\u00e1lisis se hizo a trav\u00e9s de medidas de tendencia central. Los resultados se presentan como promedio y desviaci\u00f3n est\u00e1ndar o mediana o variaci\u00f3n. Resultados. Se aisl\u00f3 RV en 264 lactantes (50.7% con predominio en varones de 6 meses a un a\u00f1o. Las manifestaciones cl\u00ednicas fueron significativamente diferentes entre el grupo rotavirus positivo y el grupo rotavirus negativo en mediana de evacuaciones por 24 horas, frecuencia de v\u00f3mitos, temperatura > 38\u00b0 C, deshidrataci\u00f3n y calificaci\u00f3n de gravedad, respectivamente. Conclusiones. Estos resultados mostraron peor pron\u00f3stico por mayor gravedad de la diarrea por RV en lactantes, con relaci\u00f3n a otra etiolog\u00eda. El texto completo en ingl\u00e9s de este art\u00edculo est\u00e1 disponible en: http://www.insp.mx/salud/index.html [Cost effectiveness of gastroenteritis (RGE) is the leading cause of diarrhea in young children in Oman, incurring on the health care burden and costs associated with rotavirus gastroenteritis (RGE) in Oman A Markov model was used to compare two including children who were administered the RV5 vaccination versus those who were not, in a hypothetical group of 65,500 children followed for their first 5 years of life in Oman. The efficacy of the vaccine in reducing RGE-related hospitalizations, emergency department (ED) and office visits, and days of parental work loss for children receiving the vaccine was based on the results of the Rotavirus Efficacy and Safety Trial (REST). The outcome of interest was cost per quality-adjusted life year (QALY) gained from health care system and societal perspectives. A universal RV5 vaccination hospitalizations, ED visits, outpatient visits and parental work days lost due to rotavirus infections by 89%, 80%, 67% and 74%, of the introduction of RV5, direct medical QALY saved would be OMR payer perspective. An RV5 vaccination program would Universal RV5 vaccination in Oman is likely to significantly reduce the health care burden and costs associated with rotavirus gastroenteritis and may be cost-effective from the payer perspective cost & resources overview why vaccinate posters buttons and banners videos ... hepatitis vaccines im/sq how to do kids infect ... vaccine safety q & a article infect kids links & resources for prevention HORIZONTE, BRAZIL DETECTED BY RIBONUCLEIC [Directory of Open Silva 2013-04-01 electrophoresis. were taken from 391 children (267 with diarrhea from the lower socioeconomic stratum who sought treatment in the Hospital Infantil Jo\u00e3o Paulo II/Belo Horizonte, during 2005 and 2006. 64/24.0% with 15/12.1% no diarrhea. The virus was strongly associated with diarrhea (p = 0.003. A total of 76/19.4% and 69/17.6% 0.001 and almost exclusively in children to three Long strains prevailed the decrease seen in 2006, rotavirus infection is still very common in our area. Although viral RNA electrophoresis is useful as a typing of rotavirus infection. We confirmed from long to short profile strains, as already described for other South American countries. [Importance of rotavirus as a cause of gastroenteritis be a very important cause of GE in younger children in both developed as well as developing countries, but causes most the latter. The recent introduction of a rotavirus vaccine in some parts of the world makes it necessary for us to determine the impact of this organism in our population with the aim of determining the need for the vaccine. In order to determine this, a study was conducted at the JUH and 3 other private hospitals. At the JUH, 64/256 (25%) of children with GE had rotavirus in 1995. The proportions of cases attributed to rotavirus in the other were 70/199 (35.2%), 69/279 (24.7%) and 76/294 The cumulative proportion of cases attributable to rotavirus gastroenteritis in all the y was 27.14%. With regard to the 3 private hospitals, is concluded that rotavirus is a significant cause of GE in Jordanian children regardless of their social background, and attempt at controlling this infection may in Japan. A two-part questionnaire was designed to determine the number of the cases and the features sudden unexpected between Of the 1365 questionnaires sent to hospitals, 963 (70.5%) were returned and analysis. We determined 58 cases of rotavirus-associated encephalitis/encephalopathy and 7 cases of unexpected prognosis of the encephalitis/encephalopathy. Copyright \u00a9 2013 The Japanese Society of Child Neurology. Published by Elsevier B.V. All rights (AJOL)](http://www.ajol.info/index.php) User estimated 453, 000 resulting in the death of a child younger than five years. In Sub-Saharan Africa and. Asia, according to Kotloff et al., (2013), rotavirus is one of the four most common causes of moderate to severe diarrhea among children <5 years of age. the documented '10 killer conditions' among ... [Factores asociados a una respuesta inadecuada a la vacunaci\u00f3n contra la hepatitis B en personal sanitario](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1135-57271998000600004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Tolosa Mart\u00ednez Natividad 1998-01-01 Full Text Available FUNDAMENTO: La vacuna recombinante contra la hepatitis B confiere inmunidad aproximadamente en el 95 % de los casos, pero existe un porcentaje que responde insuficientemente. El objetivo de este trabajo es evaluar los factores que se asocian con una inadecuada respuesta inmunitaria. M\u00c9TODOS: Se trata de un estudio observacional y anal\u00edtico en el que se sigue retrospectivamente una cohorte de sujetos vacunados frente al virus de la hepatitis B (VHB. Se recogieron las variables de inter\u00e9s del personal sanitario que cumpl\u00eda los criterios de inclusi\u00f3n, del \u00c1rea de Salud 9 de la Comunidad Valenciana (n=827. Tras la vacunaci\u00f3n se determin\u00f3 la titulaci\u00f3n de anticuerpos de superficie (antiHBs para comprobar la respuesta, consider\u00e1ndose niveles protectores los superiores a 10 mUI/ml. RESULTADOS: Se produjo una adecuada seroconversi\u00f3n en el 94,4% de los vacunados. La baja o nula respuesta a la vacuna se asoci\u00f3 significativamente y de forma independiente con variables como el sexo masculino, la edad, el \u00edndice de masa corporal (IMC y el tabaquismo. El consumo de alcohol y los niveles de GPT, aunque no se relacionaron de forma significativa con la respuesta a la vacuna, actuaron como posibles factores de confusi\u00f3n. CONCLUSIONES: La inmunogenicidad de la vacuna es satisfactoria. Es importante cuantificar los niveles de antiHBs, sobretodo cuando hay factores predictivos de mala respuesta. De esta manera, es posible identificar a aquellos que precisan dosis de recuerdo y a los no respondedores, evit\u00e1ndose as\u00ed situaciones de falsa sensaci\u00f3n de protecci\u00f3n frente al VHB. [Dose response and efficacy of a live, attenuated human rotavirus vaccine in Mexican the most cost-effective intervention to reduce the disease burden associated with this infection worldwide. The objective of this study was to determine the dose response, immunogenicity, and efficacy of 2 doses of an oral, attenuated monovalent G1[P8] human rotavirus vaccine in children from the same setting in Mexico, where the natural protection against rotavirus infection was studied. From June 2001 through May 2003, 405 healthy infants were randomly assigned to 1 of concentrations 10(4.7), 10(5.2), and 10(5.8) infectious units) and to a placebo group and were monitored to the age of 2 years. The vaccine/placebo was administered concurrently with diphtheria-tetanus toxoid-pertussis/hepatitis B/Haemophilus influenzae type b vaccine at 2 and 4 months of age. After the administration of the first vaccine/placebo dose, weekly home visits to collect information conducted. vaccine infants who received placebo. For the pooled vaccine groups, efficacy after 2 oral doses was 80% and 95% against any and severe rotavirus gastroenteritis, respectively. Efficacy was 100% against severe rotavirus gastroenteritis and 70% against severe gastroenteritis of any cause with the vaccine at the recipients. This new oral, live, vaccine was safe, immunogenic, cyclooxygenases the plasma and stool of rotavirus-infected children. We sought to determine the economics rotavirus immunization Vietnam : J. the most common cause of severe diarrhoea worldwide. Vietnam is situated in the region of high rotavirus infection incidence and eligible for financial support to introduce rotavirus vaccines into the Expanded Program of Immunization (EPI) from the GAVI. This study was [[Prospective study of rotavirus infection at the maternity hospital in Saint-Germain-en-Laye between May 24 and June 7, 1983 were followed clinically, with a special supervision looking for Rotavirus were performed in all the children and their mothers, at the 3rd and 6th days of life. No mother was found with Rotavirus infection. In neonates, Rotavirus excretion curves and the occurrence of diarrhea. All the and cell surface molecules. In this work, we ganglioside GM1, integrin subunits 2 and 3, and the heat shock cognate protein 70 (hsc70), all of which have been implicated were incubated with cells at 4 deg. C, about 10% of the total infectious virus was found associated with DRMs, and the DRM-associated virus increased to 37% in Lubrol-resistant membrane domains after 60-min incubation at 37 deg. C. The virus was excluded from DRMs if the cells were treated with methyl--cyclodextrin (MCD). Immunoblot analysis of the surface proteins became enriched in incubation being almost exclusively localized in Lubrol-resistant DRMs 2014-01-01 Before the introduction of rotavirus vaccine in Egypt, information on the burden of disease and the circulating rotavirus genotypes is critical to monitor vaccine effectiveness. A cohort of 348 Egyptian children was followed from birth to 2 years of with visits detect of children had rotavirus-associated diarrhea at least once by their second birthday. One hundred and twelve children experienced a single rotavirus diarrheal episodes (RDE) at a median age of 9 months; while 27 infants had their second RDE at a median age of 15 months and 1 infant had 3 RDE at the age of 2, 16 and 22 months. Of the 169 RDE, 82% could be assigned a G-type, while 58% had been identified a P-type. most prevalent genotype was G2P[4] rotavirus episodes were significantly associated with fever (P = 0.03) and vomiting (P = 0.06) when compared were the 50% of the second RDE while G9 represented 25% of the second RDE. Genotypes identified are similar to those detected globally except for absence of G4. Our finding that 75% of the second RDE were due to G2 and G9 indicates a possible reduction types compared with G1, where 90% of G1 cases did not experience a is a multidomain, to we two novel forms of the coiled-coil region of NSP4 of the coiled-coil NSP4 revealed that nature of at position Full (Merck & Company, Inc, Whitehouse Station, NJ, USA is an oral pentavalent rotavirus vaccine (RV5 that has shown high and industrialised countries with high medical care resources. To date, the efficacy and effectiveness data for RV5 are available in some Latin American countries, but not Brazil. In this analysis, we projected the effectiveness of RV5 than four regions of Brazil, using a previously validated mathematical model. The model inputs included hospital-based rotavirus surveillance data from Goi\u00e2nia, Porto Alegre, Salvador and S\u00e3o Paulo from 2005-2006, which the proportions of to published rotavirus serotype-specific efficacy from the Rotavirus Efficacy and Safety Trial. The model projected an overall percentage reduction of 93% diarrhea among infants and young drug available against rotavirus, largely due to the lack of an ideal target molecule which has hampered drug development. Our previous We therefore both cellular and mouse models to study the immunological safety and effectiveness of CsA as an anti-RV drug. We found that CsA treatment of HT-29 cells before, during, and after but not SOCS-2 or SOCS-3. The antiviral effect of CsA was confirmed in an RV-infected neonatal mouse model by evaluation of antigen clearance and of changes frequency CsA- vehicle-treated groups were observed. Thus, both our in vitro and in vivo findings suggest that CsA, through CsA may be of human b im/sq kids ... abcs of mmr & dtp thimerosal vaccine safety and Extremus videos mono pertussis Silence the Sounds of Pertussis Acalla los Sonidos de la Tos Ferina AAP Jeffrey 2015-04-01 Group A are among the main global causes of severe diarrhea in children under the age infections and untypeable samples obtained from hospitalised who presented with acute gastroenteritis at sentinel hospital sites that suggested these strains are diversity of rotavirus sequences and [Obtenci\u00f3n y evaluaci\u00f3n preliminar de un virus canarypox recombinante como candidato a vacuna antirr\u00e1bica Development and preliminary assessment of a recombinant Calamante 2012-01-01 En la Argentina, la rabia est\u00e1 circunscripta a algunas provincias del norte. La disponibilidad de nuevas vacunas que eliminen la manipulaci\u00f3n del virus r\u00e1bico y que permitan el control de la enfermedad es de importancia estrat\u00e9gica nacional y regional. Las vacunas basadas en poxvirus recombinantes se han utilizado con \u00e9xito como vacunas antirr\u00e1bicas a nivel mundial. SI bien estos sistemas no est\u00e1n disponibles comercialmente, la plataforma de obtenci\u00f3n de virus canarypox (CNPV) recombinantes most closely related to those of porcine of were and a human rotavirus of porcine origin. Our data provide an evidence of interspecies transmission and whole-genome transmission of nonreassorted G9P[19] porcine RVA human occurring in nature THE of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) T. A. Grechukha 2014-01-01 Full Text Available Rotavirus is a major public problem in all countries. The incidence of rotavirus infection is growing steadily in the Russian Federation and over the past 10 years increased by 7 times, amounting to 72 cases per 100,000 in 2010. The rotavirus vaccine was registered in the Russian Federation in 2012 and successfully applied from 2013. The vaccine used for more than 8 years and have enough experience on the efficacy and safety. Different foreign investigations have shown the herd immunity of the vaccine. The authors present data about effectiveness and safety most cause of severe diarrhoea worldwide. This study was designed to evaluate the rotavirus intestinal in vaccine causation](https://www.narcis.nl/publication/RecordID/oai%3Adare.uva.nl%3Apublications%2F213ab654-4e76-4031-aeda-d48134ac7b6c/uquery/rotavirus/id/6/Language/EN) Harris, V.C. 2018-01-01 Rotavirus (RV) is one the leading causes of serious gastroenteritis and diarrheal deaths in children under the age of H are important etiological agents of gastroenteritis in man and animal. In Nigeria vaccination of infants has continuously been carried out, however the disease is still a burden to the nation which remains one of the countries with the highest cases of rotavirus gastroenteritis. [Rotavirus disease in Guinea-Bissau, West Africa: a review longitudinal childhood diarrheal disease and hospital-based surveillance of April, and few cases registered from May to December. Most children (74%) experience their first infection before the age of 2 years, and rotavirus has been identified as the most pathogenic of all diarrheal agents during 2... [Efficacy, safety and immunogenicity of a human rotavirus vaccine (RIX4414) in Hong Kong children up to three years of age: a randomized, controlled trial.](https://www.ncbi.nlm.nih.gov/pubmed/23499605) Lau, Yu-Lung; trial was conducted in Hong Kong to evaluate the efficacy, safety and immunogenicity of a human rotavirus vaccine, RIX4414 (Rotarix) against severe rotavirus gastroenteritis in children to three years of age. Healthy infants aged 6-12 weeks were enrolled between two oral or (N=1512) given 2 efficacy was assessed from two weeks post-Dose 2 until the children were two and three years of age. Anti-rotavirus IgA seroconversion rate was 100 infants. Safety was assessed until the children were two years of age; serious adverse events (SAEs) were recorded throughout the study period. In children aged two and three years of life, vaccine efficacy against severe rotavirus gastroenteritis was (95% CI: 86.8%-99.9%). At least one SAE was recorded in 439 and 477 infants who were administered RIX4414 the rotavirus gastroenteritis for at least two years post-vaccination in Hong Kong children. Copyright \u00a9 2013 Elsevier Ltd. All rights of rotavirus in developed countries observational study was conducted from October 2008 to June 2009. It included 682 children up to 5 years of age with acute gastroenteritis (AGE who attended primary care (n = 18 and emergency room/hospital settings (n = 10, covering the regions Asturias (North-west Spain. All and telephone contact. enrolled children, 207 (30.4% were rotavirus and 170 (25% had received at rotavirus vaccine. The mean (standard deviation indirect cost caused by an episode of at 135.17 (182.70 Euros. Costs decision-making process of the eventual inclusion of rotavirus vaccine BACKGROUND: There has recently been a growing interest in the use of the non-pathogenic yeast Saccharomyces boulardii, in the treatment The full effects of administration the morphological effects of inoculated S boulardii on mouse intestinal villi, both in control animals and those treated with rotavirus. METHODS: Seven both rotavirus S boulardii administered together. Control animals were given saline only. Animals were killed by decapitation 48 hours post-treatment. The middle region of the small intestine was studied pentavalent rotavirus vaccine in a large urban population in the United States.](https://www.ncbi.nlm.nih.gov/pubmed/20083525) Boom, Julie of complete or practice. A case-control evaluation was conducted in February through June 2008 at an emergency department in Houston, Texas. Case patients with rotavirus AGE (N = 90) were identified through testing for rotavirus in fecal specimens obtained from 205 children 15 days through 23 months of age presenting with AGE. Control groups included rotavirus-negative AGE patients 115), concurrently enrolled patients with acute respiratory infection (ARI) (N = 228), and up to 10 age- and zip code-matched children sampled from the Houston-Harris Registry (HHCIR) for each case patient >8 months of age. Immunization were from records, health care providers, and/or the HHCIR. calculated of vaccination for case patients versus control patients, after adjustment for age at presentation and birth date. The vaccine effectiveness of a complete RV5 series was 89% (95% confidence [CI]: 70%-96%) and 85% (95% and ARI control patients, respectively. Immunization data were available for 44% of case patients (n = 40) from the HHCIR; the estimated 3-dose vaccine effectiveness with these HHCIR CI: and emergency department visits was and ARI control groups combined. In this setting, a complete series of RV5 human Text Available Rotaviruses (RV are a major cause of gastroenteritis in children. Widespread vitamin A deficiency is associated with reduced efficacy of vaccines and deficient model that mimics subclinical vitamin A deficiency in children to study its effects on an oral human rotavirus (HRV vaccine and virulent HRV challenge. Piglets derived the in pigs not fully virulence factors for vaccine development Relevancia de los factores de virulencia de helicobacter pylori para el desarrollo de vacunas](http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342009000900010) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) pylori infection that some strains could be beneficial means administration of However, is necessary to determine not these results can expressed Salmonella spp. vectors, well vaccine aluminum as adjuvant. Although these studies have achieved limited success, they have established support for the development of an effective vaccine against this infection.La infecci\u00f3n por Helicobacter pylori incrementa el riesgo de un amplio espectro de cuadros cl\u00ednicos, que van de la \u00falcera p\u00e9ptica al c\u00e1ncer g\u00e1strico. Sin embargo, la infecci\u00f3n s\u00f3lo induce ulceraci\u00f3n g\u00e1strica y duodenal o c\u00e1ncer g\u00e1strico en la minor\u00eda de los sujetos infectados debido que las cepas de H. pylori son gen\u00e9ticamente diversas y expresan diferentes factores de virulencia. As [Acute Rotavirus-Induced Diarrhea in current picture and of acute diarrhea There are presented ESPGHAN consensus (2014 was demonstrated its effectiveness according to the literature review and own data. [[Reverse genetics system of rotaviruses: development and application for Satoshi genetics is the powerful and ideal methodology for the molecular analysis of virus biology, which enables virus groups of RNA viruses, development of such a system for rotaviruses is more challenging owing in part to the technical complexity of manipulation of their multi-segmented genome. A breakthrough in the field of rotavirus reverse genetics came in 2006, when we established the first reverse genetics system for rotaviruses, which is a partially plasmid-based system that permits replacement of a viral gene segment with the aid of a helper virus. Although this helper virus-driven system these medically important viruses. In this review, I describe the development and application of our rotavirus reverse genetics system, and its future E. 1998-01-01 The main limitation of both the rabbit and mouse models of rotavirus infection is that (HRV) in conferring replication competence in a heterologous host infections. We recently reported the the P the spike protein VP4 of four lapine rotavirus strains and animal rotavirus strains of different P and G types. We also evaluated whether the parental 28 days postinoculation with 103 50% infective ALA rabbit Other HRVs infect complete challenge. Live attenuated RRV reassortant vaccine strains resulted in no, limited, or productive infection of rabbits, but all rabbits were completely protected from heterotypic ALA challenge. The altered replication efficiency the reassortants encuentro prevenci\u00f3n de la enfermedad neumoc\u00f3cica con vacunas conjugadas](http://www.scielo.org.mx/scielo.php?script=sci_arttext&pid=S0036-36342001000400012) [Directory of Open Access Full Text Available Streptococcus is one leading causes and noninvasive diseases antibioticresistant strains of the various pneumococcal disease manifestations. Thus, the the conjugate vaccine could improve outcomes by antibiotic-resistant disease. Additionally, costs associated with could be substantially reduced, particularly in developing countries. The time has come for fully applying this new advancement against S. pneumoniae, to benefit the children of the world. The Spanish version of this paper is available at: http://www.insp.mx/salud/index.htmlStreptococcus pneumoniae es uno de los principales agentes causantes de enfermedades invasoras y no invasoras en la poblaci\u00f3n pedi\u00e1trica y sigue representando uno de los principales problemas de salud p\u00fablica a nivel mundial. La incidencia creciente de cepas resistentes a diversos antimicrobianos ha complicado el tratamiento y manejo de varias de las manifestaciones de la enfermedad neumoc\u00f3cica. Con \u00e9stas consideraciones, la mejor estrategia de manejo es la prevenci\u00f3n de \u00e9stas enfermedades a trav\u00e9s de la vacunaci\u00f3n. A pesar de que se han estudiado diversas vacunas neumoc\u00f3cicas conjugadas en ni\u00f1os, solo una [Molecular characterization interspecies transmissions can generate novel G3P[8] strains in feces sampled from children Germany in 2015 and 2016, respectively. Thereof two showed a DS-1-like backbone. different countries. The reconstruction of reassortment events in the evolution of novel equine-like G3 rotaviruses suggests an independent introduction of the three human Journals Text countries occurs. In the present (NAC, detected by the percentage of viral small intestinal villi isolated from ECwt-infected ICR mice. Administration of 6 mg NAC/kg every 8 h for three days following the first diarrhoeal episode reduced viral infectivity by pioglitazone rosiglitazone decreased viral ECwt-infected mice reduced Hsc70 and PDI expression to levels those observed in villi from uninfected control mice. The present results suggest that the drugs tested in the present be assayed in preventing or treating rotaviral diarrhoea in animals. Decision to Vaccinate Their cause of health care utilization and almost all children are affected by the age of 5 years. In Canada, at the time of this survey (2008-09), immunization rates for rotavirus were less than 20%. We assessed the of parent's acceptance to have rotavirus. Text has hbv/hcv standard ... [IMPLICACIONES \u00c9TICAS Y SOCIALES DE LA INTRODUCCI\u00d3N DE LA VACUNA CONTRA EL VIRUS DEL PAPILOMA HUMANO EN M\u00c9XICO: REFLEXIONES SOBRE UNA PROPUESTA DE INTERVENCI\u00d3N IMPLICA\u00c7\u00d5ES \u00c9TICAS E SOCIAIS DA INTRODU\u00c7\u00c3O DA VACINA CONTRA O DO PAPILOMA HUMANO NO M\u00c9XICO: REFLEX\u00d5ES SOBRE UMA PROPOSTA DE INTERVEN\u00c7\u00c3O ETHICAL AND SOCIAL IMPLICATIONS OF THE INTRODUCTION OF THE VACCINE AGAINST THE HUMAN PAPILLOMA VIRUS IN MEXICO: REFLECTIONS ON A PROPOSED INTERVENTION](https://www.openaire.eu/search/publication?articleId=doajarticles::f3f4ecc159ebb48d37bb75cddc626a36) Klip; Gisela Morales Gonz\u00e1lez; Renee Witlen 2008-01-01 El objetivo de este trabajo es identificar aspectos \u00e9ticos y sociales relacionados con la introducci\u00f3n de la vacuna contra el virus del papiloma humano (VPH) en M\u00e9xico para una decisi\u00f3n informada y justa que considere no s\u00f3lo los aspectos financieros. De acuerdo con la informaci\u00f3n sobre eficiencia y costo de la vacuna, su introducci\u00f3n al sistema p\u00fablico mexicano puede acarrear consecuencias no previstas para las participantes y para toda la sociedad, por lo que debe examinarse en el contexto ... [Presence of rotavirus and free-living population limited access to clean water supplies. Here, plants that supply drinking water samples from rotavirus and free-living amoebae. Rotavirus was present in water domestic tap water samples had a prevalence of only 5%. Out of 20 water samples from filtration plants, 13 (65%) were positive for Acanthamoeba spp., and one (5%) was positive for B. mandrillaris. Out of 20 drinking water samples collected from different areas of Karachi, 35% were positive for Acanthamoeba spp. Rotavirus was detected in drinking water samples tested. Overall, these findings showed for the first time presence of rotavirus, addition to pathogenic free-living amoebae in drinking water supplies of Karachi that could be an important public health risk for the affected population. PMID:28591260 rotavirus population limited access to clean water supplies. Here, plants that supply drinking water samples from rotavirus and free-living amoebae. Rotavirus was present in water domestic tap water samples had a prevalence of only 5%. Out of 20 water samples from filtration plants, 13 (65% were positive for Acanthamoeba spp., and one (5% was positive for B. mandrillaris. Out of 20 drinking water samples collected from different areas of Karachi, 35% were positive for Acanthamoeba spp. Rotavirus was detected in drinking water samples tested. Overall, these findings showed for the first time presence of rotavirus, addition to pathogenic free-living amoebae in drinking water supplies of Karachi that could be an important public health risk for the affected study, we describe rotavirus infection in the first 2 years of life in sites with and without rotavirus vaccination programs. Children were recruited by 17 days of age and followed to 24 months with collection of monthly for antirotavirus rotavirus gastroenteritis. Household overcrowding and a high pathogen load were consistent risk factors for infection and disease. Three prior protection against subsequent infection not disease relatively infection and by site. Protection by vaccination may not be sustained in the second year of life in settings with high burdens of transmission and poor response to oral vaccines. \u00a9 The Author 2017. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com. [Desarrollo de vacunas contra el virus de la inmunodeficiencia humana tipo 1: Relevancia de la inmunidad celular contra subtipos Development of vaccines for HIV-1: Relevance Ana Mar\u00eda Rodr\u00edguez 2010-12-01 Full Text Available Han pasado casi 30 a\u00f1os de la detecci\u00f3n de los primeros casos de infecci\u00f3n con HIV-1 y a\u00fan no se ha conseguido desarrollar una vacuna efectiva y segura. A pesar del impacto positivo sobre la pandemia que se ha conseguido gracias a los avances en la terapia antirretroviral (TARV, el HIV/sida sigue constituyendo un grave problema para la salud p\u00fablica, especialmente en los pa\u00edses en desarrollo, donde es dif\u00edcil el acceso al tratamiento. En el mundo, 33 millones de personas viven con el virus del sida, mientras que en la Argentina se calcula que habr\u00eda unos 120 000 infectados. Uno de los desaf\u00edos para lograr una vacuna contra el HIV es la variabilidad viral. El grupo M, responsable de la pandemia, se encuentra dividido en 10 subtipos y varios sub-subtipos, adem\u00e1s de las 48 formas recombinantes circulantes y m\u00e1s de cien formas recombinantes \u00fanicas. La epidemia de HIV en nuestro pa\u00eds es tan compleja como en el resto del mundo, con la co-circulaci\u00f3n principalmente de virus pertenecientes al subtipo B y recombinantes BF (CRF12_BF y derivadas. A pesar de la cantidad de trabajos dedicados a la caracterizaci\u00f3n de la respuesta inmune y al desarrollo de vacunas, no queda claro cu\u00e1l es el impacto de la variabilidad en la elecci\u00f3n del ant\u00edgeno. Trabajos realizados en nuestro laboratorio demuestran el papel que juega la inmunidad celular con respecto a las variantes recombinantes BF, tanto en humanos como en modelos animales. Estos resultados son de importancia en el desarrollo de futuras vacunas para nuestra regi\u00f3n.It has been almost 30 years since the detection of the first HIV-1 cases and yet an effective and safe vaccine though HIV/aids remains a major concern for developing countries, where access to therapy is limited. The last report from UNAIDS notified 33 million people living with HIV/aids, worldwide [Rotavirus and surveillance before vaccine Ignacio; Ezequiel Agust\u00edn; Group A Rotavirus has been as one of the most important infantile diarrheal pathogens worldwide. In Argentina, it is responsible for over 200,000 acute diarrhea cases and from 30 to 50 deaths annually in children under 5 years. The aim of this study is to analyze frequency, seasonality, age group distribution, and circulating genotypes based on data notified in the 2012-2014 turn to assess the pre-vaccine scenario, considering that rotavirus vaccine was introduced were taken from Viral of samples tested, and higher rates in children under 2 were observed. Rotavirus positive cases were observed. In represents the last survey taken 300,000 deaths) were attributed to rotavirus in 2010. About a third of these deaths occurred in India and Ethiopia. Public finance of rotavirus in these two Ethiopia, financial and distributional consequences into the systematic economic evaluation of vaccine policy, illustrated here with the case study of public finance for rotavirus vaccination. This enables selection of vaccine packages based on the quantitative inclusion of information on equity and on how much financial risk protection is being bought per dollar expenditure on vaccine policy, in addition to how much health is being bought. Copyright \u00a9 2013 Elsevier being strain of Lactobacillus also more effective than HBC alone in reducing diarrhea in a rotavirus infection. In order to further improve this form of on the surface of the bacteria as well binding and a combination of L. effective This antibody capturing platform, tested here the first time in vivo, could potentially be used to target additional gastrointestinal pathogens. Copyright \u00a9 2013 Elsevier Ltd. All rights reserved. in two multi-site, randomized, placebo-controlled field trials; one in Asia (Vietnam and Bangladesh) and the other in sub-Saharan Africa (Ghana, Kenya and Mali). The efficacy results for the Mali site of the multi-country trial are presented here. We randomly assigned infants in a 1:1 ratio to receive 3 doses of PRV/placebo at approximately 6, 10, and 14 weeks of age. Gastroenteritis episodes were captured passively at the local health centers and home visits. The primary study outcome was severe RVGE, as using the Vesikari Clinical Scoring System occurring 14 days after the third dose until the end of the study. Other efficacy analyses included efficacy against severe RVGE through the first year and during the second years of life, as well as efficacy after receiving at least one dose of vaccine. In total, 1960 infants were enrolled in the trial at the Mali site and sera were collected on a subset of infants (approximately 150) for immunogenicity testing. In the first year of follow-up, largely due to cultural practices to visit traditional healers as the first point of care, the point estimate of efficacy was unreliable: the per protocol vaccine efficacy against severe RVGE (95% confidence During the second year after surveillance system was modified to adapt to local customs and health care seeking practices, the point estimate virus Since it is unclear if CT will be approved for human use, we evaluated the of mixed with LT and LT-R192G were totally protected (100%) from rotavirus challenge, while mice of routine infant rotavirus immunisation program without defining which vaccine to be evaluated, which reflects the current deliberation at the Health Science Council in charge of Immunisation and Vaccine established by the Ministry of Health, Labor and Welfare of Japan. Three ICERs were estimated, one from payers' and it is vaccine alone scenario. program to should 2-year-old Text Available Rotavirus and norovirus are common with gastroenteritis children. Although rotavirus occasionally induces central nervous system disease, with rotavirus-induced acute myositis have been reported in the treated a female patient with acute with rotavirus and norovirus. Having present and review the previous cases including those reported in the Japanese literature. [Obtenci\u00f3n y evaluaci\u00f3n preliminar de un virus canarypox recombinante como candidato a vacuna antirr\u00e1bica Development and preliminary assessment of a recombinant canarypox virus [Directory of Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Flavia Zanetti 2012-06-01 Full Text Available En la Argentina, la rabia est\u00e1 circunscripta a algunas provincias del norte. La disponibilidad de nuevas vacunas que eliminen la manipulaci\u00f3n del virus r\u00e1bico y que permitan el control de la enfermedad es de importancia estrat\u00e9gica nacional y regional. Las vacunas basadas en poxvirus recombinantes se han utilizado con \u00e9xito como vacunas antirr\u00e1bicas a nivel mundial. SI bien estos sistemas no est\u00e1n disponibles comercialmente, la plataforma de obtenci\u00f3n de virus canarypox (CNPV recombinantes ya ha sido implementada en nuestro laboratorio. El objetivo de este trabajo fue obtener y evaluar un candidato a vacuna antirr\u00e1bica basado en CNPV recombinantes que expresan la glicoprote\u00edna G (RG del virus r\u00e1bico (RV. Se construy\u00f3 un virus recombinante que expresa la secuencia codificante de RG (CNPV-RG. La inoculaci\u00f3n de ratones con este virus indujo altos t\u00edtulos de anticuerpos seroneutralizantes de RV (3,58 y 9,76 Ul/ml despu\u00e9s de una o dos inmunizaciones, respectivamente y protegi\u00f3 al 78 % de los animales desafiados intracerebralmente con RV. Adem\u00e1s, se determin\u00f3 que el CNPV-RG posee una potencia relativa de 3,5 Ul/ml. Los resultados obtenidos constituyen la primera etapa en la evaluaci\u00f3n del CNPV-RG como candidato a vacuna antirr\u00e1bica. Se requerir\u00e1n nuevos ensayos para confirmar su utilidad en especies de inter\u00e9s veterinario.In Argentina, rabies is limited to some northern provinces. Availability of new vaccines abolishing the handling of the rabies virus and allowing disease control has regional and national been previously set up in our laboratory. The aim of this work was the development and evaluation of an antirabic vaccine of Full Text Available The aim research was to investigate the prognostic and diagnostic value of some clinical the of acute intestinal rotavirus infection in children. We observed 161 children aged 1 month to 6 years. 81 children were diagnosed with rotavirus infection, and 80 \u2014 with secretory diarrhea of unknown origin. Treatment of children was carried out in a hospital. Analysis of clinical and anamnestic data enabled to choose the association of rotavirus infection, which would highlight the groups of children with high risk of rotavirus infection, which requires treatment in a hospital. The practical application of the results of this work should be the optimization of early of rotavirus infections and timeliness of preventive measures. [Vacunas para la prevenci\u00f3n de la gripe en personas de edad avanzada](http://www.sciencedirect.com/science/article/pii/S0716864010706088) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Tom Jefferson 2010-09-01 Conclusiones de los autores: Las pruebas disponibles son de calidad deficiente y no proporcionan orientaci\u00f3n con respecto a la seguridad, la eficacia o la efectividad de las vacunas contra la gripe en las personas de 65 a\u00f1os de edad o m\u00e1s. Para resolver la incertidumbre se debe realizar un ensayo aleatorio controlado con placebo, con financiamiento p\u00fablico y con poder estad\u00edstico adecuado, durante varias estaciones. [Genetic Factors in the Pathogenesis of Available The paper presents the results of examination of 40 children with a diagnosis > T at position 13910 of lactase gene (LCT. It is found that the most severe course of infection is associated with genotypes in Full Text Available Background: Diarrhoea remains the second most common cause of in of is The Committee. Materials and Methods: Stool years, hospitalised for acute were subjected for rotavirus antigen be used vaccine. Thus, an emergence of characterisation of rotaviruses to improve efficacy. [Estimating and national rotavirus deaths in children Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Andrew Clark Full Text Available Rotavirus is a leading cause of diarrhoeal mortality in children but there is considerable 5 years (U5 rotavirus deaths at the global, regional and national level using a standard year (2013 and standard list of 186 countries. The global estimates were 157,398 (CHERG, 122,322 groups methods: (i to select data points for rotavirus-positive proportions; (ii to extrapolate data points to individual countries; (iii to account for rotavirus vaccine that watery diarrhoea hospitalisations based on data from 84 hospital sites in 9 countries, and 65% (95% CI diarrhoea reanalysed data from the Global Enteric Multicenter Study (GEMS and found 44% (55% in Asia, in 31-36%. This increased by a factor of 1.08 (95% CI 1.02-1.14 when the GEMS results were reanalysed using and River natural organic matter (NOM) were studied by time-resolved dynamic light scattering, quartz crystal microbalance, and atomic force microscopy. In NOM-containing NaCl solutions of up to 600 mM, rotavirus suspension remained stable for over 4 h. MgCl2 solution compared to those MgCl2 or NaCl solutions at the ionic suggested that divalent cation complexation with carboxylate groups in NOM and on virus surface was an important mechanism in the deposition and of severe diarrhea in children under-5-years-old in Indonesia. to [Progress in the introduction of the rotavirus vaccine in Latin America and the Caribbean: four years of accumulated experience.](https://www.ncbi.nlm.nih.gov/pubmed/21183843) de became available in 2006 and have been recommended for use in all countries by the World Health Organization. This article provides an update on the use of rotavirus vaccine in Latin American and Caribbean (LAC) countries. Data reported by LAC countries to the Pan American Health Organization (PAHO) were reviewed. As of May 2010, 14 LAC countries and 1 territory have introduced the rotavirus vaccine into their national expanded program on immunization (EPI). Reported coverage levels for rotavirus vaccine are lower than those for other EPI vaccines recommended at the same age. A total of 15 LAC countries are part of the PAHO's LAC rotavirus surveillance network; 12 of them learned on the public health implications of introducing a new vaccine into the EPI. Nine countries and the Cayman Islands pay for the entire cost of the vaccine using government funds. All other new vaccines, but coverage levels strengthened the effect of vaccine use. LAC countries will continue to provide rotavirus and major of circulating strains and monitor the effectiveness and safety Plateau State using RT Thirty one rotavirus isolates recovered from nested RT - and surveillance of rotavirus in Mexico.](https://www.ncbi.nlm.nih.gov/pubmed/29329758) De La Cruz Hern\u00e1ndez, Sergio Isaac; Anaya Molina, Yazmin; G\u00f3mez Santiago, Fabi\u00e1n; Ter\u00e1n Vega, Heidi Rotavirus produces diarrhea in children 5 of those conventional methods such as allows getting the results in only one day. this study a real-time RT-PCR assay was tested using a panel from patients with acute gastroenteritis, and characterized by PAGE RT-PCR should be part of a routine analysis, and as a support of the diagnosis of rotavirus in Mexico. Copyright \u00a9 of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Divina das Deres de Paula Cardoso 2003-01-01 Full Text Available A total of 2,605 faecal specimens from children up to 10 years old with or without diarrhoea were collected. Samples were obtained from A detection rate of from August, dry season in Goi\u00e2nia, and different frequencies of viral detection throughout related to hospitalization illness in children up to 24 months old. This study reinforces the importance of rotavirus as a cause of diarrhoea in children and may be important in regards to the implementation of rotavirus vaccination strategies in our country. [Reactogenicidad e de una nueva vacuna de toxoide tet\u00e1nico y dift\u00e9rico con concentraci\u00f3n reducida en adolescentes cubanos](http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S1025-028X2006000200003&lng=es&nrm=iso&tlng=es) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Rolando Felipe Ochoa. 2006-08-01 Full Text Available Se realiz\u00f3 un estudio aleatorizado, controlado y a doble ciegas en 225 adolescentes cubanos entre 13 y 16 a\u00f1os de edad, con el objetivo de evaluar la reactogenicidad y la inmunogenicidad de una nueva vacuna de toxoide tet\u00e1nico y toxoide dift\u00e9rico con concentraci\u00f3n reducida, producida en el Instituto Finlay, con respecto a su similar comercial IMOVAX dT adult de Aventis Pasteur. Se tomaron muestras de suero antes y 21 d\u00edas despu\u00e9s de la vacunaci\u00f3n. La reactogenicidad de ambas vacunas fue similar. Los s\u00edntomas y signos, tanto locales como generales fueron moderados y aparecieron principalmente durante las primeras 72 h despu\u00e9s de la vacunaci\u00f3n. Todos los voluntarios vacunados alcanzaron niveles protectores (\u00b30,1 UI/mL de antitoxina contra el t\u00e9tanos y la difteria. El 99,25% de los inmunizados con la vacuna experimental y el 98,36% de los voluntarios del grupo control presentaron niveles de antitoxina tet\u00e1nica correspondientes a una protecci\u00f3n de larga duraci\u00f3n (\u00b31,0 UI/mL; para la antitoxina dift\u00e9rica se alcanzaron estos niveles en el 81,20% y 80,33% de los voluntarios en cada grupo. Los t\u00edtulos medios geom\u00e9tricos de antitoxina tet\u00e1nica (21,73 UI/mL y antitoxina dift\u00e9rica (2,55 UI/mL inducidos por la nueva vacuna fueron superiores (p<0,05 a los del grupo prevent a substantial amount of life-threatening gastroenteritis in young African children. This paper presents the results of prospective cost-effectiveness analyses for rotavirus vaccine introduction for and Uganda. In each country, a national consultant worked with a national technical working group to identify of $0.20 both countries, and from the societal perspective admissions respectively in children under 5 years in Kenya. In Uganda, the respective number of undiscounted deaths and hospital 329,779 2016 and 2035. Over the 20-year period, the discounted vaccine program costs are around US$ 80 million in Kenya and US$ 60 million in Uganda. Discounted government health service costs avoided are US$ 30 million in Kenya and US$ 10 million in Uganda (or US$ 18 million including household costs). The cost per (DALY) averted from a government perspective is US$ 38 in Kenya and US$ 34 in Uganda (US$ 29 from a societal vaccine range plausible scenarios. The involvement of national experts improves the quality of data used, is likely to increase acceptability of the results observational study was conducted from October 2008 to June 2009. It included 682 children up to 5 years of age with acute gastroenteritis (AGE) who attended primary care (n = 18) and emergency room/hospital settings (n = 10), covering the regions Asturias (North-west Spain). All interviews and telephone contact. 682 enrolled children, 207 (30.4%) were rotavirus positive and 170 (25%) had received at rotavirus vaccine. The mean (standard deviation) indirect cost caused by an episode of at 135.17 (182.70) Euros. Costs with RVAGE were admitted to hospital more frequently than with other etiologies (47.8% vs 14%, p decision-making process of the eventual inclusion of rotavirus vaccine developed [Pediatric prevalence of paediatric Rotavirus gastroenteritis India. importance diagnosis to understand the current prevalence and seasonal distribution of cases in Mumbai and its surrounding areas. Overall Rotavirus positivity rate was 37.9 %, with peak positivity in winter seasons. Infections were more common upto 2 years of age. Incidence of bacterial and parasitic coinfections was and affects primarily developing because of the of vaccines and high rates of mortality present Rotarix stymie their and they to be associated with a slight risk of intussusception. While different programs are being implemented worldwide to enhance vaccine distribution and monitor vaccine administration for possible intussusception in light of recent WHO recommendation, another major problem persists: that of the existing rotaviral vaccines in developing countries over time. The Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) V. V. Kudryavtsev 2013-01-01 Full Text Available The article presents data on the peculiarities of the rotavirus infection spreading in the Russian Federation levels factors. It has been established that children 0-3 years of age are the most susceptible to rotavirus infection. The epidemic process development intensity is higher clinical and laboratory The examinees and methods: The examinees were children under the age of five years treated at the Pediatric Clinic due to acute of patients (850) suffering from acute gastroenteritis, feces test Association Between FUT2 Secretor Status and Severe Rotavirus Gastroenteritis Children inpatient by age and month, from December 1, 2011, through March 31, 2013. MAIN OUTCOMES AND MEASURES Paired fecal-saliva specimens were tested for made rotavirus cases RESULTS rotavirus test-positive cases was a nonsecretor, compared with 188 (23%) of 818 healthy control participants (P < .001). Healthy control participants of Hispanic ethnicity were significantly less likely to be nonsecretors (13%) compared with healthy children who were not of Hispanic ethnicity (25%) (P < .001). After controlling for vaccination and factors, attachment factor for rotaviruses for decades. this is for causing infections in animals, and up new avenues to by known regarding the growth parameters. We have investigated growth of AlGaN, GaN and InGaN on (20 anti 21)GaN substrates by MOVPE. Smooth GaN layers with a rms roughness <0.5 nm were obtained by low growth temperatures and pressures. The layers exhibit undulations along [10 14] mobility due to the binding energy of Al and the low growth temperature respectively or layer tilt by formation of misfit dislocations, due mechanism leads a reduced critical layer thickness of (20 anti 21)AlGaN layers and InGaN multi quantum wells (MQW) in comparison to (0001). PL spectral broadening of (20 anti 21)InGaN single QWs emitting at 415 nm can be Naspleda Pardo, Joan 2015-01-01 En aquest treball, a partir de la teoria de l'actor-xarxa i la Sociologia del Coneixement Cient\u00edfic (SCC), analitzem la creaci\u00f3 i evoluci\u00f3 de la vacuna contra la mal\u00e0ria de l'equip del Dr. Manuel Elkin Patarroyo, durant els anys 80 i 90 del passat segle, per mostrar com les interaccions socials participen de manera decisiva en l'acceptaci\u00f3 o rebuig d'una proposta cient\u00edfica. En este trabajo, a partir de la teor\u00eda del actor-red y la Sociolog\u00eda del Conocimiento Cient\u00edfico (SCC), analizamos l... [La segunda expedici\u00f3n de Balmis, revoluci\u00f3n y vacuna](https://www.openaire.eu/search/publication?articleId=od_______935::d513a40dc09e50440853f4ad3258003a) Tuells Hern\u00e1ndez, Jos\u00e9; Duro Torrijos, Jos\u00e9 Luis 2013-01-01 Cuatro a\u00f1os despu\u00e9s de concluir la Real Expedici\u00f3n Filantr\u00f3pica de la Vacuna (REFV) (1803-1806) en calidad de director, Francisco Xavier Balmis emprendi\u00f3 una nueva comisi\u00f3n con destino a M\u00e9xico que le mantuvo all\u00ed desde 1810 a 1813. El objetivo inicial para el que fue comisionado pasaba por verificar si la estrategia de vacunaci\u00f3n implantada a trav\u00e9s de las Juntas era eficaz y, asimismo, encontrar una fuente de fluido vacuno aut\u00f3ctona que permitiera continuar la acci\u00f3n vacunadora. Balmis ejer... [Stability for a high burden especially in low-income countries. An appropriate formulation, packaging, and delivery device for oral rotavirus vaccine has the potential to reduce the manufacturing cost of the vaccine and the logistical impact associated with introduction of a new vaccine, simplify the vaccination procedure, and ensure that the delivered to Single-dose prefilled use; however, typically more expensive, can be a bottleneck during production, and occupy a greater volume per dose vis-\u00e0-vis supply chain storage and medical waste disposal, challenge in low-resource wastage of vaccine and the need for separate delivery devices. In this study, the goals were to evaluate both the compared to a standard glass vial. The results showed that none of the preservatives tested were compatible with a live attenuated rotavirus vaccine because they had a detrimental effect on the viability of the virus. In the presence of preservatives, vaccine virus titers declined to undetectable deaths from diarrhea among children younger than 5 years of age worldwide, with a disproportionate effect in sub-Saharan Africa. We conducted a randomized, placebo-controlled trial in Niger to evaluate the efficacy of a live, oral bovine rotavirus pentavalent (BRV-PV, gastroenteritis. Healthy infants received three doses of the vaccine or placebo at 6, 10, and 14 weeks of age. Episodes of gastroenteritis were assessed through active and passive surveillance and were graded on the basis of the score on the Vesikari scale (which ranges indicating more severe disease). The primary end point was the efficacy of three doses of vaccine as compared with placebo against a first episode of laboratory-confirmed severe rotavirus gastroenteritis (Vesikari score, 11) dose 3. Among the 3508 infants who were included in the per-protocol efficacy analysis, there were 31 cases of severe rotavirus gastroenteritis in the vaccine group and 87 cases in the placebo group (2.14 and 6.44 cases per 100 person-years, respectively), for efficacy of 66.7% (95% confidence interval [CI], 49.9 to 77.9). Similar efficacy was seen in the intention-to-treat analyses, which showed a vaccine efficacy of 69.1% (95% 55.0 to 78.7). There was no significant between-group difference in the risk of adverse events, which were reported in 68.7% of the infants in the vaccine group and in 67.2% of those in the placebo group, or in the risk of serious adverse events (in 8.3% in the vaccine group and in 9.1% in the placebo group); there were 27 deaths in the vaccine group and 22 in the placebo group. None of the infants had confirmed intussusception. Three doses of BRV-PV, an oral rotavirus vaccine, had an efficacy of 66.7% against severe rotavirus gastroenteritis among infants in children hospitalized Available Abstract Background & Aim: Rotavirus infection is the most common cause of dehydrating and gastroenteritis among children worldwide. . The aim of this study was to determine the prevalence of rotavirus in children hospitalized with acute gastroenteritis of Yasuj. Methods: This cross sectional - descriptive study was done on 184 stool samples of children younger than 7 years of age hospitalized at Imam Sajjad hospital of Yasuj in 2011 due acute All samples analyzed for detection by Enzyme Immunoassay (EIA test. Data was analyzed by SPSS version 16, Chi-square test and Fisher's exact The highest incidence of rotavirus was seen in autumn with frequency (48.08% and the lowest in Internet Search Data to Monitor Rotavirus Vaccine Impact in the United States, United Kingdom, and Mexico.](https://www.ncbi.nlm.nih.gov/pubmed/28369477) Shah, Minesh P; found between internet search and public health surveillance data. Less is known about how search data respond to public health interventions, such as vaccination, and the consistency of responses in different countries. In this study, we aimed to study the correlation between internet searches for \"rotavirus\" and rotavirus disease activity in the United States, United Kingdom, and Mexico before and after introduction of rotavirus vaccine. We compared time series of internet searches for \"rotavirus\" from Google Trends with rotavirus laboratory reports from the United States and United Kingdom and with hospitalizations for acute gastroenteritis in the United States and Mexico. Using time and location parameters, Google quantifies an internet query analyzed the correlation between IQS and laboratory and hospitalization data before and after national vaccine introductions. There was a strong positive correlation between the rotavirus IQS and laboratory reports in the United States (R2 = 0.79) and United Kingdom (R2 = 0.60) and between the rotavirus IQS and acute gastroenteritis hospitalizations in the United States (R2 = 0.87) and Mexico (R2 = 0.69) (P United States and by 70% (95% CI, 55%-86%) in Mexico. In the United Kingdom, there was a loss of seasonal variation after vaccine introduction. trends mirrored national rotavirus laboratory trends in the United States and United Kingdom and gastroenteritis-hospitalization data in the United States and Mexico; lower correlations were found after rotavirus vaccine introduction. Published by Oxford University Press on behalf of The Journal of the Pediatric Infectious Diseases Society 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US. [Improving hepatitis B immunization among high-risk adolescents: a low-cost intervention on the Mexico-United States border Mejores pr\u00e1cticas de inmunizaci\u00f3n anti-hepatitis B para adolescentes en alto riesgo: intervenci\u00f3n de bajo costo en la frontera mexicano-estadounidense](http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S1020-49892001000400004) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Kathleen M. O'Rourke 2001-04-01 tercera dosis de la vacuna anti-hepatitis B. Resultados. En total, 32% de los adolescentes recibieron la primera dosis de vacuna, 9% la segunda y 2% la tercera. El factor de mayor valor predictivo en relaci\u00f3n con haber recibido una o dos dosis de vacuna fue el haber proporcionado la vacuna en la cl\u00ednica para ETS, en vez de haber remitido al adolescente a una cl\u00ednica independiente para la vacunaci\u00f3n (riesgo relativo [RR] de haber recibido la primera vacuna = 7,3; RR de haber recibido la segunda = 3,8. Tambi\u00e9n se encontr\u00f3 una asociaci\u00f3n entre diversas creencias en materia de salud y el haber sido vacunado. Conclusiones. Los resultados de nuestro estudio indican que los programas de vacunaci\u00f3n contra la hepatitis B pueden mejorarse si la vacuna se aplica en un local de f\u00e1cil acceso, si se instruye a los adolescentes sobre los factores de riesgo de contraer la hepatitis B y si se subrayan las dificultades que entra\u00f1a el tratamiento de esta infecci\u00f3n. [Impact of rotavirus vaccination to the age of 5 years. Rotavirus vaccination has now been available for several years in some countries, and data have been collected evaluate the of impact estimates and observed data on disease-specific hospitalisation reductions in years using vaccine efficacy data from clinical development trials. Data on the number of rotavirus-positive gastroenteritis hospitalisations in children aged <5 years between 1 June 2004 and 31 May 2006 (pre-vaccination study period or 1 June 2007 to 31 May 2010 (post-vaccination study period were analysed from nine hospitals in Belgium and compared with the observed data indicated indirect vaccine protection in children too old or too young for vaccination. This herd effect is difficult to capture in static Markov cohort models and therefore was not included in the model. Second, the model included a 'waning' effect, i.e. reduced vaccine effectiveness over time. this waning effect did not occur during so the model systematically underestimated vaccine effectiveness during the first 4 years after vaccine implementation. CONCLUSIONS: Model predictions underestimated the direct medical economic value rotavirus vaccination during the first 4 years when assessing [Cost-effectiveness of primary visits against rotavirus are registered, routine two years of in Brazilian children](http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762012000700002&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Maria Cleonice Justino 2012-11-01 Full Text Available In a large Phase III trial conducted in 10 Latin American countries, the safety and efficacy of the live attenuated during the first two years of life. Bel\u00e9m was the only site in Brazil included in this multicentre trial. The study in Bel\u00e9m included a subset of 653 infants who were followed up until 24 months of age rotavirus gastroenteritis. These subjects were randomly assigned in a 1:1 ratio to receive two doses of vaccine (n = 328 or two doses of placebo (n = 325 at approximately two and four months of age. Of the 653 enrolled infants, 23 dropped out during the study period. For the combined two-year the of efficacious against severe rotavirus gastroenteritis in Bel\u00e9m during the first two years of life and provide high protection against the worldwide emergence and risk of intussusception, the World Health Organization (WHO recommended in 2009 that rotavirus immunization should be initiated by age 15 weeks and completed before 32 weeks. These restrictions could with up to age 3 years. Countries were grouped on the basis of child mortality rates, WHO data. Inputs were estimates of WHO rotavirus mortality by week of age from a recent study, mortality based on a literature review, rates week of age from USAID Demographic and Health Surveys, the United Nations vaccine efficacy and vaccine-associated intussusception risk. On the basis of the error estimates and distributions for model inputs, percentile, provide of the uncertainty in We with Pakistan.](http://europepmc.org/articles/PMC3692488?pdf=render) [Directory of Open Access on rotavirus associated disease burden and the country. We investigated 1306 stool samples collected over two years (2008-2009 from hospitalized children under 5 years of age for the presence of rotavirus strains and its genotypic diversity in Lahore. The prevalence rate during 2008 and 2009 was found to be 34% (n = 447 out of 1306. No significant difference was found between different age groups positive for A through RT-PCR (49.43% samples, out of total 89 EIA positive samples, were found positive. G and P type recommended vaccines in Pakistan based on the proven and recognized vaccine efficacy across the globe. Our findings and support the immediate introduction of rotavirus vaccine in the routine immunization program of the country. [A proposed framework for evaluating and yielded different point estimates of different populations. While population rotavirus vaccine trials that may affect point estimates of efficacy, and propose a framework for evaluating new rotavirus vaccines. Copyright Published of rotavirus immunization for developing a leading cause of mortality for children under 5 years of age, and rotavirus is identified as the main cause of severe diarrhea worldwide. Since 2006, two rotavirus vaccines, Rotarix and Rotateq, have been available in the market. These vaccines have proved to have efficacy sarampo, contra sarampi\u00f3n, varicela y rub\u00e9ola Anaphylaxis associated with the vaccine cujo Curitiba, Nacional de Vacina\u00e7\u00e3o de que o total A resposta vacinal casos, da vacina e poss\u00edvel rea\u00e7\u00e3o cruzada com o dextrano.Estudio del tipo caso-control cuyo objetivo fue describir los casos y las causas de anafilaxia asociada a la vacuna contra sarampi\u00f3n, varicela y rub\u00e9ola. Fueron estudiados 22 casos notificados en ni\u00f1os de Curitiba, Sureste de Brasil, durante Campa\u00f1a Nacional de Vacunaci\u00f3n de 2004, que presentaron manifestaciones mococut\u00e1neas. Para el control, fueron seleccionados 66 ni\u00f1os vecinos de los casos, que no presentaron sintomatolog\u00eda posterior a la aplicaci\u00f3n vacunal. Fueron realizadas dosificaciones s\u00e9ricas de anticuerpos para los ant\u00edgenos vacunales, IgE total y espec\u00edficas para diversos al\u00e9rgenos, y pruebas cut\u00e1neas. La respuesta vacunal fue adecuada, la dosificaci\u00f3n de IgE espec\u00edfica y las pruebas cut\u00e1neas mostraron que los al\u00e9rgenos potenciales constituyentes de la vacuna y la atopia no fueron relacionados a las reacciones anafil\u00e1cticas. Las pruebas cut\u00e1neas con la vacuna y el dextrano fueron positivas solamente en los casos, sugiriendo [Reduction in Rotavirus-associated Acute Gastroenteritis Following Rotavirus vaccines were introduced into the funded Australian National Program (NIP) in July 2007. Due to purchasing [Validaci\u00f3n del m\u00e9todo de Ellman para la determinaci\u00f3n de la concentraci\u00f3n de grupos sulfhidrilosa muestras de la producci\u00f3n de la vacuna sint\u00e9tica contra el Haemophilus influenzae tipo Text Available e valid\u00f3 el m\u00e9todo de Ellman para la determinaci\u00f3n de grupos sulfhidrilos de la producci\u00f3n del Ingrediente Farmac\u00e9utico Activo de la vacuna contra el Haemophilusinfluenzaetipo b (Hib. Se evaluaron los par\u00e1metros: linealidad, rango de trabajo, especificidad, exactitud y precisi\u00f3n. El m\u00e9todo fue lineal en el rango de 0,25-4 mM/L. Se demostr\u00f3 que la t\u00e9cnica fue espec\u00edfica con una exactitud entre 95 y 105%. La repetibilidad y la precisi\u00f3n intermedia mostraron coeficientes de variaci\u00f3n inferiores al 5% y 10% respectivamente, por debajo de los criterios de aceptaci\u00f3n requeridos para estos par\u00e1metros. Se estableci\u00f3 el reactivo hidrocloruro de L-ciste\u00edna monohidratado como control positivo del m\u00e9todo. Este ensayo por su precisi\u00f3n, especificidad y exactitud se convierte en una eficaz herramienta para el control del proceso de obtenci\u00f3n de esta vacuna. [Que hay en el horizonte sobre el virus del papiloma humano, vacunas y el control del c\u00e1ncer](http://www.scielo.org.pe/scielo.php?script=sci_arttext&pid=S1726-46342007000300011&lng=en&tlng=en) [Directory of Open Access Journals (Sweden)](https://doaj.org/search#.V6PA8bgrK70) Patricia J. Garc\u00eda 2007-07-01 Full Text Available Esta revisi\u00f3n provee una visi\u00f3n general sobre las infecciones genitales producidas por el virus del papiloma humano (VPH y de las neoplasias relacionadas con \u00e9ste y la informaci\u00f3n sobre las expectativas crecientes de la vacunaci\u00f3n como medio de prevenci\u00f3n. Se explora como se han desarrollado las vacunas contra el VPH y que aspectos hay que tener en cuenta para una posible implementaci\u00f3n de un programa de vacunaci\u00f3n para prevenir el c\u00e1ncer cervical, como los costos, el p\u00fablico objetivo (varones, mujeres o ambos, grupos de riesgo, a que edad vacunarlos, consideraciones que debemos tener en cuenta en la promoci\u00f3n de la vacuna, que pasar\u00eda con los programas de detecci\u00f3n precoz de c\u00e1ncer cervical y cuales son los potenciales problemas que tendr\u00eda en pa\u00edses en desarrollo. [Molecular characterization of group A rotaviruses detected in children with in Ireland Health Repository)](http://www.lenus.ie/hse/) human rotavirus are responsible for millions of gastroenteritis cases in children worldwide, chiefly and human rotavirus infections in Ireland, between 2006 and 2009, a total of 420 rotavirus strains were collected and analysed. Upon either PCR genotyping and sequence analysis, a variety throughout the period 2006-2008, with slight fluctuations seen in the very limited samples available in 2008-2009. Upon either PCR genotyping and sequence of selected strains, the genogroups Wa- and Kun-like, respectively. Upon sequence at (AGE) is as a global, to child survival, especially in developing countries. Rotavirus, in particular, has as a leading cause of severe AGE; however, there numerous rotavirus of protecting against AGE caused by and the vaccine were studied in multiple populations, including children of the Navajo and White Mountain Apache tribes in the southwestern United States. Stool specimens were collected from children enzyme a vaccine effect on incidence, severity, and duration of AGE in which rotavirus was not detected. The majority of AGE (N = 558: 472 nonrotavirus vs 86 rotavirus) occurred between August 2002 and March 2004 among children ranging from ages 4 to 23 months. The incidence of nonrotavirus AGE was similar by vaccine groups with an incidence rate ratio of interval 0.89-1.29). The hazards of first, second, third, or any AGE in which rotavirus was not detected differed little by vaccination status (P > 0.05). Duration of symptoms and severity of nonrotavirus AGE were similar by vaccine group. There was no vaccine effect on frequency or severity of nonrotavirus which best identified the proportion of disease that was vaccine preventable. Of 648 AGE patients, 158 (24%) were EIA positive, and 157 were also qRT-PCR positive. An additional 65 (10%) were qRT-PCR positive but EIA negative. Of 500 healthy controls, 1 was EIA positive and 24 (5%) for whom was by qRT-PCR alone. Children with rotavirus detected by qRT-PCR but not by EIA were not protected by vaccination, suggesting that rotavirus detected by qRT-PCR alone might in patients. [Overcoming financial barriers all countries should consider introducing rotavirus vaccines into their National Immunization Programs, as of June 2013 only 45 have done so. One major consideration appears to have been the costs of the vaccine to countries. Of concern, is that Asian countries on new vaccine introduction are very complex and vary by country and region, economic evaluations are often pivotal once vaccine efficacy and safety has been established, and disease burden documented and communicated. vaccine is high,\" even though this might be based on Health Organization's Revolving Fund provides one example of how vaccine price can be made more competitive and transparent through a regional tendering a leading cause of severe gastroenteritis and diarrhoea in young children, accounts for around deaths annually worldwide. Rotavirus specifically infects the intestinal epithelial cells in the host small intestine and has evolved strategies to antagonize interferon and NF-B other host factors participate in antiviral responses in intestinal mucosa. The mechanism by which enteric viruses are sensed cells and restricts rotavirus in and may present useful targets in the a leading cause of severe gastroenteritis and diarrhoea in young children, Rotavirus specifically intestinal epithelial small intestine and has evolved strategies to antagonize interferon and NF-B other host factors participate in antiviral responses in intestinal mucosa. The mechanism by which enteric viruses are sensed cells and restricts rotavirus in and may present useful targets in the host 2009, reaffirmed all countries should consider introducing rotavirus vaccines into their National Immunization Programs, as of June 2013 only 45 have done so. One major consideration appears to have been the costs of the vaccine to countries. Of concern, is that Asian countries on new vaccine introduction are very complex and vary by country and region, economic evaluations are often pivotal once vaccine efficacy and safety has been established, and disease burden documented and communicated. vaccine is high,\" even though this might be based on Health Organization's Revolving Fund provides one example of how vaccine price can be made more competitive and transparent through a regional tendering of severe diarrhea in young children, resulting in nearly VP7 DNA vaccine levels of IgG in mice but cannot protect mice against challenge (Choi, A.H., McNeal, M.M., Ward, R.L., 1998. 250, maintain The mucosal IgA titer was as high as 1000, while serum IgG titer was only 600. Neutralizing the potential usefulness of production and delivery of edible rotavirus vaccines [Rotavirus Vaccine will Improve Child perception of rotavirus as amidst a background of competing health priorities and limited resources. In the largest pediatric hospital of Bangladesh, where there is a fierce competition for beds, we found that between November 2015 and October 2016, 12% of 23,064 admissions were due to gastrointestinal infections, 54% of which were caused by rotavirus. One in four cases requiring hospitalization, refused because (17%), preterm birth complications (7%), and meningitis (2%), all of which bear high risks of death or disability, if not treated the mortality cases that are refused admission because of the of children with disease as rotavirus diarrhea. In our hospital, routine use of a rotavirus vaccine with 41% efficacy will release 629 beds per year to accommodate previously refused cases. Based on evidence, we make the case that introduction of this vaccine in Bangladesh and the surrounding region will prevent morbidity and mortality, both and well-being all children. [Costs cost-effectiveness of a rotavirus immunization program in Kyrgyzstan, a country eligible for vaccine funding from the GAVI Alliance. We estimated the burden of rotavirus disease and its economic consequences by using national and international data. A cost-effectiveness analysis was conducted from government and indirect in a 2-dose regimen. At current GAVI Alliance-subsidized vaccine price a vaccine price $9.41/dose, according to the cost-effectiveness standard set by the 2002 World Health Report. Addition of rotavirus vaccines to childhood immunization in and costs. Vaccination would be from assembly. In this study, we sought gain The new questions about the Kelly, Deborah F. [Virginia Tech Carilion School of Medicine and Research Institute, Roanoke, VA (United States); McDonald, Sarah M., E-mail: mcdonaldsa@vtc.vt.edu [Virginia Tech Carilion School of Medicine and Research Institute, Roanoke, VA (United States); Department of Biomedical Sciences and Pathobiology, Virginia\u2014Maryland Regional College assembly. In this study, we sought gain The new questions about the in this study. in group C (30.0% had a significantly higher hypokalemia (7.3% or S (8.8%. Group C consisted of 33 cases of the 895 reviewed cases (3.7%. In a child with rotavirus gastroenteritis, concomitant infection with Salmonella should be considered child has sustained a high fever ( 39\u00b0C for over 4 days and a green stool with mucus and blood. [Potential safety issues and other administration of live oral rotavirus vaccine. In addition to concerns, other factors may also affect of strains escaping from administration of live oral rotavirus vaccine. In addition to concerns, other factors may also affect of strains escaping from Published by Elsevier Ltd. [Methodology and lessons-learned from the efficacy clinical D rotavirus vaccine (PRV), RotaTeq(\u00ae), was conducted at Matlab field site of ICDDR,B, Bangladesh from March 2007 to March 2009. The methodology, including operation logistics, and lessons-learned are described was organized at 41 fixed-site clinics twice/month. A total of 1136 infants were randomized receive 3 doses of PRV/placebo 10-, routinely visited study participants for safety good Data entry was the source documents to a central database developed by sponsor infants, efficacy follow-up was conducted for a median of 554 days. For the evaluation of immunogenicity, blood samples were collected from 150 participants predose 1 and from 147 (98%) of the same participants post dose 3. of study participants were some of the challenges identified. This is the first vaccine trial in rural Bangladesh with online data entry. The study was well accepted in the community and was completed Elsevier Ltd. rights reserved. a\u00e2\u00ac\" are concerns of countries?](https://www.openaire.eu/search/publication?articleId=dedup_wf_001::65b6b604c194368acb33dec6a36fd039) SHAH, Nitin K 2010-01-01 It is estimated that 0.6 million children die annually due to rotavirus diarrhea under the age of 5 years world over. 90% of these deaths occur in developing countries. Western data gastroenteritis concerns while using the same in developing countries. Data from African trial has shown 76% efficacy against severe RVGE. Efficacy in malnourished children has been found to be 73% as against 7... [Vacunaci\u00f3n de la poblaci\u00f3n de 65 a\u00f1os en Castilla-La Mancha con la vacuna antineumoc\u00f3cica conjugada Available La estrategia de vacunaci\u00f3n antineumoc\u00f3cica en adultos a partir de los 65 a\u00f1os de edad ha ido modific\u00e1ndose, tras la aprobaci\u00f3n de la vacuna 13valente conjugada (VNC13 para adultos y la recomendaci\u00f3n de los Centros de Control y Prevenci\u00f3n de enfermedad de EEUU (CDC en el a\u00f1o 2014 de incluir la vacuna VNC13 a la poblaci\u00f3n a partir de 65 a\u00f1os de edad, a partir de los resultados del estudio CAPiTA. Diversos pa\u00edses, y en Espa\u00f1a varias Comunidades Auto- n\u00f3micas, ya han incluido la vacuna VNC13 en los calendarios vacunales de adultos a partir de los 65 a\u00f1os. En este documento, las sociedades: Sociedad de M\u00e9dicos Generales y de Familia de Castilla-La Mancha, Sociedad Castellano Manchega de Patolog\u00eda Respiratoria, Sociedad Castellano Manchega de M\u00e9dicos Preventivistas, Sociedad Castellano Manchega de Geriatr\u00eda, Sociedad Castellano Manchega de M\u00e9dicos Internistas (Secci\u00f3n Infecciosas, Socie- dad Castellano Manchega de Farmacia Familiar y Comunitaria presentamos a la Direcci\u00f3n General de Salud P\u00fablica de la Junta de Comunidades de Castilla-La Mancha nuestra propuesta y justificaci\u00f3n para la inclusi\u00f3n de la vacuna VNC13 en cohorte de 65 a\u00f1os de edad de Castilla-La Mancha "}